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Abstract
The application of cold injury to cells for the treatment of cancer is not a new concept. 
Prostate cryotherapy has developed rapidly over the last decade thanks to significant 
advances in cryoprobe technology. The ideal temperature for tissue destruction was 
identified to be <-40°C which is technically difficult to achieve, and would pose 
significant damage to neighbouring organs if applied. As a result, local and systemic 
failure is frequently observed. To date, the strategies for modifications of the techniques 
and delivery mechanisms have been associated with improved outcome and reduce 
complications.
During freezing, tissues within the ice ball are exposed to various damaging stresses 
which may actually be insufficient to ensure complete tissue ablation especially in the 
peripheral zone. With better understanding of the molecular mechanisms involved in 
cryogenic injury, it may be possible to identify and use candidate adjunctive therapies, 
either as sensitisers pre- or concomitantly with cryotherapy, to enhance the efficacy of the 
procedure. This study has sought to advance understanding on the effects of cryoinjury 
on human prostate cancer cell biology.
We developed a robust and reproducible in vitro model of prostate cryoinjury, which was 
then used to identify key transcriptional changes in cells by microarray analysis. 
Specifically, we found specific changes in gene expression of TNF - a  receptor 
superfamily, caspase 3 and caspase 8 which suggested potential synergy between TRAIL 
treatment and cryotherapy. This synergy was confirmed using our in vitro model; the
II
mode of death was mainly by necrosis. Local tumour cell kill by necrosis is associated 
with an infiltration of antigen presenting cells (dendritic cells), uptake of released 
antigen, trafficking of these cells to regional lymph nodes to prime antitumour T cells 
responses. We evaluated the immunological effect of cryotherapy-treated prostate cancer 
cells on monocyte derived DC as this exact scenario may potentially occur during 
prostate destruction in vivo by cryotherapy. We demonstrated that cryotreated tumour 
cells are overall stimulatory to DC phenotypically and in terms of functionally. In this 
way, ‘cryoimmunotherapy’ may be a credible means of generating antigen specific T cell 
responses to target micrometastases and remote sites of tumour spread. We evaluated of 
the role of the AQPs expression in prostate cancer cells. AQPs are membrane proteins 
that facilitate selective water and small solute movement across the plasma membrane. 
AQP3 expression was increased upon exposure to fi-eezing injury. Inhibition of AQP3 
was successful in increasing the sensitivity of prostate cancer cells to ciyoinjuiy and a 
significant increase in cell death was attained at -10°C freezing temperature. The 
observed effect was possibly due to increased intracellular ice formation at higher 
freezing temperatures.
Overall, new insights into the molecular and immunological aspects of cryotherapy may 
lead to the logical design of new clinical strategies to improve the overall efficacy of 
cryotherapy. Most likely, sensitisation of prostate cancer by local or systemic delivery of 
agents designed to accentuate direct or indirect cell injury followed by cryotherapy will 
form the next generation of clinical trials for a clinical scenario for which there remains 
no standard of care.
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Chapter 1
Introduction
1.1 Prostate gland
1.1.1 Anatomy
The prostate gland is a fibromuscular exocrine gland. It is part of the male reproductive 
system. It produces and secretes a complex proteolytic fluid which constitutes 1/3 of the 
volume of the seminal fluid. The prostate develops by the 10* week of fetal life from 
multiple epithelial buds which grow from the urogenital sinus into the surrounding 
mesoderm and by the end of 15* week, under the effect of high level of testosterone, the 
secretory cells are functional. The prostate lies at the base of the bladder surrounding the 
prostatic urethra and separated posteriorly from the rectum by Denonvillier’s fascia, a 
location which allows the prostate to be palpated easily through the rectum. The 
ejaculatory ducts enter posteriorly and join the urethra within the prostate.
The prostate gland has 2 ends, 4 zones and 5 lobes. The base is the proximal end which 
lies opposite to the bladder. The apex is the caudal end and lies on the urogenital 
diaphragm. The peripheral zone comprises 65% of the normal prostatic volume in young 
man and forms the posterolateral aspects of the gland. The anterior fibromuscular zone 
accounts for 5% of the total volume of the gland and composed of muscle and fibrous 
tissue. The central zone surrounds the ejaculatory duct and is morphologically distinctive 
from the other zones: it constitutes 25% of the normal prostatic volume. The transition 
zone is located around the proximal part of prostatic urethra and comprises 5% of the 
normal prostatic volume. The transition zone is assumed to be the site of benign prostatic 
hyperplasia. A former classification divided the prostate gland into 5 lobes, the anterior 
lobe lies in front of the prostatic urethra, the middle lobe lies above the ejaculatory duct
and behind the prostatic urethra, the posterior lobe lies below the ejaculatory duct and 
behind the prostatic urethra and the right and left lateral lobes lies on both sides of the 
prostatic urethra. The prostate is enveloped by the prostatic capsule which is a 
condensation of the fibromuscular stroma and is adherent to the gland and is surrounded 
by another fascia, the fibrous sheath, made up of fibrous tissue with embedded venous 
plexus.
1.1.2 Histology of the gland
The prostate is divided into 2 histological distinct parts
1- The glandular tissue which is composed of 3 main cell types, epithelial cells, basal 
cells and neuroendocrine cells.
2- The stroma: which comprises mainly smooth muscle cells and fibroblast with 
interposing collagen, blood vessels and lymph vessels, it enhances the emptying of 
the prostatic secretions into the urethra.
Histologically the peripheral zone is characterized by columnar secretory epithelium. The 
central zone acini are lined by cuboidal epithelium and the stroma appear more compact 
than the peripheral zone. The transition zone glandular tissue is similar to the peripheral 
zone while the stroma resembles that of the central zone.
1.1.3 Prostatic secretion
The fluid secreted by the prostate is slightly alkaline and it contributes to the fluid 
volume of the ejaculate. It is rich in zinc, citric acid, proteolytic enzymes, acid 
phosphatase, seminin, plasminogen activator and prostate specific antigen (PSA).
Although the function of the prostatic secretion is unknown, it provides adequate 
environment for the spermatozoa to function, the proteolytic enzyme liquefy the 
coagulated semen and zinc and citric acid may act as antimicrobial.
1.2 Pathology of the prostate
1.2.1 Prostatic intraepithélial neoplasia (PIN)
PIN is a clinically significant finding on prostate biopsies that is associated with the 
presence of invasive prostate cancer (Qian, Wollan, and Bostwick 1997). It was first 
reported in the mid 1980s when McNeal and Bostwick (McNeal and Bostwick 1986) 
described the presence of intraductal dysplasia within the prostate. It is characterized by 
increasing cellular proliferation within pre-existing ducts and acini with cytological 
changes including nuclear pleomorphism, prominent nucleoli, and loss of basal layer 
continuity and lack of stromal invasion. Early microinvasion of the basement membrane 
represents the earliest evidence of carcinoma of the prostate (Bostwick et al. 1993). High 
grade PIN is associated with 30-50% risk of having invasive adenocarcinoma of the 
prostate on repeating the prostate biopsy (Keetch et al. 1995) hence it is now considered 
as a precursor lesion for invasive prostate cancer.
1.2.2 Prostate cancer
Almost all prostate cancers are adenocarcinomas arising from the epithelial lining of the 
acini. They tend to arise from the peripheral zone in 85% of cases and are multifocal in 
origin. It characterized by the absence of the basal cell layer and invasion of the basement 
membrane with large pleomorphic nuclei and prominent nucleoli. Prostate cancers are
graded by pathologist depending on their differentiation from the normal prostate tissue. 
The most widely used classification is the Gleason grading system which uses low power 
architectural finding on microscopy to define the grade of the tumour. Five different 
grades has been identified ranging from grade 1 (the most differentiated and least 
aggressive) to grade 5 (the least differentiated and most aggressive) then the 2 most 
common grades in the specimen combined together to calculate the final Gleason score 
which range from 2 to 10. Gleason score is one of the 3 most important prognostic 
variables for localised prostate cancer in addition to initial prostate specific antigen level 
and clinical stage of the tumour (Stamey et al. 1999). Higher Gleason score greater than 7 
is associated with higher clinical risk and poor prognosis (D'Amico et al. 1998).
1.2.2.1 Incidence, Mortality and geographical distribution 
Prostate cancer is the most common none dermatological cancer in the UK. It accounts 
for 1 in 4 of all newly diagnosed male cancer. The average risk of developing prostate 
cancer in the UK is 1 in 14. Every year in the UK more than 32,000 men are diagnosed 
with prostate cancer and more than 10,000 die from the disease which represents around 
14% of male deaths from cancer in the UK. Prostate cancer is the second most common 
cause of cancer death in men, after lung cancer (Jemal et al. 2007). In older men aged 85 
and over, prostate cancer is the most common cause of cancer deaths accounting for 
approximately 26% of all cancer deaths (Cancer research UK 2007).
The incidence of prostate cancer has doubled since 1980 and more new cases are being 
diagnosed at an earlier stage (Quinn and Babb 2002). Increasing incidence is likely to be
due to the widespread use of transurethral resection of the prostate and the introduction of 
PSA test screening (Hsing, Tsao and Devesa 2000). In contrast, mortality rates have been 
much more stable (Quinn and Babb 2002). Prostate cancer is uncommon before the age 
of 50. More than 60% of the newly diagnosed cases are above 70 (Cancer research UK 
2007). Incidence rate climbs steeply with age to reach a peak in the ninth decade. Over 
the age of 80, 70 % of males will have a focus of cancer in their prostate but only 1 in 25 
will die from the disease (Quinn and Babb 2002).
There is a wide geographic variation in the incidence and mortality rates of prostate 
around the world. The highest reported incidence is from the western world and the 
lowest in China. This may be related to a higher incidence of PSA testing in these 
countries (Cancer research UK 2007). In the UK the reported incidence is 50 per 100 000 
per year. There is little variation in the incidence of prostate cancer with the south east 
region showing higher than average rates (Moller and Quinn 2007). Variation in the 
mortality rate is similar to the incidence rate. In the United States, African American 
population have an incidence which is twice the rate for white population, which may be 
related to genetic factors (Parker et al. 1998)
1.2.2.2 Risk factors and aetiology:
The aetiology of prostate cancer is not clear. A number of risk factors have been 
identified.
Age: is the strongest predetermining risk factor for the development of prostate cancer. 
Prostate cancer is rare below the age of 50 and the incidence rate increase with increasing 
age (Quinn and Babb 2002).
Race: prostate cancer is more common in African-American population than the white 
Americans. In the UK, English south Asian incidence rates are significantly lower than 
non- south Asian rates (Winter et al. 1999).
Family history and genetics: it was estimated that 5-10% of prostate cancer cases have a 
genetic basis. The loss of tumour suppressor genes on chromosome 1 and X chromosome 
have been detected in some patients with family history of prostate cancer (Smith et al. 
1996) (Xu et al. 1998). The risk of developing prostate cancer increases 2-3 times if the 
first degree family members are affected. The risk increases with decreasing age of 
diagnosis and increasing number of the first degree relative affected (Bratt et al. 1999).
Hormones: androgens play an important role in prostate development. Normal prostate 
growth and development are induced by dihydrotesterone. Furthermore, prolonged 
dihydrotesterone exposure was demonstrated to induce prostate cancer in rat model 
(Noble 1977). Androgen ablation causes regression of prostate cancer. Both facts support 
the role of androgen in the development of prostate cancer.
Diet: it was observed that ingestion of saturated fat is associated with higher risk of 
developing prostate cancer. On the contrary, omega 3 fatty acids and fish products seems 
to exert a protective effect (Stacewicz-Sapuntzakis et al. 2008) (Damber and Aus 2008)
(Leitzmaim et al. 2004). The effect of dietary factors such as lycopene, selenium, vitamin 
E, K and D on prostate cancer risk have been extensively studied for their tumour 
preventive effect (Damber and Aus 2008).
Alcohol: increased consumption of alcohol may be associated with higher risk of 
development of prostate cancer (Sesso, Paffenbarger and Lee 2001).
Sexual activity: it has been suggested that frequent early life sexual activity, multiple 
sexual partners and a history of sexually transmitted diseases may all increase the risk of 
prostate cancer (Sarma et al. 2006).
Viruses: antibodies against human papilloma virus type 18 and 16 were associated with 
increased risk of developing prostate cancer (Dillner et al. 1998). A highly significant 
association between prostate cancer and human herpes virus type 8 seropositivity was 
demonstrated (Hoffman et al. 2004). The possible association between herpes simplex 
virus type 2 and prostate cancer was excluded (Korodi et al. 2005).
Other risk factors: reduced risk is found in diabetic patients (Rodriguez et al. 2005) and 
in patients on aspirin treatment (Mahmud, Franco and Aprikian 2004). Sun light and 
vitamin D may play a protective role (John et al. 2004). High level of insulin growth 
factor -1, vasectomy may be important predictors of risk for prostate cancer development 
(Giovannucci et al. 1993) (Wolk et al. 1998).
1.2.2.3 Natural history of prostate cancer.
The natural history of localized prostate cancer is variable, low grade tumours have more 
indolent course while high grade tumours tend to have more aggressive course. This 
concept has been supported by several studies. Johansson et al. (1996) observed 223 
patients with early prostate cancer treated by watchful waiting for mean time of 21 years, 
most patients had indolent cancer for the first 10-15 years of observation and only 17% of 
patients developed metastatic disease. Further observation between 15 to 20 years 
revealed a reduction in survival without metastasis from 77% to 51%, prostate cancer 
specific survival from 78.7% to 54.4% and prostate cancer mortality increased from 15 to 
44 deaths per 1000. Chodak et al. (1994) performed a pooled analysis of 828 case records 
of patients with localized prostate cancer who were treated with watchful waiting or 
delayed hormone manipulation with a median follow up of 6.5 years. Patients with poorly 
differentiated cancer (grade 3) had a lower survival rate 34% compared to 87% of 
patients with well differentiated and moderately differentiated tumours (grade 1 and grade 
2). The natural history of prostate cancer can be summarized in 3 steps: The development 
of occult tumour, the progression to clinically significant prostate cancer and aggressive 
metastatic disease. The timescale between step 1 and 3 may takes between 15-20 years 
(Kirby, Christmas and Brawer. 2001).
1.2.2.4 Clinical diagnosis.
Clinical presentation of patients with prostate cancer has changed after the introduction of 
PSA testing as more patients are presenting at an earlier stage. Before the introduction of 
serum PSA test, patients with prostate cancer usually presented with locally advanced
disease. Weight loss, bone pain, bladder outlet obstruction and lethargy were prominent 
symptoms. More recently patients are detected at an earlier asymptomatic stage.
Symptoms:
1- Localized prostate cancer: frequency, urgency, urge incontinence, poor stream, and 
haematuria.
2- Locally advanced prostate cancer: haematuria, bone pain, dysuria, loin pain, 
impotence, symptoms of renal failure and symptoms of cord compression.
3- Metastatic prostate cancer: systemic symptoms such as weight loss, lethargy and bone 
pain.
Signs:
Clinical examination of patient with prostate cancer may reveal no signs. Digital rectal 
examination may reveal enlarged prostate with an irregular, indurated or nodular area 
with indistinct margin, or fixed distorted prostate.
Clinical staging of prostate cancer:
There is a widely used system of staging prostate cancer called the TNM System. This 
system describes the extent of the primary tumour (T stage), the degree of spread to 
regional lymph nodes (N stage) and the degree of distant spread, or metastasis (M stage). 
Another staging system which is less commonly used is The Whitmore-Jewett staging 
system. It uses ABCD to stage prostate cancer with stage A and B refer to cancer 
confined to the prostate and stage C and D refer to more advanced stages.
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Prostatic specific antigen:
PSA is a kallikrein-like, serine protease that is produced exclusively by the epithelial 
cells of all types of prostatic tissue; it has a molecular weight of 34 KD and contains 240 
amino acids (Watt et al. 1986). Its function is to lyse seminal vesicle proteins. Part of 
secreted PSA is absorbed in the blood stream and carried by 2 proteins, alpha 
macroglobulin and antichymotrypsin. It was first detected in the serum and has been 
introduced as a clinical marker in prostate cancer in 1980s (Kuriyama et al. 1981) 
(Seamonds et al. 1986) (Stamey et al. 1987).
Although PSA represents the best available serum marker for prostate cancer, an isolated 
serum PSA level alone is not reliable and of limited value to determine the clinical or the 
pathological stage in primary prostate cancer (Haukaas et al. 2006) (Oesterling 1991). 
Many clinical conditions causing disruption of the prostatic architecture can falsely 
elevate the serum PSA level and there is a marked overlap between prostate cancer and 
benign prostatic hyperplasia. Prostatic needle biopsy, urethral instrumentation and 
transurethral resection of the prostate all raise the serum PSA level. PSA has higher 
positive predictive value than DRE and TRUS. In order to improve the sensitivity and 
specificity, PSA level was adjusted for age, race, total prostate volume (PSA density) and 
rate of change (PSA velocity) (Carter 2000) (Morgan et al. 1996) (Catalona et al. 2000) 
(Catalona et al. 1994). For a treatment decision, PSA needs to be used in combination 
with Gleason score and clinical stage (Partin et al. 1997).
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Digital rectal examination (DRE):
DRE has been the principle method of clinical staging of prostate cancer. It is important 
for diagnosis, assessment and predicting the prognosis of prostate cancer specially if 
combined with PSA level and Gleason score (Partin et al. 1997). However this technique 
has it limitation. Not all prostatic malignancies are palpable and there is a considerable 
inter-examiner variability. Brawer et al. (1993) demonstrated that prostate cancer was 
diagnosed only in 39% of patients with abnormal DRE. The sensitivity and positive 
predictive value of DRE increases with increasing PSA to reach up to 83% in men with 
PSA levels of 3.0-9.9 ng/mL (Schroder et al. 1998).
Trans-rectal ultrasounds scan (TRUS) and prostate biopsy:
Since the introduction of TRUS and needle biopsy of the prostate, it resulted in major 
improvement in the diagnosis and staging of prostate cancer. Abnormal DRE and/or 
elevated serum PSA remains the 2 most common indications for TRUS and biopsy of the 
prostate. The main advantage of TRUS is to assess prostate volume, guide the biopsy 
needle and measure PSA density. Unfortunately TRUS is operator dependent and has 
high false negative results with accuracy of 64%, sensitivity 78-99% and specificity of 
59-78% (Bostwick, Myers and Oesterling 1994) (Smith 1996). Transperineal prostate 
biopsy (saturation biopsy) obtains at least 25 cores and it is more sensitive than 
transrectal biopsy in detecting early stage cancers (Chan et. al. 2001).
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Pelvic Magnetic Resonance imaging (MRI):
MRI is rapidly developing new technology which is used recently in staging prostate 
cancer. National Institute for Health and Clinical Excellence (NICE) recommended that 
men with high-risk localised and locally advanced prostate cancer should have pelvic 
MRI prior to any radical treatment. Studies have shown that the accuracy of MRI scan 
(conventional body coil, fat suppression and body coil and with endorectal coil) is poor in 
detecting capsular invasion of less than 1 mm with accuracy rate ranging from 54-68%, 
sensitivity 43% and specificity 84% and when compared with TRUS, there was no 
statistically significant difference between the two tests (Rifkin et al. 1990) (Tempany et 
al. 1994).
Bone scan:
Radionuclide bone scan is an important step in staging patients with prostate cancer. It 
can detect skeletal bone metastasis. It is superior to radiography (X-ray) in detecting 
metastasis. Bone scan is less sensitive than MRI scan in detecting early bony metastasis 
(Thurairaja, MacFarlane and Gren wood 2006) (Fujii et al. 1995) (Gosfield et al. 1993). 
The prognostic value of MRI as an outcome measure for patients with metastatic prostate 
cancer was evaluated. It was demonstrated that PSA response was correlated more with 
the MRI findings than with bone scan findings in patients with progressive disease (73% 
vs 46%, respectively). On the contrary, in patients with stable PSA, the correlation with 
PSA was slightly lower for MRI than that for the bone scan (64% versus 71%, 
respectively). (Gignac et al 2006).
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1.2.2.5 Treatment for localised prostate cancer
There are 3 standard approaches to manage early prostate cancer, radical prostatectomy, 
external beam radiotherapy and active surveillance. After the introduction of PSA blood 
test, an increasing numbers of patients with early stage of prostate cancer were 
diagnosed. It is well known that early prostate cancer has an indolent and slow growing 
course (Johansson 1996). Therefore, active surveillance represents an alternative 
approach to the radical treatment. It is based on close monitoring of patients with early 
disease to identify those who are unlikely to encounter significant disease progression 
while offering radical treatment to those who are at risk. There is no long term outcome 
data on this approach.
Choo et al. (2002) investigated the feasibility of expectant management protocol for 
prostate cancer patients with selective delayed intervention based on predefined 
progression criteria. Two hundred and six patients recruited in the study. At a median 
follow up of 29 months, 137 patients remained disease progression free and 36 patients 
met the criteria for disease progression. The probability of remaining progression-free 
was 81% and 67% at 2 and 4 years, respectively. Carter et al. (2002) evaluated the active 
surveillance strategy in patients with Tic prostate cancer. A total of 81 men followed for 
23 months. Thirty one percent of the observed patients had disease progression and 52% 
underwent a radical treatment. Both studies have demonstrated that active surveillance 
with delayed curative treatment is feasible in patients with low grade disease.
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Radical prostatectomy represents the gold standard treatment for early prostate cancer. In 
a large retrospective study, Han et a l (2003b) reviewed the clinical progression of 2091 
men who underwent radical prostatectomy for a localised prostate cancer with a median 
follow up of 5.9 years. The actuarial biochemical recurrence (measured as PSA > 0.2 
ng/ml) free survival rate was 61% at 15 years. Gleason score, clinical stage and PSA 
level were important prognostic variables. Bill-Axelson et a l (2005) recently reported 
their 10 year results of randomised clinical trial comparing radical prostatectomy with 
watchful waiting for the treatment of early prostate cancer. The study included 695 men 
with early prostate cancer randomly assigned for radical prostatectomy or watchful 
waiting and followed for a median of 8.2 years. A significant survival benefit was 
observed for the radical prostatectomy arm (mortality rate was 8.6% versus 14.4%).
External beam radiotherapy is an alternative therapeutic option available for patients with 
early prostate cancer. In the last decade, technology improvements in radiotherapy 
planning and delivery have allowed the safe delivery of higher doses of radiation to the 
prostate gland preserving the surrounding structures. A more recent advance is the 
intensity modulated radiotherapy (IMRT) which allows greater dose escalation to the 
target tissue and provides higher conformality of the radiation than conventional 
radiotherapy. The biochemical failure rates following external beam radiotherapy proved 
to be equivalent to radical prostatectomy (D'Amico et a l 1998) (Kupelian et a l 2004).
Prostate brachytherapy involves the insertion of radioactive seed implant within the 
prostate. Renewed interest in brachytherapy has increased following the development of
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TRUS which allowed accurate positioning of the radioactive seeds. There have been no 
randomised trials comparing this treatment to radical prostatectomy, external beam 
radiotherapy or active surveillance. The biochemical recurrence free survival defined by 
the American Society of Therapeutic Radiation Oncology criteria (ASTRO) is reported to 
be > 95% (Khaksar et ah 2006) (Merrick et ah 2001).
1.2.2.6 Treatment for advanced prostate cancer
The introduction of PSA screening test has allowed early detection of prostate cancer. 
Nevertheless, metastatic prostate cancer remains common finding at diagnosis. In patients 
with advanced, metastatic prostate cancer hormone therapy is almost generally accepted 
as the initial treatment of choice and produces good responses in most patients. Most 
prostate cancers are primarily hormone dependant; however, many will progress into 
androgen independence state which occurs in a few years in most men (Denis and 
Murphy 1993).
There are various methods to manipulate the androgen levels in prostate cancer patients. 
Bilateral orchiectomy was the standard method in this aspect and has been practiced for a 
long time. More recently, luteinising hormone releasing hormone agonists and anti­
androgens represent the comer stone for hormone therapy for prostate cancer. Various 
prospective randomised clinical trials demonstrated a survival benefit from the long term 
use of hormone therapy in patients with locally advanced prostate cancer (Roach et al.
2000). Messing et a l (2006) investigated whether immediate hormone therapy has any 
survival benefit in men with node positive prostate cancer who have undergone radical
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prostatectomy and pelvic lymphadenectomy. They demonstrated a significant 
improvement in the overall survival, cancer specific survival and progression free 
survival with immediate hormone therapy.
Hormone refractory prostate cancer (HRPC) is defined as a progressive disease despite 
castrate levels of testosterone which no longer responsive to androgen ablation. The 
treatment options in this group of patients are limited. Systemic chemotherapy has been 
evaluated for the treatment of HRPC in various studies. The main problems with systemic 
chemotherapy are the poor response and tolerance to treatment. The current practice is to 
use mitoxantrone and corticosteroids (Kantoff et al. 1999). It was demonstrated that there 
is an advantage in term of disease progression and pain control in favour of mitoxantrone 
and hydrocortisone over hydrocortisone alone. Taxane has been used recently in the 
treatment of HRPC. Eisenberger et al. (2004) demonstrated that docetaxel and prednisone 
protocol was more effective than mitoxantrone and prednisone in overall survival, pain 
control and PSA response.
1.3 Cryotherapy for prostate cancer
The treatment of prostate cancer is evolving rapidly. Improvement in early detection and 
staging of prostate cancer have made it necessary to introduce new treatment modalities 
to deal with an increasing numbers of patients diagnosed with early disease. Radical 
prostatectomy and extemal-beam radiotherapy remains the most common primary 
treatments for localized prostate cancer with acceptable results although may be 
associated with varying degrees of morbidity (Arai et al. 1996) (Aus et al. 2005)
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(Kupelian et al. 2004) (Lim et. al. 1995). Cryosurgical treatment of the prostate has 
emerged as an alternative treatment option for patients with prostate cancer with intent 
for local control and to prolong survival. It is a minimally invasive procedure, can be 
repeated and has a relatively short hospitalization time.
1.3.1 History of cryosurgery
The use of low temperature in the treatment of cancer was introduced in mid 1880 by 
James Amott (1797-1883) a physician from Brighton, England. He used iced saline in the 
treatment of advanced breast and cervical cancer. Cold temperature resulted in reduction 
in the size of the tumour and pain relief following treatment. He made an important 
conclusion following his observation on the use of cryotherapy in the treatment of cancer 
“Congelation arresting the accompanying inflammation, and destroying the vitality of the 
cancer cell, is not only calculated to prolong life for a great period, but may not 
improbably, in the early stage of the disease, exert a curative action” He published his 
work in the Lancet in 1850 and his cryotherapy apparatus was shown in the Great 
Exhibition in London in 1851 (Amott 1850). The development in the cryotherapy field 
continued in the late 19^  ^ century in two directions, the development of more effective 
cryogen and the improvement of instmments to facilitate the application of the cryogen to 
different organs.
1.3.1.1 The development of the cryogens
The cmshed iced saline which was used by Amott produced a temperature in the range of 
-18° to -24°C which was enough to produce anaesthetic effect and not enough to
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completely destroy the malignant tissue. There was a great need for more powerful 
cryogen for cryotherapy to develop. Liquid air (produces a temperature -190°C) and solid 
carbon dioxide (produces a temperature of -78°C) was commercially available in early 
18^  ^ century. The use of both cryogens was limited to treat various skin conditions. 
Liquid oxygen which became available few years later was not successful in the clinical 
applications because of the hazard associated with its use. Freons (fluorinated 
hydrocarbon) came into clinical use in 1940s, achieving a higher temperature than solid 
carbon dioxide (-40°C) and associated with much easier use. Freons was reserved to treat 
gynaecological conditions when limited freezing was needed.
Liquid nitrogen was introduced to the clinical practice by Allington in 1950. He used a 
cotton wool dipped in liquid nitrogen to treat various benign skin diseases (Allington 
1950). Liquid nitrogen was effective in local freezing (producing temperature of -196°C) 
but its use was limited to the superficial lesions. Other cryogenic agents were available 
using the Joule-Thompson effect (rapid expansion of a compressed gas will produce low 
temperature) such as nitrous oxide and argon, both agents have cooling capacity inferior 
to the liquid nitrogen but were more easy to use with the newly developed devices.
1.3.1.2 The development of cryotherapy apparatus
With the rapid development of various cryogenic agents which were widely available, 
there was an increasing difficulty in establishing a proper apparatus to deliver these 
agents to the different body organ. In the early days of cryotherapy the commonest 
method used is the cotton swab dipped in the cryogen and applied with pressure directly
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to the lesion to produce the maximum effect. Solid carbon dioxide was compressed into 
sticks and was applied directly to the skin. Various type of applicator made of copper was 
described in 1930s and 1940s for dermatological and gynaecological use (Carpenter 
1943). It was not until 1961 that the neurosurgeon, Irving Cooper and engineer, Arnold 
Lee developed a vacuum insulated needle delivery system for liquid nitrogen. This 
allowed an iceball to be formed at the needle tip and variants of this system were used to 
treat benign and malignant conditions at a variety of sites including malignant brain 
tumours (Cooper 1963) (Cooper and Lee 1961).
1.3.1.3 The development of prostate cryotherapy procedure 
The development of Cooper’s instrument led to an important progress in prostate 
cryotherapy. In 1964, Gonder et al. (1964) developed a modified probe which was 
suitable for transurethral freezing of the prostate. Two years later they performed the first 
cryotherapy of the prostate (Gonder, Soanes and Shulman 1966). The procedure was 
monitored by digital rectal examination and was associated with high complication rate 
especially urethral sloughing and rectourethral fistula. In 1972, Flocks et al. (1972) were 
the first to try an open perineal approach in an attempt to reduce the complication rate. 
Urethral sloughing rate was improved but, rectourethral fistula and incontinence rates 
were significantly high. In 1974, Megalli et al. (1974) used a closed perineal approach 
with a single probe which was replaced several time during the procedure to cover the 
entire prostate. Complication rates were significant following these early attempts and 
prostate cryotherapy was abandoned fi-om the clinical practice. The main disadvantage of 
the procedure was the lack of adequate control of the freezing process. With the
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introduction of transrectal ultrasound by Onik et a l (1993) and thermocouple by Lee et 
al (1994) there was renewed interest in prostate cryotherapy. The transrectal ultrasound 
guided the probe placement and allowed more precise monitoring of freezing process. 
The thermocouple monitored the temperature distribution around the prostate. Both 
advances resulted in well controlled procedure and lower complication rate.
Another major advance of modem prostate cryotherapy was the introduction of the 
urethral warming catheter for urethral protection during the procedure. It resulted in a 
significant reduction in urethral sloughing and improved incontinence rates (Cohen, 
Miller and Shuman 1995). Improvement in the cryotherapy devices continued and in 
1996, Endocare, Inc., Irvine, CA has launched the first second generation cryo-system 
(Cryocare™), a multiprobe argon-helium system which was faster and more efficient 
than the liquid nitrogen probes. Galil Medical (Oncura Inc., Plymouth Meeting, PA, 
USA) introduced their third generation cryotherapy system (Seednet™) in the late 1990s. 
They developed ultra thin 17-gauge needle probes which allowed more uniform coverage 
of the prostate. In 2003, Endocare introduced their fourth generation cryotherapy system 
(Cryocare™ CS), which superseded their previous argon-helium system, introduced in 
the mid 1990’s. The latest developments of the technique resulted from the constant 
improvement in the quality of transrectal ultrasound images due to the evolution of high 
definition multi-planar ultrasound arrays over the last 20 years. This has led to an ability 
to more accurately monitor the iceball (which can be seen as a hyperechoic rim with 
acoustic shadowing) and more accurately place the thermocouples used for temperature 
monitoring.
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1.3.2 Mechanism of tissue injury in prostate cryotherapy 
The aim of prostate cryotherapy is to destroy neoplastic tissue and preserve vital 
structures around the prostate i.e. the bladder, rectum and external sphincter. This 
requires precise freezing process to achieve the maximum tissue ablation within the 
prostate without damage to the critical structures. In prostate cryotherapy, several 
cryoprobes are used and cells are exposed to variable thermal parameters depending on 
their location from the freezing probe. Larson et al. (2000) reported 2 areas of tissue 
damage surrounding the cryotherapy probe, area near to the probe undergo a coagulative 
necrosis, and at a greater distance from the probe tissue will undergo a sequamous 
metaplasia and haemorrhage which will be replaced by polymorphonuclear leukocytes 
infiltrate (Seifert et al. 2003). The mechanism of cell death by cold injury has been 
investigated for many years. It is well known that two mechanisms are responsible for 
cell death: direct injury caused by ice formation and indirect ischemic effect caused by 
micro vascular changes.
1.3.2.1 Freezing phase
Cold injury starts when temperature falls into subzero levels and extra-cellular ice start to 
form at a temperature range between -7 and -20°C. A hyperosmolar extracellular 
environment draws water from the cells and lead to cell dehydration and shrinkage. This 
effect is described as the solute effect injury (Gage and Baust 1998). Ice will also 
contribute to mechanical cell disruption. At further lower temperatures (less than -15 °C), 
ice will extend to the intracellular space either through disrupted cell membrane by 
extracellular ice (Muldrew and McGann 1994) or micropores in the cell membrane
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(Mazur 1984). Homogenous intracellular ice crystal is noticed at temperature lower than - 
40°C. Intracellular ice will exacerbate cell dehydration and cause disruption of organelles 
and cell membranes and is almost always lethal to the cells (Gage and Baust 1998).
1.3.2.2 Thawing phase
Thawing phase is important mechanism of cell destruction during freeze-thaw cycle. 
During thawing cells are exposed to different damaging mechanisms including solute 
effect, ice crystal recrystallization and reperfusion injury (Gage and Baust 1998).
1.3.2.3 Vascular effect
Microvascular effect starts with vasoconstriction and tissue anoxia during the freezing 
phase which results in tissue necrosis. This followed by vasodilatation, increased vascular 
permeability and tissue oedema during thawing phase which will contribute to the solute 
effect cell injury. Following freezing, blood vessels will show endothelial cell damage 
and microthrombus formation and complete cessation of circulation will follow in few 
hours (Whittaker 1984).
1.3.2.4 Gene regulated cell death (apoptosis)
During cryotherapy, the central zone adjacent to the cryo probe is exposed to lethal 
freezing injury and cells undergo necrosis. At the peripheral zone of the cryo lesion cells 
are exposed to sublethal temperature and the mode of cell death in this area is not clear. 
Few studies have investigated the involvement of apoptotic cell death in cryoinjury 
(Baust and Gage 2004) (Hollister et al. 1998). Hollister et al. (1998) demonstrated that
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prostate cancer cells exposed to temperature range between -5 and -15°C showed non- 
random DNA fragmentation commonly associated with apoptosis. An apoptotic inhibitor 
has resulted in blockade of DNA fragmentation and increased cell survival. Similar 
finding was demonstrated in cryotherapy of a colorectal cancer model (Yang et ah 2003)
1.3.3 Physical parameters in prostate cryotherapy
To optimize cryosurgical treatment it is crucial to understand various thermal parameters 
of the freeze-thaw cycle that control the freezing injury in prostate tissue (Tatsutani et al. 
1996). Target temperature, freezing rate, thawing rate, duration of freezing and the 
number of freeze-thaw cycles appear to influence the biological tissue changes described 
above and require careful attention for successful application of prostate cryotherapy.
1.3.3.1 Freezing rate
Rapid freezing is essential for intracellular ice formation and is associated with higher 
rate of cell death (Mazur 1984). However, there was no agreed definition of rapid 
freezing. In vitro studies demonstrated that intracellular ice formation can be achieved 
with freezing rate between 3-50 °C/minute (Bischof et al. 1997) (Hong and Rubinsky 
1994). The effect of freezing rate on human prostate cancer cells were studied in an in 
vitro prostate cancer model (Tatsutani et al. 1996). They demonstrated that freezing rate 
of 25°C/minute is important for intracellular ice formation. It resulted in a significant 
increase in the percentage of cell death when treated to final freezing temperatures of -5 
to -15°C. Formation of ice starts at the centre of the cryo probe and expand distally 
toward the warm tissues away from the probe. As a result, prostate tissue between the
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cryo probe and the edge of the ice ball is exposed to variable freezing rate. Tissue 
adjacent to the probe will experience rapid freezing to a lower temperature while tissues 
at the edge of the ice ball are exposed to slow freezing and higher terminal temperature. 
Other factors that will affect freezing rate are the vascularity of the treated organ and 
water content in the tissue (Tatsutani et ah 1996).
1.3.3.2 Target temperature
For cryotherapy to be an effective treatment for prostate cancer, all tumour cells should 
be exposed to a lethal temperature. The critical temperature which results in complete 
ablation of the prostate tissue is not well defined. Early reports demonstrated a 
temperature of -20°C or less is essential to kill the cells (Cooper 1964) (Dow and 
Waterhouse 1970). More recently, studies shown that -40°C is required for complete 
destruction of prostate tissue (Klossner et al. 2007) (Gage and Baust 2004). Interstitial 
temperature around the cryo probe increase with increasing distance from the probe 
centre. As a result, prostate tissue is exposed to a wide range of temperature gradient 
range from -170°C at the centre of the cryo probe to 0°C at the edge of the advancing ice 
ball (Hollister et al. 1998). In an attempt to determine the critical temperature required 
for complete ablation of the prostate, Larson et al. (2000) reported on 6 prostate cancer 
patients who underwent prostate cryotherapy using single cryo probe followed by radical 
prostatectomy as a definitive treatment. They demonstrated that the critical temperature 
required to achieve uniform coagulative necrosis was -41.4°C in the double freeze-thaw 
cycle compared to -61.7°C in the single freeze-thaw cycle. A recent report investigated 
the critical temperature required for complete cell death in an in vitro model (Klossner et
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al 2007). LNCaP human cell line representing an early stage prostate cancer was more 
sensitive to freezing injury and complete cell ablation was achieved at -25°C for 15 
minutes. PC-3 cell line representing advanced stage prostate cancer was more resistant to 
freezing and cells were able to recover following exposure to -40°C to 40% of the 
original culture after 8 days.
1.3.3.3 Thawing rate
The effect of thawing rate has been studied in several reports. It was demonstrated that 
slow thawing is associated with increased cell damage (Mazur 1984) (Gage et a l 1985) 
(Gage and Baust 1998) (Whittaker 1984). A more recent report demonstrated that slower 
thawing rates is associated with a significant increase in cell death compared to active 
thawing (Klossner et a l 2007). Slow thawing exposes the tissues to prolonged time of 
osmotic imbalance, oxidative stress and growth of ice crystals and hence associated with 
increased cell death (Baust and Gage 2005) (Baust et a l 2004).
1.3.3.4 Duration of freezing
Although the optimum duration of freezing is not well defined yet. It is well known that 
the length of exposure to freezing temperature affect cell viability post cryotherapy 
(Bischof et a l 1997) (Gage et a l 1985). Early reports suggested that duration of freezing 
is less important when the tissue is treated to a temperature less than -40°C as a smaller 
amount of water remain unfrozen. At higher freezing temperature more than -40°C,
prolonged freezing duration is associated with increased cell death as a result of the 
solute effect and recrystallization (Gage and Baust 1998). Klossner et a l (2007)
26
demonstrated that longer freezing time is associated with decreased cell viability 
following single freeze-thaw cycle. Prostate cancer cells held at the critical temperature 
of -40°C for 2 minutes showed the maximum ablative level (~ 93%) compared to cells 
which just reached the critical temperature (24%).
1.3.3.5 Repetition of the freeze-thaw cycle
The importance of double freeze-thaw cycle for complete ablation of prostate tissue has 
been identified in early reports of cryotherapy (Gage et al. 1985) (Cooper 1965) 
(Tatsutani et al. 1996). In vivo studies showed clearly the beneficial effect of double 
freeze-thaw cycle on tissue ablation (Larson et al. 2000). The volume of necrotic tissue 
has significantly increased from 4% to 13% following double freeze-thaw cycle. Critical 
temperature for cryoablation was increased from -61.7°C to -41.4 °C following double 
freeze-thaw cycle. A second freeze-thaw cycle enhanced lethal effect of cryotherapy 
which was best observed in temperature range of -10 to -20°C. (Klossner et al. 2007). 
The mechanism behind increased cell death following the second freeze-thaw cycle is not 
well understood. It could be a result of extended exposure to cold injury or cancer cells 
are more sensitized to cold temperature following the first freeze (Klossner et al. 2007). 
Cellular disruption and loss of cell membrane integrity following the first freeze cause 
increase thermal conductivity during the second freeze which results in faster and more 
extensive tissue freezing during the second freeze-thaw cycle (Poppendiek et al. 1967).
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1.3.4 /w vitro cryotherapy models
In vitro cryotherapy models provided better understanding of the direct damaging effect 
of freezing on the cells. Nevertheless they failed to address the vascular response to 
freezing which contributes to the delayed microcirculatory failure and tissue ischemia. 
Various in vitro models were described in the literature to treat cell monolayers with 
cryotherapy. Tatsutani et al. (1996) used the directional solidification stage to investigate 
the effect of thermal parameters on prostate cancer cells survival. The apparatus was 
designed by Rubinsky et a l (1985) and consists of 2 copper blocks which sit on the 
microscope stage adjacent to each other. The 2 block are connected to a temperature 
control system and are set to the desired temperatures (one above and one below the 
freezing temperature). A microscope slide containing the cells in suspension is moved 
mechanically at a constant velocity between the 2 blocks to initiate freezing and thawing. 
The whole process of freezing and thawing is viewed by the light microscope. A similar 
system was used by Takamatsu et a l (2006) to study the solution effect during freeze 
injury.
Klossner et a l (2007) investigated the effects of freezing variables using a circulating 
temperature controlled water bath. Prostate cancer cells were grown in a 96 well plate 
and placed on an aluminium block which is partially submerged into the water bath. Ice 
nucléation was induced by a wire cooled in liquid nitrogen. A cryogenic chamber with a 
controlled rate freezing system was used to freeze human colorectal cancer cells in vitro 
(Yang et a l 2003). Temperatures of the chamber and samples were monitored during 
treatment. A three dimensional tissue engineered human prostate cancer model was used
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to simulate in vivo cryotherapy models (Robilotto et a l 2007). While this model provides 
cell to cell and cell to matrix interaction, specific thermal variable is difficult to assess 
and studying the molecular effects of cryotherapy on individual cells is not possible.
1.3.5 Primary cryotherapy of the prostate
Cryotherapy can be used as a primary treatment for localized or locally advanced prostate 
cancer. There is an increasing competition firom other treatment options such as 
radiotherapy and radical prostatectomy and cryotherapy is infrequently used as a primary 
treatment for prostate cancer in the UK. Guidance was issued from the UK National 
Institute of Clinical Excellence (NICE), based on their literature review which was 
prepared in 2004. This stated that in view of the current scarcity of evidence on the 
efficacy and safety of primary cryotherapy, it was not recommended for men with 
localised prostate cancer other than in the context of controlled clinical trials comparing 
their outcomes with those of more established interventions. Best practice guidelines 
from the AUA on prostate cryotherapy suggest that although there is a scarcity of 
evidence, short term outcomes for intermediate and high risk organ confined disease may 
be similar to those from radiotherapy at follow up durations<8 years (Babaian et. al 
2008)
Biochemical recurrence free survival (BRFS) rates were variable ranging from 60-90% 
following primary prostate cryotherapy. It depends on the criteria used in defining the 
cut-off PSA recurrence rate. Outcome also varies depending on risk groups with better 
outcome in the low risk patients (those with a PSA level <10 ng/ml, a Gleason score < 6
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and a clinical stage < T2b) compared to the high risk patients (those with two or more 
unfavourable risk factors from a PSA level >10 ng/ml, a Gleason score > 7 and clinical 
stage > 2b) (Blasko et ah 2000). The use of preoperative hormone ablation therapy has 
affected the long term results of the procedure. Table 1.1 summarizes the results of the 
recent case series studies of the primary prostate cryosurgery. Cohen et ah (2008) 
assessed a case series of 370 men who had undergone prostate cryotherapy as primary 
treatment for locally advanced prostate cancer. Using a nadir plus 2 ng/ml definition for 
biochemical recurrence, the 10 years actuarial biochemical recurrence free survival 
(BRFS) for low risk, medium risk and high risk were 80.56%, 74.16% and 45.54% 
respectively. The 10 years positive biopsy rate was 23%. Comparable results to with 
regard to local cancer control were demonstrated recently (Hubosky et al. 2007). Long et 
al. (2001) presented multi-institutional report following primary prostate cryotherapy. A 
total of 975 patients were treated over 5 years. Two PSA thresholds were used (0.5 and 1 
ng/ml) to define the biochemical disease recurrence. Seventy five percent of the patients 
were in the intermediate and high risk group. The 5-year actuarial BRFS rates were 60% 
in the low risk patients compared to 36% in the high risk group (PSA cut-off 0.5ng/ml). 
Positive biopsy rates ranged from 18-24%. These results were comparable to the 
conformai radiotherapy and brachytherapy treatment. Bhan et al. (2002), reported on 590 
patients who underwent cryoablation of the prostate and followed for 7 years, BRFS rate 
was defined as PSA level < 0.5 ng/ml. The 7-year actuarial BRFS rate were 61%, 68%, 
and 61% for the low-risk, intermediated-risk and high-risk groups respectively with a 
positive biopsy rate of 13%. Complication rates are low following primary prostate 
cryotherapy apart form erectile dysfunction which remains a serious problem (Hubosky
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et a l 2007). Table 1.2 summarises the complication rate following primary cryotherapy 
of the prostate. Recto-urethral fistulae are very uncommon in modem primary 
cryotherapy series (Polascik et. a l 2007). Impotence rate in the primary cryotherapy 
ranges from 53-96%. Donnelly et a l (2002) reported that the nerves have the potential to 
recover 12 months following cryotherapy and half of their patients had recovered potency 
by 36 months. Incontinence rates varied considerably but were <10% in most series.
1.3.6 Salvage cryotherapy of the prostate
There is a widespread use of extemal-beam radiotherapy to treat localised and locally 
advanced prostate cancer. Patients with unfavourable presentation (PSA>10 ng/ml, 
Gleason score > 7 and clinical stage > T2b) are at increased risk of clinical failure after 
radiotherapy (D'Amico et a l 1998) (Crook et a l 1995). Stamey et a l  (1993) reported 
that 80% of men in the high risk group treated with radiotherapy for localised prostate 
cancer had an increasing PSA level at mean follow up of five years. Patients with 
localised prostate cancer, who failed their radiotherapy treatment, have limited treatment 
options available. As a result, patients are left with either watchful waiting or hormone 
therapy in which progression to androgen independence occurs in a few years in most 
men (Denis and Murphy 1993). Repeating radiation therapy is not successful as these 
tumours are radio resistant and is associated with high risk of radiation skin and organ 
toxicity (Cumes et a l 1981). Salvage radical prostatectomy is a technically difficult 
procedure and has been associated with significant comorbidities (Touma, Izawa and 
Chin 2005). Therefore, this group of patients is potentially the largest group who are 
suitable for salvage prostate cryotherapy.
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Prostate cryotherapy which is started in the early 1960s was abandoned because of high 
rates of significant complication. In the 1990s, cryotherapy was revived following two 
major advances. Firstly, the development of gas-driven cryosystems based on the Joule- 
Thompson effect resulted in more efficient tissue destruction. Secondly, improved 
monitoring of the procedure by real time ultrasound scan (Onik et a l 1993). These 
technical advances markedly reduced the complication rate and led to dramatic 
improvement in clinical outcome. The use of urethral warming catheter markedly reduced 
urethral sloughing rates following the procedure (Cohen, Miller and Shuman 1995). As a 
result, prostate cryotherapy has re-emerged as an alternative minimally invasive salvage 
procedure. Several reports described salvage prostate cryotherapy as a safe, well tolerated 
and effective treatment. It is less invasive than radical surgery, can be repeated and is 
associated with low morbidity (Ismail et al 2008)
1.3.6.1 Patient selection for salvage cryotherapy
Rising serum PSA level is the first sign of treatment failure in prostate cancer. The PSA may 
fluctuate in the first 18 months following radiotherapy (Katz and Ghafar 2002). Therefore, 
PSA should be monitored and interpreted carefully after radiotherapy. If there is a persistent 
rise in PSA which meets the Phoenix definition of biochemical failure (the nadir PSA+2 
ng/ml) then staging investigations for salvage therapy may be instigated (Dudderidge, Payne 
and Emberton 2007). The possibility of lower urinary tract infection should be excluded. 
Restaging pelvic MRI scan and bone scan is mandatory to exclude patients with metastatic 
disease prior to prostrate biopsy. Prostate biopsy is mandatory to confirm local recurrence. 
Saturation prostate biopsy (20-40 cores) is more sensitive than transrectal biopsy (10 cores)
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in detection of recurrent cancer in irradiated patients (Chan et ah 2001). Patients at higher 
risk of having locally advanced disease (those with two or more unfavourable risk factors 
from a PSA level > 10  ng/ml, a Gleason score > 7 and clinical stage > T2b) should have 
pelvic lymph nodes biopsy prior to their procedure. Patients with radiological or histological 
evidence of pelvic lymph node involvement or metastatic disease should be excluded. All 
patients considered for salvage cryotherapy should be assessed in a specialized cryotherapy 
clinic by an experienced clinician. Prostate dimensions are measured by transrectal 
ultrasound scan. Patients with prostate volume of more than 40 cc  ^ require 3 months 
hormone therapy to decrease prostate size in order to facilitate the procedure and reduce the 
risk to the surrounding structures (Ghafar et al. 2004).
1.3.6.2 Oncological results of salvage cryotherapy series
There has been controversy in evaluating clinical response following cryotherapy of the 
prostate. Serum PSA level, biopsy results and clinical assessment are essential to define 
failure post cryotherapy (Touma, Izawa and Chin 2005). PSA level cut offs of 0.1, 0.2 
(above nadir), 0.3, 0.4, and 0.5 ng/ml have been used to define biochemical failure (de la 
Taille et al. 2000) (Ghafar et al. 2001) (Chin et al. 2001) (Bahn et al. 2003) (Han et al. 
2003a). Connolly et al. (1997) demonstrated that PSA cut off value of > 0.5 ng/ml is a strong 
predictor of positive biopsy at 12 months post cryotherapy. Table 1.3 summarises the 
outcome of the recent salvage cryotherapy case series.
In our centre the first 100 salvage cryotherapy patients were followed with 3 monthly serum 
PSA level over a mean follow up period of 33 months. We used the ASTRO definition and
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cut off value > 0.5 ng/ml to define biochemical failure. Using the ASTRO definition 60% of 
men remained disease free at 3 years follow up. Unsurprisingly, high risk patients showed 
the least favourable outcome as most patients had biochemical recurrence at their last follow 
up. This may reflect undetected subclinical systemic disease, persistent local cancer 
progression or involvement of the seminal vesicle (Pisters et al. 1997). Seventy three percent 
of low risk patients with no risk factor remained disease free from biochemical recurrence at 
five years follow up.
A recent retrospective case series reported on 279 patients who had undergone salvage 
cryotherapy for recurrent prostate cancer (Pisters et al. 2008). At 5 years, 59% were showed 
freedom from biochemical failure and 67.4% had a negative biopsy following the procedure. 
Bahn et al. (2003) presented the longest follow up series of salvage cryotherapy. At 7 years 
follow up, the combined biochemical disease fi*ee survival using PSA cutoff of 0.5 ng/ml 
was 59%. At the London Health Sciences Centre in Ontario, 187 patients with locally 
recurrent prostate cancer have been treated with salvage cryotherapy (Ng et al. 2007). They 
reported BRFS of 56% with a mean follow up of 39 months. Preoperative PSA level was an 
independent predictor for BRFS and patients with preoperative PSA less than 4 ng/ml had 
better outcome.
Case series studies of salvage cryotherapy of the prostate demonstrated that complete 
ablation of cancer tissue some times fails either due to resistance of cancer cells to freezing 
injury or inappropriate freezing process. Therefore, significant numbers of high risk patients 
show disease recurrence. To improve the long term clinical outcome of prostate cryotherapy.
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combination with a sensitising agent may be needed to increase the sensitivity of cancer cells 
to cryoinjury.
1.3.7 Complications of salvage prostate cryotherapy
Almost all patients following salvage cryotherapy will have some degree of lower urinary 
tract symptoms (LUTS) secondary to urethral slough most of which will resolve in the 
first 6 months (Ismail et al. 2007). Urethral slough rate have been reduced from 40% 
(Bales et al. 1995) to 5% (Chin et al. 2001) (de la Taille et al. 2000) since the 
introduction of urethral warming catheter which protects urethral mucosa during 
cryotherapy. Although urethral warming has been successful in reducing urinary 
morbidity, it can compromise cancer control by protecting a rim of prostatic tissue around 
the urethra from freezing. Gould et al. (1999) showed a significant improvement in 
biochemichal disease free survival in men undergoing total cryotherapy (without 
warming catheter) compared to men having standard cryotherapy (with warming 
catheter).
In early reported series of prostate cryotherapy, urinary incontinence was reported to be 
as high as 95% (Bales et al. 1995). This may be related either to the lack of protection of 
the urethra and external sphincter or periurethral scarring post-radiation therapy (Pisters 
et al. 1997). Urinary incontinence rate has dropped dramatically with with recent studies 
reporting incontinence rates of 3-6% (Polascik et #72007) (Pisters et al. 2008). (Table 
1.4).
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The most serious complication of salvage cryotherapy is the development of rectourethral 
fistula. New treatment advances and better control of the procedure have significantly 
reduced this complication to 0-3% in salvage cases (Lam et #72005) (Chin et #7 2001).
Erectile dysfunction is the most frequently occurring complication following prostate 
cryotherapy (Ismail et #7 2007) (El Hayek et al. 2007), primarily due to the ice ball 
extending into the neurovascular bundles when attempting to completely eradicate the 
tumour. Impotence rate in salvage cases range from 56-100%. In salvage cryotherapy 
most patients suffer from a degree of erectile dysfunction owing to previous hormone 
therapy and pelvic irradiation (Perrotte et al. 1999).
1.3.8 Advances to reduce cryotherapy complication
1.3.8.1 Focal nerve sparing cryotherapy
In prostate cryotherapy the whole prostate gland is frozen including the periprostatic 
tissue with neurovascular bundles to eradicate all tumour cells. As a result, the incidence 
of erectile dysfunction is high. In an attempt to preserve potency, Onik et al. (2008) 
described focal nerve sparing prostate cryotherapy where they treated part of the prostate 
which contain the tumour. After a mean follow up of 50 months, 95% of the treated 
patients had stable PSA and 80% maintained their potency. In a different approach, the 
neurovascular bundle was successfully preserved by active warming, but this resulted in 
an incomplete ablation of prostate tissue (Janzen et al. 2005). Lambert et al. presented 28 
months (range 9 to 72 months) follow up of 25 patients treated with primary focal 
cryotherapy. Eighty four percent of patients had not experienced biochemical failure and
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14% showed positive biopsy on the treated site. Potency was maintained in 71% and no 
patient reported any worsening lower urinary tract symptoms or incontinence (Lambert et 
al 2007). Focal nerve sparing cryotherapy has not been applied in salvage treatment.
1.3.8.2 Laser assisted cryotherapy (LAC)
LAC is a new technique that protects healthy tissue around the prostate without limiting the 
cryoablation of unwanted tissue. Laser rays irradiated from the urethra into the prostate 
during freezing process maintain temperature in the urethral wall and surrounding region 
above the damaging level and at the same time lethal temperature is achieved in the 
surrounding prostate tissue. The margin of laser protected area increases with injecting light 
absorbing dye into the periurethral tissue (Romero-Mendez, Franco and Aguilar 2007).
1.3.8.3 Rectal wall protection
The rate of rectourethral fistula following prostate cryotherapy is low. Avoiding excessive 
freezing at the posterior margin of the prostate protects the rectum from freezing injury. 
Therefore, whole gland ablation which is necessary for complete eradication of prostate 
cancer will always be associated with risk of fistula. Modifying the cryotherapy technique to 
achieve lethal temperature (< -40°C) posteriorly while avoiding potential rectal injury was 
attempted using different techniques. Cytron et a l (2003) inserted 2 cryo needles into the 
Denonvellier’s fascia for active warming using the thawing phase when the temperature 
drops below 0°C in the posterior prostate. This approach successfully maintained a PSA 
level of <0.5 ng/ml in 80.6% of the patients treated and no rectal injury was reported. Other 
studies have addressed this issue by manipulating the transrectal ultrasound probe to increase
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distance between the rectal wall and the prostate. The mean distance was increased by 7.1 
mm without impairing the ultrasound quality image (Jones 2007).
1.3.9 Advances to increase the efficacy of prostate cryotherapy
It is well known that successful application of cryotherapy depends on several factors 
including tumour stage and thermal parameters in the ffeeze-thaw cycle (Gage and Baust 
2004). It is crucial to optimize these parameters to achieve total tumour ablation in order to 
increase the efficacy of prostate cryotherapy. There are limitations to the maximum delivery 
of cold temperature to the prostate given the close relationship between the critical structures 
which surround the prostate. Therefore, complete ablation of the prostate some times fails 
and a significant number of patients will have disease recurrence. Other options for 
improving outcomes include the application of treatments adjuvant to the application of cold.
1.3.9.1 Cryochemotherapy
Freezing results in necrotic cell death; three mechanisms are responsible for this a) 
extracellular ice crystal formation which leads to cell hyperosmolarity and post 
hypertonic lysis b) direct cell damage caused by intracellular ice crystal formation c) 
vascular stasis and tissue ischemia (Bischof et al 1997). The use of anticancer drugs as 
sensitising agents to enhance apoptotic cell death at the peripheral zone of the cryogenic 
lesion may improve the efficacy of cryotherapy. Clarke et al (2007) demonstrate that the 
combination of cryotherapy and tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL) resulted in enhanced prostate cancer cell death at -10°C. The synergistic effect 
of both treatments was primarily due to increased apoptosis. Exposure to either treatment
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alone resulted in minimal cell death. The same group demonstrated enhanced efficacy of 
cryotherapy when combined with sub-lethal concentration of 5-fluorouracil in vitro 
(Clarke et a l 2004). The limitation of those studies has been the lack of a representative 
model which simulates the clinical situation in order to design strategies to enhance the 
killing effect further.
Goel et a l (2007) investigated the ability of tumour necrosis factor alpha (TNF-a) to 
enhance cryoinjury in vivo. Temperature threshold for necrosis was increased with the 
addition of TNF-a prior to cryotherapy and the combined treatment resulted in growth 
delay of the tumour in the experimental animals. Systemic toxicity of TNF-a was reduced 
by delivering the drug combined with gold nano particles. Cryochemotherapy may 
represent a potentially effective therapeutic model for the treatment of prostate cancer 
and further studies and clinical trials are required.
1.3.9.2 Cryoimmunotherapy
The cryoimmune response has been studied in several animal models. Both 
immunostimulatory and immunoinhibitory effects have been reported (Joosten et al
2001) (Sabel et al 2005) (Grana et al 1981) (Boimey et a l 1978) (Fazio et a l 1982) 
(Fukagai et al 1990) (Javadpour, Bagley and Zbar 1979) (Muller et a l 1985) (Friedman 
et a l 1997) (Hoffmarm et a l 2001). The precise mechanism of the immunostimulatory 
effect is not clear. Early cytokine mediated response was reported (Joosten et a l 2001) 
(Sabel et al 2005). The involvement of T cell immunity and enhanced natural killer (NK) 
cells cytotoxicity was also described (Sabel et a l 2005) (Grana et a l 1981) (Hayakawa et
39
al. 1982). Other reports suggested the development of anti tumour antibodies (Moore et 
al. 1968) (Yantomo et al. 1967). Suppressed immunity and enhanced tumour growth and 
métastasés have also been reported following cryotherapy (Friedman et al. 1997) 
(Hayakawa et al. 1982) (Hoffinann et al. 2001).
In an attempt to develop an effective immunotherapy for prostate cancer, Udagawa et al. 
(2006) attempted administration of stimulated dendritic cells into cryotreated tumours in 
animal model. Cryoablation enhanced the uptake of tumour antigens by dendritic cells 
which migrated to the draining lymph nodes and induced tumour specific cytotoxic T- 
lumphocytes (CTLs) and CD8^ T cell-dependent tumour regression. Similar approaches 
and results have been reported concerning enhancing antitumour immune responses using 
the cryoimmunotherapy (Machlenkin et al. 2005). Those results warrant further studies 
and application of similar protocols in clinical trials.
1.4 Tumour immunology
The immune system plays a critical role in monitoring and maintaining tissue 
homeostasis. It eliminates infectious pathogen and controls cancer growth and metastasis 
(Ragde and Bhan 2006). Tumours arise from uncontrolled cellular proliferation which is 
able to overcome the host defences. The role of immune system in regulating and 
controlling neoplastic growth has been questioned for a long time since the early studies 
of Ehrlich in 1909. In 1970, Burnet has introduced the concept of immune surveillance 
which states that the immune system survey the body to recognize and destroy any 
abnormal growth (Prestwich et al. 2008). More recently the immune surveillance theory
40
has been criticized specially following the observation in nude mice (mice lack of thymus 
gland and unable to produce cytotoxic T lymphocytes) which are not at increased risk of 
developing primary tumours. Furthermore immune compromised patients have relatively 
low risk of developing non viral associated solid epithelial tumours (de Visser, Eichten 
and Coussens 2006).
In the contrary, immune compromised patients are at increased risk of developing virus 
induced tumours such as Kaposi sarcoma. In vivo studies demonstrated increased 
incidence of spontaneous and chemically induced cancers in certain immune deficient 
mice compared to the control (Dranoff 2003). Furthermore, various reports have 
established a strong correlation between T cells infiltrating the tumour microenvironment 
and favourable clinical outcome (Mihm, Clemente and Cascinelli 1996) (Zhang et ah
2003). Recently, a paradoxical role of immune system in cancer growth and development 
has been suggested (de Visser, Eichten and Coussens 2006). Whereas the activation of 
the innate immune response in the tumour microenvironment may promote tumour 
growth and survival, stimulation of the adaptive immune response may participate in 
tumour eradication. This raises an important question, how can tumour cells recruit local 
immune environment, which originally designed to eradicate damaged and abnormal 
tissue, to promote their growth and development?
1.4.1 The role of immune system in cancer growth and development
Cancer studies in mouse models demonstrated that premalignant conditions of skin and 
cervix is characterized by local infiltration of activated innate immune cells such as
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macrophages, dendritic cells (DC), natural killer (NK) cells and mast cells (Giraudo, 
Inoue and Hanahan 2004) (van Kempen et al. 2002). The infiltration of innate immune 
cells into the tumour microenvironment has been shown to be associated with poor 
prognosis. It was demonstrated that macrophages infiltration into mammary neoplastic 
microenvironment increased the tendency of the primary tumour for local invasion and 
metastasis (Lin et al. 2001) (Pollard 2004). Similar findings were demonstrated in 
bladder and endometrial cancers (Hanada et al. 2000) (Soeda et al. 2008). Tumour 
infiltrating mast cells secrete potent angiogenic cytokines such as vascular endothelial 
growth factor (VEGF) and are reported to be important for tumour angiogenesis 
(Crivellato, Nico and Ribatti 2008). Mast cells infilteration into tumour 
microenvironment was correlated to poor prognosis in lung cancer and malignant 
melanoma (Imada et al. 2000) (Ribatti et al. 2003)
Furthermore, it was demonstrated that chronic inflammatory conditions can promotes 
tumour development (Balkwill, Charles and Mantovani 2005). The disturbed interaction 
between the innate and adaptive immune response in chronically inflamed tissue will lead 
to excessive tissue remodelling, loss of tissue architecture and tissue destruction which 
will eventually lead to cancer development (de Visser, Eichten and Coussens 2006). 
Various examples reflect the interaction between chronic inflammation and cancer such 
as ulcerative colitis, chronic hepatitis and bilharziases. The use of anti-inflammatory 
drugs has been shown to reduce the risk of cancer development (Prestwich et al. 2008). 
Innate immune cells reside in the peripheral tissues and have great capacity to modulate 
the local environment through the secretion of active mediator such as cytokines.
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chemokines, histamine, and matrix metalloproteinases. These agents can promote tumour 
growth and survival through regulation of cell survival and death; enhancing 
angiogenesis, increasing tissue remodeling and extracellular matrix metabolism. It also 
induces DNA damage through the production of oxygen free radicals and has a negative 
inhibitory effect on the adaptive immune response (de Visser, Eichten and Coussens
2006).
1.4.2 The role of immune system in cancer eradication
The immune system must recognize tumour cells as altered self cells before it can mount 
an immune response against them. Tumours induced by viral oncogenes and carcinogens 
can induce a strong immune response in the host. This is mainly because viral particles 
are recognized as foreign antigens. Unfortunately most of the self induced tumours are 
weakly immunogenic. Although those tumours express foreign antigens, they are 
recognized by the immune system as self tissue. Tumour antigens can be categorised into 
2 main types a) Tumour-specific antigens (TSA) which is unique to the tumour cells and 
are not found in the normal tissues, b) Tumour associated antigen (TAA) which is 
expressed by normal tissue and over expressed or aberrantly produced by tumour cells. 
The exquisite specificity of antigen recognition by the immune system represents the 
basis for cancer immunotherapy. Nevertheless, spontaneous immune response against 
tumours has been identified in different type of cancer, mainly melanoma and renal 
tumours (Sanchez-Ortiz et al. 2003) (Wagner et al. 1998).
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Macrophages represent the first line of defence against cancer cells. They secrete 
immunoregulatory cytokines which activate DC and NK cells in the tumour 
microenvironment, both help to initiate and activate tumour specific immune response. 
Immune system is involved in the destruction of the tumour cells either by direct 
cytolytic effect or modifying their biological behaviour especially the migration 
properties of tumour cells. Various immune mechanisms are involved in the direct 
destruction of the tumour cells.
1.4.2.1 Specific mechanism
T cells play an important role in immune response against tumours. They can 
differentiate into CD8  ^CTLs, CD4^ T helper cells and suppressor T cells. CTLs provide 
a specific antitumour immunity. TAA expressed on the surface of the tumour cells are 
processed by antigen presenting cells (APC) which then presents the specific antigens to 
the CTLs. A costimulator molecules are presented to CTLs at the same time which will 
help in the differentiation of tumour specific CTLs.
CD4^ helper T-lymphocytes play an essential role in the differentiation of CTLs. Most 
tumours express HLA class I molecule and not class II which is required for CD4^ T cell 
recognition. CD4^ T cells provides help to CTLs to achieve full activation of tumour 
specific CTLs. However, there is strong evidence that CD4^ T cells may play a vital role 
in cancer immunology. It was demonstrate that CD4^ T cells not only provide help during 
the priming phase of tumour rejection, but also they can secrete Thl and Th2 cytokines 
which can recruit other antitumour immune cells such as eosinophils and macrophages in
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addition to CTLs (Corthay et a l 2005). In vivo studies demonstrated that CD4^ T cells 
are more effective than CD8^ cells in tumour eradication (Perez-Diez et a l 2007). CD4^ 
T cells efficiently cleared MHC class II negative tumour cells using indirect methods and 
were supported by NK cells (Perez-Diez et a l 2007).
Tumour antigens stimulate B lymphocytes to secrete antibodies against these antigens. 
Various studies identified antibodies against common tumour antigens (Disis et a l 1994) 
(McNeel et a l 2000). Nevertheless, there is no clear role for those antibodies in tumour 
rejection. Tumour cells can be destroyed by either activating complement or induction of 
antibody dependant cell mediated cytotoxicity through NK cells and macrophages.
1.4.2.2 None specific mechanism
Natural killer cells (NK) represent an important defence mechanism against tumours and 
certain t>pe of infections and may be responsible for immune surveillance against 
tumours and viral infections. They have long been known to participate in the innate 
immune response and adaptive immune regulation. NK cells can destroy tumour cells 
through different mechanisms. It has a spontaneous cytolytic function against tumour 
cells because they are not MHC restricted using a perforin dependant and independent 
mechanisms (Orange and Balias 2006). NK cells secrete various Cytokines such as IFN-y 
which enhances Thl cell response and promotes NK cell function (Robertson 2002) 
(Schroder et a l 2004). Hayakawa et a l (2002) demonstrated the role of NK cells in 
inhibition of tumour angiogenesis through IFN-y production. IL-12 has been used to 
potentiate NK cells response against primary tumours in mice (Smyth 2008).
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Furthermore, NK cells promote T and B lymphocytes proliferation, survival and 
cytokines production by providing a costimulatory signals such as CD40L and OX40L 
(Orange and Balias 2006).
NKT cells are specialised population of alpha/beta T cells that express special receptors 
of NK cells, usually defined as (NKl.LapXCR^) and they have great capacity to secrete 
large amount of immunoregulatory cytokines The important role of NKT cells in tumour 
rejection particularly in experimental immunotherapeutic models was identified (Smyth 
et al. 2002).
Macrophages are derived form blood monocytes which are recruited into the tissue by 
chemokines (CCL2, CCL5 and CSFl) and undergo differentiation into macrophages. 
Two types of macrophages were identified, type I (Ml) which produce large amounts of 
immunostimulatory cytokines, express high levels of MHC molecules and play a key role 
in elimination of pathogens and tumour cells. On the contrary type 2 macrophages (M2) 
act as a scavenger to eliminate waste products and promote angiogenesis and remodelling 
(Sica et al. 2006). It is strongly believed that macrophages play a dual role in cancer 
immunology. It became clear that most of tumour associated macrophages are of M2 type 
which promotes tumour growth, angiogenesis and metastasis (Lamagna, Aurrand-Lions 
and Imhof 2006). Polymorphonuclear leukocytes (PMNs) are attracted from the blood 
stream to the tumour site by several mediators such as selectins, intigrins and cytokines. 
They exert their cytotoxic activity on the tumour cells through releasing several
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mediators including reactive oxygen species, proteases, perforins and cytokines (TNF-a 
and IFN) (Di Carlo et al. 2001).
1.4.3 Mechanism of immune evasion by tumour cells
Malignant cells acquire unique characteristics by changing their gene expression, which 
give them a selective growth advantage over the normal cells. During malignant 
transformation cells may gain new surface antigen or even lose their normal tissue 
antigens so they can avoid immune recognition. Furthermore, cancer cells can hijack the 
local immune cells in favour for their growth and survival. Studies have shown that 
individuals suffering from malignant diseases have a functionally impaired immune 
system. They have a higher level of regulatory T cells (T regs) and myeloid suppressor 
cells in their circulation which has a negative effect on CTLs and may enhance tumour 
development. (Curiel et al. 2004). Tumour cells can evade the immune recognition 
through various mechanisms.
1.4.3.1 Anatomical changes
Tumour cells modulate their local environment in favour for their survival and growth at 
their initial stages before métastasés. Anatomically, tumour tissue has defective blood 
vessels; lack lymphatic vessels and their extra cellular matrix contain fibrous tissue. The 
interstitial pressure is high compared to the normal tissue (Zou 2005). Such environment 
represents a poor and defective medium for immune cells maturation and function.
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1.4.3.2 Cytokines imbalance
Tumour cells can produce wide range of immunosuppressive factors which interfere with 
APCs recruitment, differentiation and maturation. This may explain the fact that mature 
DC are rare in the tumour microenvironment (Troy et ah 1998). VEGF is secreted by 
tumour cells into their microenvironment; it is a potent angiogenic factor which is 
essential for the growth of both primary and metastatic tumours (Carmeliet and Jain
2000). Over expression of VEGF by the tumour cells resulted in elevated number of T 
regs in the tumour microenvironment. Blockade of VEGF receptors is associated with 
increased numbers of activated CD4^ and CD8  ^TIL (Li et al. 2006). Furthermore it was 
reported that VEGF receptor 1 is responsible for inhibition of maturation and impaired 
antigen presenting function of myeloid DC enhancing tumour evasion of immune 
response (Dikov et al. 2005) (Gabrilovich et al. 1996).
Cytokines secretion by tumour cells and their function in protecting tumour cell from 
immune recognition was investigated extensively. IL-6, IL-10, IL-8 and TGF-p are the 
main immunosuppressive cytokines released by tumour cells which inhibit DC 
maturation and the generation of effective tumour specific T cells, promoting tumour 
progression and survival (Cabillic et al. 2006) (Toutirais et al. 2003). IL-6 and 
macrophage colony-stimulating factor (M-CSF) secreted by renal cell carcinoma cell line 
were responsible for directing the differentiation of CD34^ progenitors toward 
monocytes-macrophages lineage and inhibiting DC maturation (Menetrier-Caux et al.
1998). IL-6 also can decrease cell adhesion and improve cellular mobility and hence 
improve metastatic potential of tumour cells (Tamm et al. 1994). IL-6 is secreted by
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androgen independent prostate cancer cell lines (PC-3 and DU 145) and promotes cell 
differentiation, proliferation and survival (Shida et al. 2007). Serum level of IL-6 was 
higher in patients with advanced prostate cancer and significantly correlated with patient 
survival which may suggest its role in tumour progression (Nakashima et al. 2000).
TGF-P is one of the most potent immunosuppressive cytokines. Over production of TGF- 
P by tumour cells results in inhibition of DC maturation, increase tumour angiogenesis, 
extracellular matrix deposition, and tumour progression. Blocking TGF-P signals in DC 
pulsed with prostate tumour lysate resulted in induction of potent tumour specific 
cytotoxic T cell response and complete tumour resolution in experimental mice (Wang
2007). Adoptive transfer of tumour reactive, TGF-p insensitive CD8^ cells into prostate 
cancer bearing mice resulted in heavy infiltration of the tumour site with CD8  ^ cells 
associated with reduced tumour size and increased apoptosis (Zhang et al. 2006).
IL-10 interferes with tumour angiogenesis by inhibiting matrix metalloproteinases 1 
(MMPl) and MMP9 secretion and hence interferes with tumour growth and métastasés 
(Steams, Rhim and Wang 1999). In contrast IL-10 may help tumour cells to escape 
immune recognition through suppression of DC maturation and differentiation. It also 
promotes apoptosis in mature myeloid DC by down regulation of B-cell lymphoma 2 
(BCL-2) antiapoptotic genes (Chang et al. 2007). High levels of prostaglandin E2 
(PGE2) in the tumour microenvironment were found to stimulate IL-10 production by 
mature DC. Those DC were able to induce T regs type 1 response in the tumour 
environment (Akasaki et al. 2004). This suggests that over expression of cyclo-
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oxygenase-2 gene by tumour cells represents an effective and important mechanism to 
escape immune recognition. In the contrary to the high levels of immunosuppressive 
factors secreted in the tumour microenvironment, immunostimulatory molecules are rare. 
There are low detectable levels of IL-4, IL-12, IFN-y and GM-CSF which creates an 
imbalance in the tumour microenvironment in favour for tumour growth and progression 
(Zou 2005).
1.4.3.3 Increased expression of co-inhibitory molecules
The induction of T cell immune response requires expression of MHC/peptide complex 
and co-stimulatory molecules on the surface of APCs. The function of these molecules is 
to enhance T cells proliferation and the secretion of stimulatory cytokines. B7.1 and B7.2 
(CD80 and CD86) are well known co-stimulatory molecules expressed on the surface of 
DC upon maturation. B7-H1 is newly identified molecule of the B7 family. It is 
expressed on the surface of the majority of human cancer cells. Tumour secreted factors 
(IL-10, VEGF) upregulate the expression of B7-H1 molecule on tumour associated DC 
and is thought to contribute to immune evasion by tumour cells (Dong and Chen 2003). 
B7-H1 selectively stimulates the production of IL-10 cytokine by naive T lymphocytes 
and induces apoptosis in activated T cells (Dong et al. 2002). Moreover, B7-H1 is 
thought to inhibit activated T cell response through ligation to the PDl receptor which is 
expressed on activated T and B lymphocytes (Dong and Chen 2003). The expression of 
B7-H1 by the tumour cell promotes resistance to cytolysis (Subudhi, Alegre and Fu 
2005). Over expression of B7-H1 molecules in the tumour associated myeloid DC 
impaired T cell activation, increased IL-10 production and impaired tumour specific T
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cell immunity. Blockade B7-H1 molecules enhanced T cell activation, reduced IL-10 and 
increased IL-2 and IFN-y production (Curiel et a l 2003).
B7-H4 is another recently identified B7 family molecule. It is expressed on the surface of 
the tumour associated DCs. It plays a critical role in immune evasion by tumour cells. IL- 
6 and IL-10 secreted in the tumour microenvironment upregulats B7-H4 molecules on the 
surface of DC. It negatively regulates on T cell immunity through inhibition of T cell 
growth and proliferation, and down regulation of stimulatory cytokines secretion 
(Kryczek et a l 2006) (Sica et a l 2003).
1.4.3.4 CD4+CD25+ regulatory T cells (T regs)
T regs constitute 5-10% of CD4 cell population which is further identified by CD127^°T 
Functionally it inhibits immune response either directly by cell to cell contact or 
indirectly by secretion of immune inhibitory cytokines. T regs play crucial role in 
controlling immune tolerance to self antigen in order to avoid autoimmunity (Sakaguchi 
et a l 2001). Tolerance to tumour antigens can be mediated through the same mechanisms 
that induce T cell tolerance to normal self-antigens. Miller et a l (2006) demonstrated 
increased T regs in tumour tissue and in peripheral blood from prostate cancer patients. 
Furthermore these cells exhibited immune suppressive properties in vitro. It has been 
shown that increased number of T regs cells localized in tumour microenvironment is 
associated with higher mortality of ovarian cancer patients (Carmeliet and Jain 2000). 
Tumour cells and associated immune cells secrete chemical mediators that attract T regs 
to the tumour microenvironment. T regs recruitment into tumour microenvironment is
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mediated by CCL22 a chemokine secreted by tumour associated macrophages. CCR4 the 
receptor for CCL22 is expressed on the surface of T regs (Curiel et al. 2004). 
Furthermore, IL-10 and TGF-P cytokines mediates the induction and differentiation of T 
regs.
1.4.3.5 Dysfunction of tumour infiltrating lymphocytes (TILs)
At advanced stages of tumour progression, alterations in T-cell signal transduction is the 
predominant mechanism of T cell dysfunction. T cell receptors (TCR) are transmembrane 
receptors which undergoes a series of tyrosin phosphorylations in response to antigen 
bound to MHC molecules. Studies have demonstrated decreased expression of TCR-Ç 
chain in tumour associated and peripheral blood T lymphocytes in cancer patients (Healy 
et al. 1998) (Reichert et al. 1998). Furthermore, reduced expression was correlated to 
tumour progression and poor prognosis in cancer patients (Matsuda et al. 1995). Down 
regulation of TCR-^ chain complex is responsible for reduced T cell proliferation, 
decreased Thl response and cytolytic function (Lai et al. 1996). The actual mechanism of 
TCR-^ chain complex down regulation is unknown. It might be related to T cell apoptosis 
(Rabinowich et al. 1998) or oxygen radicals secreted by tumour associated macrophages 
(Kono et al. 1996).
P56 lymphocyte cellular kinase (P56^ ^^ ) is essential for antigen specific signal 
transduction and T cells maturation, proliferation and activation. TILs from cancer 
patients showed markedly reduced expression of P56^ ^^  and were associated with reduced 
T cell proliferation and production of immunostimulatory cytokines (Finke et al. 1993)
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(Lai et al. 1996). Nuclear factor kappa B (NF-kB) is transcription factor involved in 
regulation of inflammation and host defence (Wulczyn, Krappmann and Scheidereit 
1996). Impaired activation of NF-kB has been reported in TILs isolated from renal cancer 
patients and tumour bearing mice (Buggins et al. 2001). Tumour derived gangliosides 
mediate the inhibition of NF-kB and induction of apoptosis in TILs (Thornton et al. 
2004).
1.5 Immunological response to cryotherapy
Systemic antitumour immune response has been postulated following prostate 
cryotherapy. Early clinical reports observed regression of metastatic disease and 
symptoms relief following cryotherapy of the primary tumour which implies that a 
protective immune response may be induced (Soanes, Ablin and Gonder 1970) (Gursel, 
Roberts and Veenema 1972). It was believed that tissue destruction by cryotherapy 
sensitize the body immune system to the tumour antigen through the formation of cryo 
necrotic tissue which can be recognized by APCs (den Brok et al. 2004). The term 
cryoimmunology was used to describe the immunological response to cryotherapy and it 
has been investigated in several animal models. There was a huge controversy on the 
effect of cryotherapy on antitumour immune response. Both immunostimulatory and 
immunoinhibitory effects have been reported (Yamashita et al. 1982) (Sabel et al. 2005) 
(Bonney et al. 1978) (Fazio et al. 1982) (Grana et al. 1981) (Javadpour, Bagley and Zbar 
1979) (Hoffmann et al. 2001) (Friedman et al. 1997) (Muller et al. 1985).
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Hoffmann et al. (2001) investigated the potential immune effect of cryotherapy of dunning 
ATI prostate tumour in the Copenhagen rats. They studied the 3 parameters, antibody 
response, secondary tumour rechallenge and the nature of immune infiltrate into the 
secondary tumour. They compared 6 different immunostimulatory treatments including 
cryotherapy and open surgery. They demonstrated that cryotherapy did not confer any 
protective immune response against secondary tumour challenge. Javadpour et al. (1979) 
demonstrated the efficacy of cryosurgery in eliminating local tumour, but it did not 
eradicate microscopic lymph node metastasis in animal model. In the contrary, intralesional 
injection of BCG was successful in preventing the growth metastasis in a significant 
number of animals. Friedman et al. (1997) studied the effect of cryosurgery of the normal 
ventral prostate of Copenhagen rats on the subsequent development of protective immunity 
against further subcutaneous tumour challenge, rats exposed to cryotherapy with freund’s 
adjuvant were more susceptible to secondary challenge with syngeneic tumour compared to 
the control group. Other studies showed that antitumour immunity following cryosurgery is 
at the lowest level in the early period after cryosurgery and it increase gradually thereafter 
(Misao et al. 1981) (Miya et al. 1986). It was demonstrated that partial freezing injury may 
incur a survival benefit compared to complete freezing injury (Hanawa 1993). The 
observed immune suppression by cryotherapy may be due to the activation of suppressor T 
cells which capable of inhibiting the proliferation of immune competent T lymphocytes, 
such response was noticed in animal models in early period following cryotherapy (Wing et 
al. 1988). Early rechallenge of the secondary tumour after cryotherapy may coincide with 
the period of immune suppression. Another reason may be due to the use of aggressive
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early metastasizing prostate tumour in animals which always has the ability to overcome 
any immune response induced by cryosurgery.
The second group of reports demonstrated an obvious and measurable immune response 
following prostate cryosurgery. Early clinical reports described symptomatic relief of 
metastatic lesions following cryotherapy of the primary tumour. Two case studies of 
advanced prostate cancer with distant métastasés was presented. The first patient had a 
palliative single freeze prostate cryosurgery, 3 years following the treatment there was a 
measurable regression of the lung métastasés. The second was treated with double freeze- 
thaw cycle 1 month apart, within 2 weeks of the treatment, patient showed clinical 
improvement of pain and parasthesia coincide with obvious bone re-growth in the cervical 
spine (Soanes, Ablin and Gonder 1970). The exact mechanism of such clinical observation 
was not clear. Although such observations provide strong evidence that cryotherapy might 
play a role in distant métastasés regression, these observations lack control groups. In 
addition other treatments which might be received at the same time of cryosurgery may 
also play a role. The systemic antitumour response induced by cryotherapy was evaluated 
in two mouse tumour models (Joosten et a l 2001). There was a significant inhibition of the 
secondary tumour growth in animals treated with cryotherapy compared to surgical 
excision. Animals treated with cryotherapy showed higher levels of serum IL-lp and TNF- 
a and less lung métastasés. Similar results were demonstrated by Sabel et a l (2005). 
Furthermore, Tumour specific T-cell responses were evident after cryotherapy in 
lymphocytes from tumour draining lymph nodes. Cryotherapy also increased NK activity 
compared to surgery (Sabel et al 2005).
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1.6 The aquaporin water channels
1.6.1 Background
The aquaporin (AQP) family of water channels are intrinsic membrane proteins that 
facilitate selective water and small solute movement across the plasma membrane 
(Verkman and Mitra 2000). They were initially characterised in human red blood and 
renal cells (Nielsen et al. 1993) (Preston et al. 1992). Subsequently, they were identified 
in mammals, plants, yeasts and arthropods. Up to date, 13 members of the aquaporin 
family have been identified in mammals (AQPO-12). Mammalian aquaporins were 
stratified into two subgroups, the first subgroup including AQPl, AQP2, AQP4, AQP5, 
AQP6 and AQP8 is highly selective for the passage of water across the plasma 
membrane. The second group is the aquaglyceroporins which include AQP3, AQP7, 
AQP9 and AQP 10; these permit the transport of small non ionic molecules such as 
glycerol in addition to water (Ishibashi et al. 1994).
1.6.2 Structure of the aquaporins
Analyses of the structure of AQP have revealed that all aquaporins share the same basic 
structural design. The protein comprises of 2 internal tandem repeats each consists of 3 
transmembrane helices (I-III and IV-VI respectively) and one hydrophobic highly 
conserved loop which includes a conserved asparagine, proline, alanin motif (NPA) 
following the second transmembrane helix (Magni et al. 2006). The six transmembrane 
helices (I-VI) are connected by 3 extracellular loops (loop A, C and E), and two 
intracellular loops (loops B and D). All subunits have N- and C-termini facing the 
cytosol. The B intracellular and E extracellular loops containing the highly conserved
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NPA motif form short a helices folding within the plasma membrane bilayers. The 2 
loops are connected within the membrane forming a narrow aqueous pathway in which 
the two NPA motifs are oriented 180° to each others (Jung et al. 1994). This hourglass 
structure is functionally essential for water permeability and proton exclusion mechanism 
(Magni et al. 2006) (Figure 1.1).
A C
NH2
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V  \
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Intracellular
COOH
B D
Figure 1.1 The structure of the AQP protein. It is composed of six transmembrane helices 
labelled 1-6, which are connected by five loops identified by letters A-E. The two NPA 
motifs are highlighted by green circles.
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1.6.3 Function of the AQPs
Water is an important component of the living tissues. In order to maintain the cell 
function, water balance has to be maintained in and outside the cell. Aquaporins are 
implicated in numerous physiological processes. They allow high flux of water through 
the plasma membrane in response to osmotic pressure variation and cell volume changes 
(Heymann and Engel 1999). Water channel proteins reduce the energy used by plasma 
membrane for water transport from 20 kcal/mol to < 5kcal/mol which allows high flux of 
water through the channel under hydrostatic or osmotic pressure (Heymann and Engel 
1999).
Aquaporins are selective water transport channels. They permit the passage of water and 
small non-ionic molecules. On the other hand it does not permit any ionic transport and 
form a highly efficient electrostatic filter. This may be due to a strong positive charge on 
the cytoplasmic side and a negatively charged end on the extracellular domain. Another 
possible mechanism is the size of hydrated ions (Heymann and Engel 1999).
AQPO is expressed in the eye lens tissue. It acts as both water channel and adhesion 
molecule between lens fiber cells (Magni et al. 2006). AQPl is an important member of 
the aquaporins which allow specific water transport in different tissues. It has been 
localised in the apical and basolateral membrane in the proximal tubules, thin descending 
limb of henle and the nonfenestrated endothelium of descending vasa recta (Nielsen et al. 
1995). It plays an essential role in the urinary concentrating function of the nephrons. 
AQPl was identified in the micro vascular endothelium of the endothelial-epithelial
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barrier of the lung, salivary gland, pleura and peritoneal membrane (Verkman 2002). It 
participates in maintaining the fluid osmotic water permeability in those tissues. In the 
upper gastrointestinal tract it plays a role in the bile production and dietary fat processing 
and absorption (Marinelli et al 1999). AQPl has also been localised in the blood brain 
barrier of the choroids plexus where it facilitate cerebro-spinal fluid formation and 
absorption (Frigeri et a l 1995). AQPl is expressed also in the endothelial cell of the 
cornea, pigmented ciliary epithelium and trabecular meshwork endothelium and may play 
a role in aqueous fluid dynamics and intra-ocular pressure control (Zhang, Vetrivel and 
Verkman 2002).
AQP2 is located in the kidney collecting ducts and is responsible for increasing water 
permeability and urinary concentrating capacity. It is regulated by vasopressin which 
initializes the relocation of intracellular AQP2 to the plasma membrane (Fenton et a l
2008). Mutation in AQP2 gene results in nephrogenic diabetes insipidus. AQP3 is an 
important member of the aquaglyceroporins which transports nonionic small molecules 
such as urea and glycerol in addition to water. It was initially cloned from rat kidney 
(Ishibashi et a l 1994) and subsequently was identified in the human skin fibroblast and 
epidermal cells. It is involved in epidermal cell proliferation and migration which occurs 
during normal wound healing (Cao et a l 2006) (Hara-Chikuma and Verkman 2008). The 
expression of AQP3 in male reproductive tract was examined. It was demonstrated that 
AQP3 is expressed on prostate cell membrane (Wang et a l 2007). AQP3 was 
demonstrated to be heavily expressed in the basal cells of the epididymis and was
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regulated by testosterone and luminal testicular factor (Hermo, Krzeczunowicz and Ruz
2004).
AQP4 is expressed at the plasma membrane of the perivascular feet processes of the brain 
astrocytes and the ependymal cells lining the ventricles (Nicchia et a l 2003). AQP4 is 
essential for the maintenance of the blood-brain barrier integrity and CSF production 
(Nicchia et a l 2004). AQP3 and AQP4 are coexpressed at the basolateral plasma 
membrane of the renal collecting duct principal cells (Verkman 2002). AQP5 is 
expressed mainly in the luminal surface of the acinar cells of the salivary glands and is 
involved in saliva formation and secretion (Matsuki et al 2005) (Matsuzaki et a l 2006) 
(Verkman 2002).
AQP6 has a unique distribution and function compared to the other aquaporins. It localise 
in the intracellular membrane vesicle in the renal epithelium in particular the glomerular 
podocytes and collecting duct (Yasui et a l 1999). It functions as pH-activated anion 
selective channel with a limited water permeability which increases when exposed to low 
pH (Liu et a l 2005). Therefore AQP6 does not function as a simple water channel but 
participate in a complex physiological processes including acid-base balance (Yasui et al
1999). AQP7 is expressed in adipocyte plasma membrane and regulate the uptake and 
secretion of glycerol by the adipocytes (Marrades et a l 2006). Defect in AQP7 gene 
expression results in increase levels of plasma glycerol, lipid accumulation and insulin 
resistance (MacDougald and Burant 2005). AQP8 is characterised by its permeability to 
urea and it has been localised to various organs including testes, colon, gall bladder and
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liver (Magni et al. 2006). This suggests its role in spermatogenesis (Calamita et al. 2001), 
bile concentration (Calamita et al. 2005), high water permeability in hepatocytes and the 
involvement in fecal dehydration (Ma, Yang and Verkman 1997).
AQP9 is permeable to water, urea and glycerol and is expressed in hepatocytes and male 
reproductive tract (Pastor-Soler et al. 2001). In the liver it is involved in gluconeogenesis 
and bile production (Verkman and Mitra 2000). In the male reproductive tract, AQP9 
represents an important pathway for transmembrane water and solutes transport to 
modulate luminal environment in which sperm mature and reside (Pastor-Soler et al.
2001). AQP 10 is expressed in the apical plasma membrane of the enterocytes and is 
responsible for water and small solute absorption (Magni et al. 2006).
AQPl 1 and AQP 12 are distinct in their structure and function. AQPl 1 has been localised 
to the intracellular space of the kidney proximal tubules, liver, testes and brain cells 
(Gorelick et al. 2006). AQP 12 is expressed in the acinar cells of the pancreas. Both 
aquaporins carry approximately 20-30% homology to the other members of AQP family 
and their membrane transport properties are currently unknown (Krane and Goldstein 
2007) (Morishita et al. 2004).
1.6.4 Expression of aquaporins in tumour cells
It is becoming more evident that aquaporins may play a role in tumour pathogenesis. 
AQP3 have been found to be expressed in normal and malignant prostate tissue. In the 
normal tissue AQP3 was localised to the plasma membrane, whereas in the cancerous
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tissue it was limited to the cytoplasm. It was suggested that re-localization of AQP3 in 
the tumour tissue may be involved in tumour initiation and development (Wang et al.
2007). AQP9 distribution and expression has been recently studied in the male 
reproductive tract (Pastor-Soler et al. 2001). The results show that AQP9 is expressed by 
prostate epithelium in the cytoplasm and the apical plasma membrane. Mobasheri et al. 
(2005) investigated the distribution and expression of AQPl in prostate, breast, ovary, 
colon and lung cancer. They demonstrated a heterogeneous distribution of AQPl in the 
examined tumours. Normal prostate tissue showed weak expression of AQPl in stromal 
blood vessels. Prostate tumour showed prominent expression of AQPl confined to 
capillary endothelium. Possible involvement of AQPl in tumour growth and 
angiogenesis was suggested and changes in AQPl expression may be involved in 
micro vascular alteration during tumour angiogenesis.
1.6.5 The aquaporins and freezing injury
Exposure to fi-eezing temperature results in extracellular ice formation therefore 
concentrating solutes in the unfrozen extracellular water. The resulting osmotic gradient 
will draw water from the intracellular to the extracellular space leading to cell shrinkage. 
The intracellular space will become hyperosmotic providing a protecting mechanism 
from a lethal intracellular ice formation (Mazur 1970). For successful cryopreservation, 
water and cryoprotectant such as glycerol are transported into the intracellular space 
through plasma membrane water channels (Izumi et al. 2006). Few studies have reported 
on the relationship of aquaporin water channels and freeze tolerance. Studies have 
revealed that artificial over-expression of AQP3 in mouse oocytes successfully increased
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survival after cryopreservation in glycerol based medium which retained their ability to 
be fertilized (Edashige et a l 2003). Gene expression analysis in bakers yeast revealed a 
correlation between freeze resistance and the expression of AQPl and AQP2 genes 
(Tanghe et a l 2002). Deletion of the respective genes has raised the sensitivity to freeze 
injury whereas their over expression has improved freeze tolerance. Izumi et a l (2006) 
investigated the role of AQPs in the freeze tolerance in rice stem boring insect. They 
showed that during freezing water leaves the cells and are replaced by glycerol which 
was associated with increased cell survival. Mercuric chloride (HgCh) a known inhibitor 
of AQPs (Savage and Stroud 2007) has disturbed water and glycerol transport and 
resulted in reduced cell survival. The expression of AQPs in goldenrod gall fly and their 
relation to freeze tolerance of specific tissue was examined (Philip et a l 2008). They 
demonstrated that tissue survival was reduced significantly when the mercuric chloride 
was present. It was also demonstrated that mild hypothermia results in initial reduction in 
AQP4, AQP5 and AQP9 expression in cultured astrocytes followed by increased 
expression (Fujita et a l 2003). There was no report in literature on the role of AQPs 
expression in freeze tolerance in human cancer cells.
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Table 1.1 Results of the primary cryotherapy series.
Series Year No of patients
Follow
up
(mean)
months
negative
biopsy
%
PSA
failure
% BRFS (risk group)
Low Intermediate High
Cohen et al. 2008 370 150 76.9 Nadir +2 80.5 74.16 45.5
Hubosky et al. 2007 89 11 N/A <0.4 74 70 60
Polascik et al. 2007 50 18 96 <0.5 90 all patients
El Hayek et al. 2007 21 41 42 <1 42.8 at 60 months
Prepelica et al. 2005 65 35 87.5 ASTRO 83 all patients
Han et al. 2003 106 12 N/A <0.4 75 at 12 months
Bahn et al. 2002 590 (65) 87 ASTRO 92 89 89
Donnelly et al. 2002 87 (50) 98.6 <0.3 60 77 48
Long et al. 2001 975 24 82 <1 76 71 61
Koppie et al. 1999 176 62 <0.5 70 45
Wong et al. 1997 83 30
17*
90 - - - -
Shinohara et al. 1995 102 - 77 Undetectable 41 54 3
Miller et al. 1994 62 (24) 79 <0.4 51 at 20 months
Onik et al. 1993 55 (23) 93 Biopsy results - - -
* Without temperature monitoring 
 ^Mixed primary and salvage cases
Table 1.2 Complication rates following primary cryotherapy of the prostate.
Series Impotence%
Incontinence
%
Rectourethral 
Fistula %
Urethral 
Slough %
Pain
%
Stricture 
/ Retention
%
Cohen et al. N/A N/A N/A N/A N/A N/A
Hubosky et al. N/A N/A N/A N/A N/A N/A
Polascik et al. 50 4 0 0 0 0
El Hayek et al. 96 8 0 N/A N/A N/A
Prepelica et al. N/A 3.1 0 N/A 3.1 3.1
Han et al. 87 8 0 5 2.6 3.3
Bahn et al. 8^8 15.9 0.004 N/A N/A 5.5
Donnelly et al. 53 1.3 N/A 3.9 N/A N/A
Long et al. 93 7.5 0.5 N/A 2.3 13
Koppie et al. N/A N/A N/A N/A N/A N/A
Wong et al. 94 4 0 37 N/A 4
Shinohara et al. 84 4 1 N/A 3 23
Miller et al. N/A 2.7 0 1.3 N/A 1.3
Onik et al. 64 0 2.9 4.4 N/A N/A
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Table 1.3 Results of salvage cryotherapy series.
Series Year No of patients
Follow up
(mean)
months
negative
biopsy
%
PSA failure
% BDF survival (risk group) 
Low Intermediate High
Pisters et al. 2008 279 21.6 67.4 ASTRO 58.9 all groups
NG et al. 2007 187 (39) 83.4 Nadir +2 56 all groups
Ismail et al. 2007 100 N/A >0.5 73 45 11
Collins et al. 2007 195 46.5 70.59 ASTRO 69 all groups
Robinson et al. 2006 46 24 N/A >0.3 48 at 2years
Lam et al. 2005 72 6 N/A N/A 90 at 6 months
Bahn et al. 2003 59 (72.5) 100 >0.5 61 62 50
Ghafar et al. 2001 38 20.7 N/A >0.3 above nadir 74 at 2years
Chin et al. 2001 118 (18.6) 94 >0.5 34 all groups
de la Taille et al. 1999 43 (21.9) 63(5/8) <0.1 66 at 1 year
Pisters et al. 1997 150 (13.5) 77(85/110)
>0.2 above 
nadir 58
Baies et al. 1995 23 12-23 59(13/22) <0.3 14 at 1 year
Table 1.4 Complication associated with salvage cryotherapy.
Series Impotence
%
Incontinence
%
Rectourethral 
Fistula %
Urethral 
Slough %
Pain
%
Stricture 
/ Retention %
Pisters et al. 69.2 4.4 1.2 3.2 N/A 6.8
Ng et al. N/A 3 (severe) 2 14 21
Ismail et al. 86 6 (severe) 1 16 4 2
Collins et al. N/A 6.6 0 0 10.26 2
Robinson et al. 56 29( moderate to severe)
2
(early series)
24
(early series)
16 6
(early series)
Lam et al. 8L3 17.5 0 N/A 5 9
Bahn et al. N/A 8 3.4 N/A N/A N/A
Ghafar et al. N/A 7.9 0 0 39.5 0
Chin et al. 6.7 3.3 5.1 8.5
de la Taille et al. N/A 9 0 N/A 26 5
Pisters et al. 72 73 1 22 8 67
Baies et al. 100 95.5 N/A N/A N/A 40.9
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Chapter 2
Materials and methods
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2.1 Cell culture
Three human prostate cancer cell lines were used in the experiments (DU 145, PC3 and 
LNCaP) all obtained from the American Type Culture Collection (ATCC). Cell lines 
were screened for mycoplasma infection regularly. Cells were maintained in complete 
culture medium (RPMI 1640 with 10 %FCS, 1% L-glutamine and 1% 
Penicillin/streptomycin all from Sigma-Aldrich, UK) at 37° C and 5% C02. Cells were 
harvested every 6 days. Culture medium was removed from 75cm^ flask and 3 ml of 
trypsin (Sigma-Aldrich, UK) were added. Eight ml of culture medium were added to 
neutralize trypsin, cells then transferred into 50 ml falcon tube and centrifuged at 690 
rpm for 5 minutes. Supernatant removed and pellet was resuspended in 5 ml complete 
culture medium and 2 ml of the solution were added to new 75cm^ flask containing 20 ml 
of fresh complete culture medium. Cells were then incubated at 37° C and 5% C02. Cells 
were counted under light microscope and resuspended at a density of 1x10  ^cells / ml. 
One ml of cell suspension then placed in 1.5 ml eppendorf tubes and centrifuged at 10000 
rpm for 1 minute
2.2 Freezing Model
A novel In vitro model of freezing prostate cancer cells was established using Cryocare 
system™ (Endocare, Inc., Irvine, CA) to mimic temperatures achieved during clinical 
cryotherapy (Figure 2.1). Microtubes containing prostate cancer cells were placed at 6 
mm from the centre of a single freezing probe. Two samples were treated at each time. 
Samples were held in place by temperature probe the tip of which lies in the middle of 
the cell pellet at the bottom of the tube. It also measures the temperature at the centre of
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the cell pellet (Figure 2.2). Cells were treated to temperature range from 0 to -40°C. 
Freezing temperature was maintained for 10 minute, sample then thawed in 55° C water 
bath to the 20 C. samples then incubated at 37 C and 5% C02 to recover for 24 hours.
Figure 2.1 Vh vitro cryotherapy model setup. The picture show the Cryocare system™ 
(left) and a special jig with a template which hold freezing and the temperature probe in 
place. At the back of the picture are the argon gas cylinders.
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Cryo probe
(2.4 mm in diameter)
Expanding ice ball
Ultrasound gel
Temperature probe
Eppendorf tube 
containing the cell 
pellet
Figure 2.2 Schematic representation of the freezing process. A microtube containing a 
pellet of cells held in place by a temperature probe. Ice form at the tip of the freezing 
probe and expand radially to reach the microtube. Temperature probe records the 
temperature during the treatment. Ice ball is allowed to expand according to the target 
temperature needed.
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S
(B)
Figure 2.3 (A) Cryocare system™ screen show measured temperature during treatment. 
Temperature was maintained at -5 and -10°C. (B) Close picture show the microtubes 
containing the cell pellet during the freezing process
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2.3 LDH cytotoxicity assay
Lactate dehydrogenase (LDH) is an enzyme which normally present in the cytosol and 
cannot be measured extraeellularly unless cell damage has occurred it will be released 
into the supernatant. LDH assay is based on the measurement of LDH activity released 
from damaged cells. LDH activity is determined by 2 enzymatic reactions, LDH oxidizes 
lactate to pyruvate which then reacts with tétrazolium salt INT (pale yellow) to form 
formazan (red). The increase in the amount of formazan in the culture medium is directly 
correlated to the amount of damaged cells.
Complete culture medium was replaced with assay medium (RPMI 1640 with 2%FCS, 
1% L-glutamine and 1% Penicillin/streptomycin). Cells then exposed to different low 
temperature as before. Cells were then placed in 96 well plate. (TPP, Trasadingen, 
Switzerland) and incubated at 37° C and 5% C02 for 24 hours. Plate then centrifuged at 
690 rpm for 1 minute, 100 pi of the supernatant were taken from each well into new 
plate. Untreated cells used as a negative control while cells lysed with Triton-XlOO 
(Sigma-Aldrich, UK) served as a positive control. The reaction mixture was prepared by 
mixing 8.8 ml of INT dye solution 2 with 0.2 ml of catalyst 1 (Roche, Mannheim, 
Germany) and 100 pi of the reaction mixture was added to each well in the second plate. 
The plate was at room temperature in dark for 30 minute. The absorbance intensity was 
measured at 490nm. Percentage cytotoxicity was calculated by the following formula.
Experimental value- low control (untreated cells)
% Cytotoxicity = x 100
High control (Triton XlOO treated cells) - low control
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2.4 3-(4,5-dimethylthiazol-2-yl)-5-(3 -carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium, inner salt (MTS) cell proliferation assay
MTS assay is a colorimetric survival assay for determining the number of viable cells in 
culture. The reagent contains tétrazolium compound and an electron coupling compound 
(phenazine ethosulfate, PES). The tétrazolium compound is reduced by metabolically 
active cells into colored formazine. The quantity of formazine produced is directly 
proportional to the number of living cells.
Following treatment of the prostate cancer cells as described before, Cells were placed in
96 well plate (TPP, Trasadingen, Switzerland) and incubated at 37° C and 5% C02 for 24
hours. MTS reagent (Promega, Madison, USA) is dilute to a working concentration of 1:9
in culture medium and 200 pi of the reagent was added to each well. The palate then
incubated for 1-2 hours at 37° C and 5% C02. The plate mixed with hand for even
distribution of the colored reagent and absorbance intensity was measured at 490nm.
Percentage of cell survival was calculated using the following formula.
Experimental value- back ground
% cell survival = ------------------------------------------------------  x 100
Untreated cell value- back ground
2.5 Real time quantitative polymerase chain reaction (RT-qPCR)
2.5.1 RNA extraction
Prostate cancer cells were treated with cryotherapy as described before. Cells were 
incubated at 37°C and 5% C02 to recover for 24 hours. Plates were spun at 2000g for 2
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minutes and supernatants were aliquoted and stored at -80°C. RNA was extracted from 
the remaining cells using RNeasy ® Plus mini kit (Qiagen, West Sussex, UK)
Cells were lysed with 500 pi of RUT buffer and 5 pi of p-Mercaptoethanol. The samples 
were homogenized and 350 pi of the lysate was transferred to gDNA eliminator spin 
column placed in 2ml collection tube. The samples were then spun at 13000 rpm for 1 
minute. The columns were discarded and the flow-through was saved. One volume of 
70% ethanol was added to the flow-through with mixing and 700 pi of the sample was 
placed into RNeasy spin column placed in 2 ml collection tube. Samples were then 
centrifuged at 13000 rpm for 1 minute and the flow-through was discarded. The spin 
column was washed by adding 700 pi of RWl buffer and samples were spun as above. 
Columns were then washed twice with RPE buffer and spun at 13000 rpm for 2 minutes. 
The flow-through was discarded and the RNeasy columns were placed into a new labeled 
1.5 ml collection tubes. Fifty pi of RNase free water to the spin column membrane and 
tubes were spun as before. The flow-through containing the RNA was then stored at -80° 
C freezer.
2.5.2 Preparation of RT-qPCR reaction
RT-qPCR analysis was performed using Stratagene Mx3005P qPCR system. GABDH 
was used as a house keeping gene and all reactions were performed in duplicated in 96- 
well plate. Twenty five pi of PCR reaction mixture contained 1 pi cDNA, 1 pi of each 
target primer, 10.5 pi nuclease free water and 12.5 pi SYBR® Green Jump Start ™ Taq 
ReadyMix ™ (Sigma-Aldrich, Poole, UK). Primers were designed by Primer3 software
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and obtained from Eurogentec group (Eurogentec Ltd, UK). Thermal cycling conditions 
were as follow: 1 cycle (10 minutes at 95°C) followed by 40 cycles (30 s at 95°C, 1 min 
at 60°C and 30 s at 72°C) followed by 1 cycle (1 min 95°C, 30 s at 55°C and 30 s at 
95°C). The 2"^^^ method (Livak and Schmittgen 2001) was used to calculate the 
difference in Ct value between the treated sample and untreated control and is expressed 
as a fold changes in gene expression relative to the untreated cells. The results then 
normalized to an endogenous reference gene (GAPDH) whose expression is constant in 
all groups.
2.5.3 Data analysis
The relative quantification method (The 2"^^^ method) was used to analyze data from the 
RT-qPCR reaction (Livak and Schmittgen 2001). It is easy, convenient, accurate and 
reproducible way to analyze the relative expression of the target gene in the treated group 
compared to the untreated cells (the calibrator). In the ideal reaction environment the 
target quantity will approximately double in each amplification cycle of the experiment. 
This amplification is linked to the fluorescence intensity which is measured at each cycle 
in RT-qPCR. The threshold cycle Ct is the first cycle at which the fluorescence intensity 
is greater than the background and it is directly related to the starting concentration of the 
target molecule. The greater is the starting concentration of the target molecule the lower 
is the Ct value. The 2 '^^^ method calculate the difference in Ct value between the treated 
sample and untreated control and are expressed as a fold change in gene expression 
relative to the calibrator. The results then normalized to an endogenous reference gene
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(GAPDH genes) whose expression is constant in both groups. Using this formula the 2" 
for the calibrator should equal to 1.
AACT = (Ct,Target- CxReference gene)treated- (Cj,Target- CxReference gene)untreated
2.5.4 Validation of RT-qPCR reaction.
For the 2 '^^^ method to be valid, 3 conditions should be fulfilled. First the amplification 
efficiency should double each cycle of the reaction. Secondly, the amplification 
efficiency of the target and reference genes should be more or less equal. Thirdly, the 
housekeeping gene which is used as an internal control gene should not be affected by 
experimental treatment (Livak and Sehmittgen 2001).
The amplification efficiency of the RT-qPCR reaction was calculated by measuring the 
amplification of cDNA which was synthesized fi*om a known concentration of RNA and 
log diluted and amplified using RT-qPCR. A standard curve was constructed and the 
amplification efficiency was calculated using linear regression curve (= 89.1%). This 
demonstrates that the reaction is nearly doubled on each cycle which makes it appropriate 
to use the 2 '^^^ formula. (Figure 2.4)
To confirm that the amplification efficiency of the target gene and the internal control 
gene is equal, the amplification of cDNA which was synthesized from a known 
concentration of RNA and log diluted and amplified using RT-qPCR was measured. The 
average Ct of the target genes and the internal control (GAPDH) was calculated and the 
ACT (Cx,Target- Cx, GAPDH) was determined for each cDNA concentration. Data were
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analyzed using linear regression curve (Figure 2.5). The results of 2 primers are presented 
here, IL-2 and IL-10. The absolute value of the slope was (-0.2243 ± 0.1647 and -0.1428 
± 0.1652) respectively. This confirms that the efficiencies of the target genes and the 
internal control genes are equal and the 2 '^ ^  formula may be used.
To examine the effect of cryotherapy on the expression of the internal control gene 
(GAPDH), PC3 cells were cooled to different target temperatures and the expression of 
GAPDH was calculated compared to the untreated cells using the relative expression 
formula. The relative expression at each temperature was ploted against the fold change 
in gene expression (Figure 2.6). One way analysis of variance test was used to calculate 
the difference between the groups. There was no statistical significant difference between 
the treatment temperature and the expression of GAPDH (P=0.2056). Therefore, 
GAPDH represents a suitable internal control gene.
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standard Curve
■ SYBR Standards, RSq:0.999 
 SYBR, Y = -3.615*LOG(X) + 19.79, Eff. = 89.1%  SYBR Unknowns
A SYBR Unknowns
22
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Initial Quantity (reiative)
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Figure 2.4 The amplification efficiency of the RT-qPCR reaction. cDNA was 
synthesized from a known concentration of RNA and log diluted and amplified 
using RT-qPCR. A standard curve was constructed and the amplification 
efficiency was calculated using linear regression curve. The amplification 
efficiency was 89.1%. Therefore, the reaction is nearly doubled on each cycle 
which makes it appropriate to use the 2 '^^^  formula.
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Figure 2.5 Amplification efficiency of the target genes compared to GAPDH. The 
average Ct of the target genes and the internal control (GAPDH) was calculated and the 
ACT ( C t ,Target- Cx, GAPDH) was determined for each cDNA concentration. Data were 
analyzed using linear regression curve. The results of IL-2 and IL-10 primers are 
presented.
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Figure 2.6 Effect of cryotherapy on GAPDH gene expression. PC3 cells were cooled to 
different target temperatures and the expression of GAPDH was calculated compared to 
the untreated cells. Freezing did not result in any significant change of GAPDH gene 
expression (P=0.2056). Therefore, GAPDH represents a suitable internal control gene.
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2.6 Generation of monocyte derived dendritic cells (DC)
A buffy coat was obtained from National Blood Service in 40 ml transfusion bag. 
Peripheral blood mononuclear cells (PBMCs) were resuspended in complete culture 
medium at a final concentration of 3x10^ cells/ml. Four ml of cell suspension were 
incubated in 6 well plate for 2 hours at 37°C. Non-adherent cells were discarded and 4 ml 
of fresh culture medium containing lOOng/ml Granulocyte macrophage colony 
stimulating factor (GM-CSF) (Berlex, New Jersey, USA) and 50ng/ml interleukin-4 (IL- 
4) (Peprotech, EC Ltd, London, UK) was added to each well. Cells were 
characteristically dendritic in appearance. GM-CSF and IL-4 were added every 3 days up 
to 7 days. On day 3, LPS 1 mg/ml (Sigma-Aldrich, Poole, UK) was added to half of the 
wells to induce DC maturation.
2.7 DC staining and phenotyping
Phenotypic analysis of DC was performed by flow cytometry using anti-CD 14, CD 11c, 
CD86, CD80, CCR7, CD la, CL II, CD209 and CD83 antibodies. Cells were resuspended 
in 300pl FACS buffer (45Omis sterile distilled water, 5Omis of lOx calcium/magnesium
free PBS, 3gms bovine serum albumin , 3gms sodium azide, all from Sigma-Aldrich, 
Poole, UK) and stained with FITC, PE, or PECY5 conjugated monoclonal antibodies (all 
from BD biosciences Oxford UK). Cells then washed with FACS buffer and fixed with 
ISOpl FACS FIX (45Omis sterile distilled water, 60mls of lOx calcium/magnesium free 
PBS, 15mls 38% formaldehyde solution, all from Sigma-Aldrich, Poole, UK). Stained 
DC were analyzed on Epics XL flow cytometer (Beckman-Coulter, High Wycombe, 
UK).
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2.8 Tumour lysate preparation
DU 145 and PC-3 cells were resuspended in serum free RBMI-1640 medium at a density 
of IxlO^cells/ml. The cell suspension was frozen at -80°C, interrupted by 4 freeze-thaw 
cycles. The lysate was centrifuged at 1300 rpm for 10 minutes and supernatant was 
passed through 0.2 pm filter. Protein contents of the lysate were determined by Bio-Rad’s 
protein assay (Bio-Rad, Herts, UK) following the manufacturer protocol. Lysate 
aliquoted and stored at -80°C.
2.9 Measurement of cytokine levels in the supernatant using Bio-Plex 
cytokine assay
Supernatant was collected at different time points (2, 6, 24 and 72 hours) following 
treatment and stored in aliquots at -80°C. Cytokine levels secreted in the supernatant 
from the treated cells were quantified using Bio-Plex cytokine assay (Invitrogen, Paisley, 
UK) following the manufacturers’ protocol. The multiplex bead-based assay is designed 
to quantitate IL-2, IL-6, IL-12(p70), IL-15 and IFN-y. Using 96 well flat bottom filter 
plate, a standard curve was established using the lyophilized cytokine standard. Fifty pi 
of the bead working solution was added to each well and the buffer was then removed by 
vacuum filtration. After washing, the standards and samples were added to the filter plate 
which was incubated in dark at the room temperature with continuous shaking. The filter 
plate then washed 3 times with washing buffer. Twenty five pi of the detection antibody 
was added to each well and incubated as described above. Fifty pi of streptavidin-PE was 
added to each well and the plate was incubated at room temperature for 10 minutes. The 
plate was read using Bioplex 200 system (Bio Rad, Herts, UK).
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2.10 Mixed lymphocyte reaction (MLR)
Functional activity of DC was assessed in allogenic MLR. Allogenic human T cells 
(responder) was isolated from a huffy coat, and added in triplicate in at a density of 1 
xlO^ cells per well in a rounded bottomed 96-well plate. DC (1x10^) loaded with different 
cells were added into each well. Plates were incubated at 37°C in 5% CO2 for 5 days. 
Proliferation of T cells was measured after adding ^H-thymidin for 18 hours. Cells were 
harvested using Filtermate harvester (PerkinElmer, Massachusetts, USA) and the amount 
of ^ H-thymidin incorporated into the DNA is measured using MicroBeta TriLux counter 
(PerkinElmer, Massachusetts, USA). The counts were expressed as a count per minute 
(cpm).
2.11 Assessment of mode of cell death
The effect of single and combination treatment on the mode of cell death was assessed 
using annexin V-PE apoptosis kit (Becton Dickinson, Oxford UK). Treated cells were 
washed twice with BPS and then resuspended in 50 pi annexin V-binding buffer per well. 
Cells were incubated with 4 pi of annexin V-PE and 4 pi of 7-Amino Actinomycin D 
(7ADD) in dark at room temperature for 15 minutes. Samples then analysed by flow 
cytometry (Epics XL Beckman-Coulter, High Wycombe, UK).
2.12 Western blot analysis
2.12.1 Cell lysate preparation
Following treatment cells were washed with PBS and lysed with Radiolmmuno 
Precipitation Assay (RIPA) buffer containing protease and phosphatase inhibitor cocktail
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and ethylenediaminetetraacetic acid (EDTA) (Perbio Science, UK). Cells were then 
centrifuged at 13000 rpm for 5 minutes and supernatant collected and stored at -20°C. 
The protein concentration was determined by BCA protein assay kit (Perbio Science, 
UK) as per the manufacturer’s instruction.
2.12.2 Preparation of samples
Twenty five microgram of protein is added to 2.5pi of sample buffer and Ipl of reducing 
agent and incubated at 70°C for 10 minutes then loaded on Bis Tris gel (all from 
Invitrogen, Paisley, UK).
2.12.3 Transfer and detection
Proteins were transferred from within the gel onto a PVDF membrane and blocked with 
50 ml blocking buffer (PBS, 0.1% Tween 20 and 5% Bovine serum albumin). The 
membrane was incubated with the primary antibody against cleaved poly (ADP-ribose) 
polymerase (PARP) (1:1000), beta actin (1:5000) (all from Abeam, UK) and primary 
antibody against aquaporin 3 (1:1000) (Santa Cruze, USA) over night at 4°C. Membrane 
then incubated with secondary antibody (peroxidase labelled antirabbit antibody) and 
detected by the enhanced chemiluminescent detection method (GE healthcare, UK).
2.13 Cysteine-Aspartic acid Proteases 3 (Caspase 3) assay 
The EnzChek ® caspase-3 assay kit #2 (Invitrogen, Paisley, UK) was used to detect 
apoptosis by assaying for the increase in caspase-3 activity following the manufacturers 
instruction. In summary, cells were lysed using lysis buffer and freeze thaw cycle. Cell
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lysate was then incubated with 2Xsubstrate working solution (5mM Z-DEVD-RllO 
substrate and 5X reaction buffer, IM DTT and dH20) in dark for 30 minutes at room 
temperature. IX cell lysis buffer and samples incubated with Ac-DEVD-CHO inhibitor 
was used as a control. Fluorescence intensity was measured at excitation/emission ~ 496- 
520 nm.
2.14 cDNA microarray analysis for gene expression profile
Total RNA was isolated using RNeasy ® Plus mini kit (Qiagen, UK) according to the 
manufacturers’ protocol. cRNA for each sample was synthesized by using One-Color 
Low RNA Input Linear Amplification Kit PLUS (Invitrogen, Paisley, UK) and was 
labelled with Cy3 by direct labelling method. Following purification by RNeasy ® Plus 
mini kit, cRNA was fragmented by incubation in the fragmentation buffer at 60°C for 30 
minute. The fragmented and labelled cRNA was hybridized to the human 4x44 K cDNA 
chip (Invitrogen, Paisley, UK). After washing, the slides were scanned using agilent’s 
microarray scanner (Agilent, Cheshire, UK) and gene expression profiles were analysed 
by Genespring GX 7.3.1 software. One way analysis of variance test was used to extract 
significantly up or down regulated genes in the treated groups compared to the untreated 
cells. Genes with at least 2 fold changes in expression was included in the analysis.
2.15 Inhibition of aquaporins (AQPs) by mercuric chloride (HgCb)
Mercuric chloride is a well known inhibitor of AQPs which has routinely been used to 
test AQP function in animal and plants cells. It has high affinity to the reactive thiol 
moiety of cysteine residues within the AQPs causing covalent changes leading to
84
inhibition of water transport function (Savage and Stroud, 2007). In order to ascertain the 
effect of HgCh on prostate cancer cell survival, DU145 and PC-3 cells were treated with 
various concentration of HgCh (range from 0.156-20 mM) for 15 minutes and survival 
was assessed using the MTS assay. Prostate cancer cells were treated in the presence or 
absence of the aquaporin inhibitor mercuric chloride (HgCh) (Sigma-Aldrich, Pool, UK) 
at a concentration of 0.075 mM for 15 minutes. Cells were washed twice and cooled to - 
10°C for 10 minutes. Cell survival was compared to the untreated cells, cells treated in 
the absence of HgCh and cells treated with HgCL without freezing using the MTS assay 
(Promega, USA).
2.16 Small interference RNA (siRNA) synthesis
RNA duplex of 19 nucleotides specific for human AQP3 sequence was synthesized by 
Thermo Scientific Dharmacon (Lafayette, CO, USA). GN-TARGETj^/w^ siRNA smart 
pool is mixture of four siRNAs targeting AQP3 which attains the maximum target gene 
silencing and reduces the overall number of off-targets. Sense strand is modified to 
prevent the uptake by RNA-induced silencing complex (RISC) and antisense strand is 
modified to minimize off-target acitivity. ON-TARGETp/wj^ negative control which has 
minimal targeting of known genes in the human genome was used as a control siRNA. 
Target sequence (sense orientation)
GGAUCAAGCUGCCCAUCUA
CUUCUUGGGUGCUGGAAUA
UAUGAUCAAUGGCUUCUUU
GAGCAGAUCUGAGUGGGCA
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2.17 Transfection of human prostate cancer cells with siRNA
PC-3 and DU 145 cells were diluted in antibiotic free complete medium to a plating 
density of 1.0x10^ cells/ml and 500pl of cells was seeded in each well of a 24 well plate. 
Cells were incubated at 37°C with 5% CO2 overnight. SiRNA transfection was carried 
out using DharmaFECT 2 transfection reagent (Dharmacon, CO, USA) following the 
manufacturer’s protocol. A stock solution of 2pM of the AQP3 siRNA was prepared, 
aliquoted and stored at -20°C. Test siRNA was diluted 1:1 in serum free RPMI medium. 
In parallel, 3 pi of DharmaFECT 2 reagent was added to 197 pi of serum free medium. 
The two mixtures were combined and incubated for 20 minutes at room temperature for 
complex formation. After the addition of a sufficient antibiotic free complete medium 
(final concentration of AQP3 siRNA is lOOnM), 500pl of the mixture was added to each 
well and cells incubated at 37°C with 5% CO2 . Control siRNA was prepared in a similar 
way to AQP3 siRNA. Mock transfected cells are those cells which were treated with 
DharmaFECT 2 reagent only. Cell survival was assessed daily using the MTS survival 
assay and compared to the untreated cells. Cells were washed and harvested after 48 
hours for mRNA analysis and at 96 hours for protein analysis.
2.18 Cell treatment after siRNA transfection
AQP3 specific gene silencing was confirmed by 3 independent Western blot and RT- 
qPCR experiments. Untreated cells, cells treated with control siRNA and mock 
transfected cells were used as a control. Transfected cells were harvested and cooled to - 
10°C. Cell survival was assessed using the MTS assay and compared to the untreated 
cells, cells treated at -10°C without transfection and cells transfected with control siRNA.
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2.19 Immunofluorescence staining of prostate cancer cells 
PC-3 and DU 145 cells were cooled to -10°C according to freezing protocol and 
recovered for 24 hour in 37°C and 5% CO2 incubator. Cells were washed in PBS, fixed 
with 10% formalin for 10 minutes and blocked with blocking buffer at room temperature 
for 30 minutes. Cells were then incubated with the primary antibody against AQP3 
(1:200 dilution) overnight at 4°C. After washing cells were incubated with the secondary 
Ab (Donkey anti-goat IgG Antibody, Alexa Fluor ® 488 Conjugated, Invitrogen, Paisley 
UK) at room temperature for 1 hour. Negative control included cells incubated with 
dilution buffer without the addition of primary antibody to determen the levels of 
nonspecific fluorescence. Immunofluorescence was visualized using Eclipse TE2000-S 
microscope (Nikon Japan).
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Chapter 3
Prostate cancer cell 
sensitivity to freezing injury 
using a novel in vitro 
cryotherapy model
3.1 Introduction
Freezing can be used both to destroy tissue and to preserve it. Surgeons using 
cryotherapy in their clinical practice are more concerned about increasing cell death in 
the targeted tissue. Therefore, the aim of prostate cryotherapy is to destroy neoplastic 
tissue and preserve vital structures around the prostate such as the rectum and urinary 
bladder. As a result, a precise freezing process is required to effectively destroy tumour 
tissue and preserve the surrounding structures. The freeze-thaw cycle induce thermal 
gradient in the treated tissue. The area next to the freezing probe is exposed to the most 
destructive freezing temperature whilst the peripheral tissue is being exposed to the 
highest temperature reaching 0°C at the frozen/un-frozen interface (Baust et al. 2004). 
Therefore, cells at the periphery of the ice ball experience a partial freezing injury and 
may survive following cryotherapy (Izawa et ah 2006) (Chin et a l 2003). It is technically 
challenging to achieve a lethal critical temperature in all the prostatic tissue, especially at 
the periphery of the ice ball, as this will result in a high percentage of complication. 
Therefore complete ablation of prostate cancer tissue some times fails and results in local 
disease recurrence. In vivo studies identified two well demarcated zones surrounding the 
cryo probe: an internal zone of coagulative necrosis (kill zone) and a peripheral zone of 
haemorrhage and metaplasia (damage zone) (Larson et al. 2000).
The critical temperature that has to be achieved during cryotherapy for the effective 
ablation of the tumour tissue is not well characterised. Early reports demonstrated a 
temperature of -20°C or less is essential to kill cells (Cooper 1964) (Dow and 
Waterhouse 1970). More recently, studies showed that temperature less than -40°C is
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required for complete destruction prostate tumour tissue (Gage and Baust 1998) 
(Tatsutani et al. 1996). Few reports demonstrated that prostate cancer cells are able to 
survive following exposure to a temperature of -80°C in vitro (Hollister et al. 1998). In 
vivo studies showed that the critical temperature required to achieve uniform coagulative 
necrosis was -41.4°C in the double freeze cycle (Larson et al. 2000). The sensitivity of 
prostate cancer cells to cryotherapy may be greatly enhanced in vivo due to the 
microcirculatory failure that follows thawing and results into more tissue damage 
(Hoffinann and Bischof 2002).
Recent clinical case series reported biochemical disease free survival rates ranging 
between 20-70% for the salvage treatment (Ismail, Pandha and Davies 2008) and 40-90% 
following primary cryotherapy (Mouraviev and Polascik 2006). High-risk group (those 
with two or more unfavourable risk factors from PSA level of > lOng/ml, a Gleason score 
of > 7 and clinical stage of > T2b) (Blasko et al. 2000) show the least favourable outcome 
and most patients in this group will have biochemical recurrence at their last follow up 
(Ismail et al. 2007). The causes of disease recurrence could be due to undetected 
subclinical systemic disease, persistent local cancer progression as a result of failure of 
cryotherapy to ablate all the tumour tissue or involvement of the seminal vesicles which 
are not routinely treated (Pisters et al. 1997).
The mechanism of freezing injury has been studied extensively at the cellular level since 
the early work of Lovelock (1953) who demonstrated the damaging effect of 
hyperosmolarity during freezing on the red blood cells viability. The freeze-thaw cycle
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can be divided into 2 main phases, the freezing phase and the thawing phase. During the 
freezing phase the end result is the formation of ice in the extracellular and intracellular 
environment. Ice crystals in the extracellular space will remove water from the solution 
leading to hyperosmolar status in the unfrozen section. The osmotic pressure across the 
plasma membrane will increase driving water out of the cell into the extracellular space 
in an attempt to equilibrate the osmotic pressure on both sides of the plasma membrane. 
The rate of osmotic equilibrium depends on the rate of cooling and the permeability of 
the plasma membrane to water (Mazur 1970). If the slow cooling rate is maintained and 
the cells were highly permeable to water, they will remain in the osmotic equilibrium, the 
cytoplasm will be more concentrated and the cells will suffer from dehydration. At a 
critical point, the solutes start to precipitate and the cell will suffer from a chemical 
damage which was described as “the solution effect” (Mazur 1970).
In an ideal freezing environment, these conditions are difficult to maintain. Once the 
cooling rate is increased, ice will start to form in the cytoplasm. Various theories of 
intracellular ice formation were described. It has been postulated that the plasma 
membrane contains water pores through which ice crystal will propagate into the cell 
(Mazur, Leibo and Chu 1972). Another theory described an electrical transient which 
form at the frozen/unfrozen interface. These electrical transient will reach a critical level 
leading to plasma membrane damage and the spread of the ice crystals into the cell 
(Steponkus et ah 1985). Muldrew and McGann (1988, 1990 and 1994) demonstrated that 
the plasma membrane is damaged by the osmotic stress leading to intracellular ice
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formation and further damage to the plasma membrane. Intracellular ice will further 
increase the state of hyperosmolarity and lead to plasma membrane disruption.
During the thaw phase, small ice crystal will melt forming larger crystals, a phenomenon 
known as recrystallization which is more prominent during slow thawing (Gage and 
Baust 1998). Slow thawing has been associated with maximum cell death due to longer 
exposure to the solution effect and large ice crystal formation which exert a mechanical 
damage on the cells (Mazur 1984). The maximum ice crystals size can be achieved in the 
temperature range between -20 to -25°C (Gage and Baust 1998). Vascular stasis and 
tissue ischemia represents a major mechanism of cell death in the frozen tissues (Bischof 
et al. 1997). During freezing, the microvasculature will undergo vasoconstriction leading 
to tissue ischemia. As the tissue thaws, there will be vasodilatation, endothelial damage 
and increased vascular permeability leading to tissue oedema (Whittaker 1984). 
Endothelial damage will encourage platelet aggregation and microthrombi formation and 
4 hours after the cold injury most of the small blood vessels in the treated tissue are 
completely occluded by thrombosis (Gage and Baust 1998).
Apoptosis or gene regulated cell death has been reported as a mechanism of cell death 
following cryoinjury (Baust et al. 2004) (Hollister et al. 1998). Apoptotic cells were 
identified in the peripheral zone of the cryoinjury where complete ablation of prostate 
cancer was difficult to achieve (Baust and Gage 2005). Hollister et al. (1998) 
demonstrated a non random DNA degradation in prostate cancer cells treated to a 
temperature range of -5 and -15°C a pattern commonly associated with apoptosis. The
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use of an apoptotic inhibitor improved cell viability and a significant percentage of cells 
survived freezing. Baust et a l (2004) investigated the involvement of apoptosis in 
prostate cancer cell death following freezing injury. They demonstrated that the 
immediate loss of cell viability following freezing injury was mainly due to necrosis 
whereas the continued loss of viability 24 hours following freezing resulted from 
apoptosis. There was an increase in caspase 3 and 9 activity which was correlated with 
the increase in cell death in the first 24 hour post freezing.
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3.2 Study objectives
• To establish and examine the robustness and reproducibility of an in vitro 
cryotherapy model.
• To investigate the viability of various human prostate cancer cells upon exposure 
to freezing temperatures.
• To examine the mechanism of prostate cancer cell death following exposure to 
freezing temperatures.
• To investigate the role of apoptosis in cell death induced by cryoinjury.
• To investigated the molecular effect of cryotherapy on human prostate cancer 
cells.
• To evaluate the effect of combined treatment of cryotherapy and tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) on human prostate cancer cell 
viability.
3.3 Study design
PC-3 and DU 145 human prostate cancer cells were treated by cryotherapy as described in 
materials and methods. Cell density of 1x10  ^ cell/ml was placed in a microtube and 
treated by freezing to various target temperatures. Cells were then placed in a 96 well 
plate in triplicate and incubated at 37°C with 5% CO^ for 24 hours. Human recombinant 
TRAIL (Invitrogen, Paisley, UK) was diluted in water to a final concentration of 
500ng/ml. Cells were treated with TRAIL, cryotherapy or combination of both 
treatments. Three different protocols were followed for the combination treatment (Table 
3.1). Cell survival following the various treatments was assessed quantitatively using the
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MTS survival assay at 6 and 24 hour post thawing. Annexin V-PE assay was used to 
assess the mode of cell death after 2, 6 and 24 hour recovery period following each 
treatment. To assess the effect of the combination treatment on the caspase 3 activity, The 
EnzChek ® caspase-3 assay kit #2 was used following the manufacturer protocol. Cells 
were harvested 2, 8 and 24 hour post thaw, lysed using lysis buffer and equal amounts of 
protein was extracted and used to assess the caspase 3 activity.
Table 3.1 Study groups
Group Description
Cryo.
Cells treated with cryotherapy alone 
following the freezing protocol.
Cryo + TRAIL (24H)
TRAIL added straight after freezing and 
left for 24 hours (sequential treatment)
TRAIL + cryo (24H)
TRAIL added to the cells along with fresh 
culture medium just before freezing and 
cells were cooled as described. Cells left in 
TRAIL containing medium for 24 hours 
(concomitant treatment)
TRAIL(24) + cryo
Cells were pretreated with TRAIL for 24 
hours, washed and then cooled in fresh 
culture medium.
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3.4 Results
3.4.1 Validation of the cryotherapy model
3.4.1.1 Variation of target temperature
During clinical cryotherapy, the thermal history within the prostate is variable depending 
on the distance from the centre of the cryoprobe and the calibre of cryoprobe used (Smith 
et al. 1999). In the established model, thermal history during clinical cryotherapy was 
reproduced in an in vitro setting. The apparatus allows cells to be treated at a range of 
temperature between 0 and -40°C and held at specific temperatures for as long as 
required. The sensitive tip of the thermocouple is placed at the centre of the cell pellet to 
provide real time monitoring of the sample temperature. Cells were treated as described 
and target temperature was monitored for 10 minutes by recording one representative 
temperature every minute. The final target temperature was strictly maintained with very 
little variation (Figure 3.1).
3.4.1.2 Reproducibility
To evaluate reproducibility of the cryotherapy model, prostate cancer cells were frozen to 
-10°C and thawed at 55°C to room temperature, recovered in complete medium with 10% 
FCS for 1 hour and viability assessed using the MTS survival assay. The experiment was 
conducted on 3 consecutive days in triplicate and the same cell group was used in each 
experiment. During treatment, 3 temperature readings were recorded every minute (10, 
30 and 50 seconds pass each minute). Temperature reading was converted from Celsius 
to Kelvin, the mean (p), and standard deviation (SD) between triplicates was calculated.
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Variation in the temperature during each treatment was calculated by measuring the 
coefficient of variation (CV) using the following formula;
(Mean of the standard deviations of the temperature recorded each minute/ grand 
mean of the temperatures) x 100.
We pre-determined the acceptance CV for reproducibility to be less than to 5% for the 
intra-experiment CV and less than 10% for the inter-experiment CV (Reed, Lynn and 
Meade 2002). The average intra-experiment CV was 0.148% and inter-experiment CV 
0.089% (Table 3.2) indicating that the variation of temperature between experiments was 
very minimal and cells were exposed precisely to the target temperature throughout the 
treatment time with very minimal variation and reproducible results. This is shown 
graphically in (Figure 3.1). To test whether this minimal variation in the freezing 
temperature will result in any variation in cell survival, cell viability was assessed 
following treatment at -10°C for 5 minutes. The CV of survival percentage between the 
samples treated on each day was 5.27% and the CV of survival between the samples 
treated at different days was 8% indicating that the variation of temperature which was 
noticed during the treatment has insignificant effect on cell survival (P=0.06). The data 
confirm that the established model is robust and accurately reproduces the precise 
conditions of the current clinical cryotherapy.
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Figure 3.1 Box blots of temperature variation at each target temperature. Cells were 
treated as described and target temperature was monitored for 10 minutes by recording 
one representative temperature every minute. It shows that cells are exposed to the 
defined freezing temperature for the whole treatment time.
Day 1 Day 2 Day 3
SD c v % SD CV% SD CV%
Expl 262.54 0.40 0.15 263.25 0.29 0.11 263.18 0.43 0.16
Exp2 262.78 0.55 0.21 262.77 0.23 0.08 262.85 0.42 0.15
Exp3 262.64 0.38 0.14 262.95 0.31 0.12 262.75 0.45 0.17
Average intra-experiment SD = 0.389573
Average intra-experiment CV= 0.148%
SD o f the means = 0.23451989
Grand mean = 262.862156 Kelvin
Inter-experiment CV = 0.089 %
Table 3.2 The mean of temperature reading (Kelvin) recorded in 3 separate experiments 
conducted each day for 3 consecutive days. The average of intra and inter-experiment CV 
was less than 5% which indicates that the model established is reproducible.
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3.4.2 The effect of single freeze-thaw cycle on human prostate cell survival
Two human prostate cancer cell lines were used to evaluate the effects of croytherapy on 
cell survival. Cells were treated at a temperature range from 0 to -  40°C for 10 minutes. 
All the thermal parameters were fixed apart form the target temperature. Cell viability 
was assessed using the MTS survival assay. Figure 3.2 show PC-3 and DU 145 cell 
responses to a single freeze-thaw cycle. For both cell lines, a significant decrease in 
survival was noticed at all target temperature except for 0 degree (P < 0.001). Compared 
to PC-3 cells, DU 145 was slightly more resistant to freezing injury. The difference in cell 
survival between the 2 cell lines was statistically insignificant. Both cell lines were fully 
recovered when returned to normal culture conditions 5 days following treatment at all 
temperatures except -  40°C (data not shown).
3.4.3 PC-3 cell survival kinetics after exposure to freezing temperature 
PC-3 cells were treated at -10°C with and without freezing medium (complete culture 
medium with 10% DMSO). Cell survival was then compared between 3 groups, PC-3 
with freezing medium (PC-3 FM), PC-3 in fresh culture medium (PC-3 -10) and PC-3 
cells which survived the first freeze-thaw cycle at -10°C and recovered at 37°C for 24 
hour (PC-3 double freeze). Cells treated in the presence of freezing medium were 
minimally affected by the freezing temperature and were able to recover 4 days after 
treatment. PC-3 cells treated without freezing medium showed a significant decrease in 
cell viability to 20% at day one after treatment. Nevertheless, cells were able to recover 
to approximately 90% four days after treatment. Even though cells which survived the 
first freeze-thaw cycle exhibited similar pattern to the fresh PC-3 cells in the first 24
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hour, cultures were unable to recover and viability continued to decrease over the 
following few days (Figure 3.4).
The molecular changes in response to freezing were analysed in cells treated in freezing 
medium, cells frozen to -10°C and cells frozen to -10°C twice (double freeze). RNA was 
extracted from treatment groups at day 4 and gene expression assessed using gene 
microarray analysis. Thirty-five genes were differentially expressed at mRNA level 
between cells treated at -10°C and cells exposed to double freeze-thaw cycles. Among 
those genes, 28 were up regulated and 7 down regulated (Table 3.2). All alterations in 
gene expression was significant (P<0.05). Altered genes were sorted on their biological 
function which showed that cryotherapy regulates important genes involved in cell cycle 
regulation, cell death, cell communication and signal transduction. Double freeze-thaw 
resulted in up-regulation PTGS2, CEBBP, HMOXl which are involved
in inhibition of cell cycle progression (DuBois et al. 1996) (Timchenko et a l 1997) (Liu 
et a l 2004b) (Schwarze et a l 2002), whereas, CDC2, P73, AKTl and IGFl were down 
regulated. IL-6 is a pro and anti-inflammatory cytokine which regulates growth and 
differentiation of various types of cancers (Lou et a l 2000). Tenfold inerease in IL-6 
expression in the double freeze group was observed compared to the single freeze group. 
Results were confirmed by RT-qPCR (Figure 3.5). Full analysis of the molecular features 
of cryotreated prostate cancer cells by gene microarray will be discussed in chapter 6 in 
details.
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Figure 3.2 PC-3 and DU 145 cell survival following freezing at various freezing 
temperatures ranging from 0 to - 40°C. There was a significant reduction in cell survival 
at all treatment temperatures.
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Figure 3.3 DU 145 cells treated at -10°C for 10 minutes and thawed at 55°C to room 
temperature. Most of the cells are disrupted by the freezing process. Cells which survived 
freezing process appear swollen as a result of the solute effect and some show 
intracellular ice crystals.
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Figure 3.4 (A) PC-3 cell survival by the MTS assay following exposure to -10°C for 10 
minutes. PC-3 with and without freezing medium were able to recover to normal numbers 
4 days after returning to culture. Cells which survived the first freeze-thaw cycle were 
more sensitive to the second freezing injury and survival continued to drop after 
treatment. (B) Annexin V-PE staining of PC-3 cells following freezing, the main mode of 
cell death was mainly via necrosis.
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Table 3.3 Differentially expressed genes in PC-3 cells treated with freezing at -10°C. 
gene expression in 3 groups were analysed, cells treated in freezing medium (PC-3 FM), 
cells treated in fresh complete medium (PC-3 (-10)) and cells which survived the first 
freeze-thaw cycle at -10°C (PC-3 double freeze). Numbers represent fold change in gene 
expression compared to the untreated cells.
Group Gene Genbank PC-3
(FM)
PC-3
(-10)
PC-3
Double
freeze
Up-
regulated
genes
Interleukin 6 (interferon, beta 
2) (IL-6)
NM_000600 51.36 24.9 235.1
Prostaglandin-endoperoxide 
synthase 2 (prostaglandin 
G/H synthase and 
cyclooxygenase) (PTGS2)
NM 000963 9.902 8.161 56.14
Cyclin-dependent kinase 
inhibitor lA  (p2 lWAFi/cipi^
NM_000389 6.692 1.7 7.973
Heme oxygenase (decycling) 
l(HMOXl)
NM_002133 7.452 2.78 11.69
CCA AT/enhancer binding 
protein (CEBBP)
NM_005194 5.783 2.404 7.782
Down-
regulated
genes
Cell division cycle 2, G1 to S 
and G2 to M (CDC2)
NM_001786 0.323 0.412 0.479
Cyclin-dependent kinase 2 
(CDK2)
NM_001798 0.4 0.193 0.449
V-akt murine thymoma viral 
oncogene homolog 1, 
(AKTl)
NM_005163 0.48 0.367 0.347
Tumor protein (p73) NM 005427 0.24 0.0537 0.021
Insulin-like growth factor 1 
(somatomedin C) (IGFl)
NM_000618 0.237 1.15 0.0862
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Figure 3.5 IL-6 expression levels by RT-qPCR in PC-3 cells cooled to -10°C with and 
without freezing medium and cells exposed to double freeze. There was 200 times 
increase in mRNA levels on double freeze compared to the untreated cells. IL-6 may 
represent a novel marker for successful cryotherapy.
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3.4.4 The effect of TRAIL on human prostate cancer cells 
TRAIL is a member of TNT superfamily and a potent proapoptotic factor which leads to 
activation of the initiator caspase, caspase-8. Previous reports have indicted differential 
sensitivity to TRAIL by prostate cancer cell lines (Hesry et al. 2006) (Nesterov et al. 
2001). To investigate this hypothesis both cell lines were treated with various 
concentration of TRAIL. Before treatment, cells were seeded in a 96 well plate at a 
density of 1x10“^ per ml and left to grow into confluent monolayer. TRAIL was added in 
graded final concentration ranging from 0.07-2.25 pg/ml. After 24 hour cell viability was 
assessed using the MTS assay. Both cell lines were resistant to high concentration of 
TRAIL. PC-3 cells were more sensitive than DU145 and 2.25pg/ml resulted in 25% cell 
death (figure 3.6). Similar result was demonstrated in other reports (Van Ophoven et al. 
1999).
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Figure 3.6 TRAIL induced cytotoxicity on human prostate cancer cells. Cells were 
treated with various concentrations of TRAIL over 24 hour. Both cell lines were resistant 
to high concentration of TRAIL.
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3.4.5 TRAIL treatment increases the sensitivity of PC-3 cells to cryotherapy 
Gene microarray analysis of cells resistant to cryotherapy showed upregulation of TNF 
receptor superfamily, caspase 3 and 8 (full microarray data will be discussed in chapter 
6). The effect of TRAIL as a sensitising agent to enhance the effects of cryotherapy on 
human prostate cancer cells (PC-3 and DU 145) survival was investigated in vitro. Three 
different protocols are followed as explained in study design. PC-3 cells were treated at 0, 
-10, -20, -30, -40 °C for 10 minutes and thawed at 55 °C water bath to room temperature. 
Freezing at -10, -20, -30 and -40°C resulted in 79, 88, 92 and 95% loss of cell viability 
respectively. Concomitant use of TRAIL and cryotherapy (TRAIL + cryo (24)) resulted 
in 100% loss of cell viability at -10, -20, -30 and -40°C (P<0.001). When cells were 
exposed to TRAIL following freezing (cryo + TRAIL (24)), significant loss of viability 
was observed at -10°C (P<0.001) and to a lesser extent at -20°C (P<0.01) (Figure 3.7). 
There was no statistically significant difference in cell survival using both protocols 
except for treatment at 0°C where concomitant use was more effective than sequential 
use (P<0.001).
DU 145 cells were more resistant to TRAIL than PC-3 cells. Similar trends were 
observed; however the combined treatment never resulted in complete loss of viability at 
-10 and -20°C (Figure 3.8). The effect of combination treatment of TRAIL and 
cryotherapy on cell survival was assessed by calculating combination index (Cl) values 
using CalcuSyn software (Biosoft, Cambridge, UK) that uses the median effect principle. 
The Cl provides a quantitative measure of the degree of interaction between two or more 
agents (Chou and Talalay 1984). A Cl of 1 denotes an additive interaction, >1 denotes
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antagonism, and <1 denotes synergy. Experiments were completed using a range of 
temperatures in a non-constant ratio design. Figure 3.10 shows that the combination 
treatment was synergistic at all treatment temperature except 0°C.
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Figure 3.7 Effects of combined treatment of TRAIL and cryotherapy on PC-3 cell 
survival. Percent survival was assessed by the MTS assay and was calculated based upon 
comparison to the untreated cells. Cryo+TRAIL (24) represent a sequential use of 
cryotherapy then TRAIL while TRAIL+cryo (24) represent a concomitant use of TRAIL 
and cryotherapy. The graph shows that cell death was increased after exposure to 
concomitant treatment of TRAIL and cryotherapy (P<0.001). The concomitant use of 
TRAIL and cryotherapy was more effective in killing PC-3 cells than the sequential use 
and there was 100% cell death at temperature < -20°C.
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Figure 3.8 Effects of combined treatment of TRAIL and cryotherapy on DU 145 cell 
survival. Percent survival was assessed by the MTS assay and was calculated based upon 
comparison to the untreated cells. Despite DU 145 cells were more resistant to TRAIL 
than PC-3 cells, nevertheless, similar trends to PC-3 cells were observed. The combined 
treatment resulted in significant reduction in cell viability in cells cooled to -10°C 
(P<0.001) and insignificant decrease in cell viability in cells cooled to -20, -30 and -40°C 
(f>0.05).
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Figure 3.9 effects of sequential treatment of TRAIL for 24 hours then cryotherapy on PC- 
3 cells survival. Pre-treatment with TRAIL prior to freezing was not successful in 
sensitising PC-3 cells to cryoinjury (P>0.05).
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Cl For experimental values 
Cryo TRAIL Fa Cl 
(°C) (pg/ml)
1=0 0.5 0.243 1.409
2=-10 0.5 
3=-20 0.5 
4=-30 0.5 
5=-40 0.5
0.853 0.704 
0.95 0.659
0.992 0.417 
0.999 0.227
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0.2 ^  0^4 , r^O.6 0.8
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Figure 3.10 Cl plot for the concomitant use of TRAIL and cryotherapy, data represent the 
algebraic estimates of the Cl (FI.96 SD) for TRAIL (0.5 pg/ml) and cryotherapy. 
Synergism (Cl, 0.3-0.7) was seen at temperature range between -10 and -40°C. Data are 
representative of three repeats.
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Figure 3.11 PC-3 cell (A) following treatments with TRAIL (B), cryotherapy at -10°C (C) and 
concomitant treatment o f TRAIL and cryotherapy (D). TRAIL resulted in minimal cell death. 
Cryotherapy alone resulted in significant loss o f  cell survival, nevertheless, cells recovered 
and started to grow 24 hours after treatment. After the concomitant treatment o f  TRAIL and 
cryotherapy all cells were detached and floating in the culture medium and no viable cells 
could be identified.
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3.4.6 Assessment of apoptosis after TRAIL/cryo combination treatment 
To assess the mechanism of enhanced cell death resulting from combination treatment, 
the activation of caspase-3 following treatments was evaluated. Caspase-3 is one of the 
executioner caspases which is primarily responsible for cleavage of a wide range of 
proteins including PARP and a-Fodrin in the downstream events during apoptosis 
(Boulares et a l 1999). Caspase-3 activity started to increase 2 hours following exposure 
to TRAIL and peaked at 8 hours to reach more than 5 fold compared to the control. 
Concomitant treatment of TRAIL and cryotherapy resulted in a reduction in caspase-3 
activation compared to TRAIL treatment alone, with a maximum effect two hours after 
treatment. Cells exposed to cryotherapy alone demonstrated a significant reduction in the 
caspase-3 activity over the experimental time compared to TRAIL and concomitant 
treatment of TRAI and cryotherapy. Overall, caspase-3 expression was markedly reduced 
at 24 hours post- treatment in all groups (Figure 3.12).
To determine whether the synergistic effect of the concomitant treatment of TRAIL and 
cryotherapy is mainly due to increase apoptosis. Western blot analysis was used to 
examine the cleaved PARP fragment which is the down stream product of caspase-3. 
Four groups of cells were compared; untreated, cells treated with TRAIL, cells treated 
with cryotherapy and cells treated with TRAIL and cryotherapy. Cleaved PARP was not 
detected in the untreated cells. TRAIL treatment resulted in the maximum production of 
cleaved PARP compared to the other groups. After 24 hours of the treatment a strong 
signal is still detectable in the TRAIL but not in the combination treatment group. In the
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cryotherapy group the band was still detectable 24 hours after treatment though less 
intense (Figure 3.13)
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Figure 3.12 Comparison of caspase 3 activity following cryotherapy (cryo), TRAIL and 
concomitant treatment of TRAIL and cryotherapy (combo) at different time intervals. 
TRAIL resulted in marked increase in caspase 3 activity which is peaked after 8 hours. 
The increase in caspase 3 activity after TRAIL treatment was statistically significant at 
all time points compared to the other groups (P<0.001). Cryotherapy and concomitant 
treatment of TRAIL and cryotherapy resulted in a lesser degree of caspase 3 activation 
mainly 2 hours after treatment before the level start to decrease after 24 hours to 
insignificant levels compared to the control (P>0.05). Cryotherapy resulted in inhibition 
of caspase 3 activation when it was combined with TRAIL treatment and there was no 
statistically significant change in caspase 3 activity at 8 and 24 hours after cryotherapy 
and concomitant treatment (P>0.05).
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Figure 3.13 Western blot analysis of cleaved PARP. Cells were exposed to TRAIL, 
cryotherapy or concomitant treatment of TRAIL and cryotherapy. Cells were harvested at 
6 and 24 hour and protein was extracted. Cleaved PARP levels were assessed using 
Western blot analysis. Cleaved PARP was not detected in the untreated cells. Levels were 
markedly increased 6 hours after TRAIL treatment and after 24 hours a strong signal was 
still detectable. Similar trend was noticed after cryotherapy but to a lesser extent. 
Combination treatment resulted initially in a strong signal before it fades away 24 hours 
after treatment. [UT=untreated cells, T=TRAIL, Cr=Cryotherapy and Co=combination 
treatment].
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3 .4 .7  M o d e  o f  c e l l  d e a t h  a f t e r  c o m b i n a t i o n  t r e a t m e n t
To identify the mechanism of cell death following combination treatment, PC-3 cells 
were treated with cryotherapy, TRAIL or combination of TRAIL and cryotherapy. 
Apoptotic cells were identified using annexin V-PE staining 2 and 24 hour after 
treatment. Cells stained positive for annexin V regarded as apoptotic and cells stained 
positive for 7 AAD or double stained regarded as necrotic. The main mode of cell death 
was though necrosis which was more significant following combination treatment. There 
was minimal change in the number of apoptotic cells 24 hour after treatment. The 
percentage of apoptotic cells detected after cryotherapy was higher compared to the other 
treatments but this was statistically insignificant. There was a significant increase in cell 
death over time and more than 85% of cells were dead 24 hour following combination 
treatment (Figure 3.14).
114
(A)
(B)
1
o
o tni
UT TRAIL COMBO
1 n
2 Hour
U n trea ted
Anusdn
Crynühexspy
TRAIL CRYO
Tem perature
24 Hour
TRAIL
Amadn
Co ndl> îna tio  n.
i
s  V iable cells 
3 apop to tic  cells 
■ D ead  cells
I n
: “1
■'1
1 | # v . i i - r -
-
' " ” ■”1 ■ ' """1 ........ . V.--' - •
r
■
fiiV ' :  '
^”■"1...- , IM11
Axtusdn
Figure 3.14 Mode of cell death in PC-3 cells assessed by annexin V-PE stain. (A) 
Percentage of cells death was measured 2 and 24 hours after various treatments. The 
main mode of cell death was through necrosis which was more significant following 
combination treatment. There was no increase in apoptosis after combination treatment. 
(B) Two parameter annexin/7ADD analysis of PC-3 cells 24 hour after various 
treatments. Viable cells stained negative for annexin and 7ADD (black dots). Cells 
stained positive for annexin V regarded as apoptotic (blue dots) and cells stained positive 
for 7 AAD or double stained regarded as necrotic (red dots).
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3.5 Discussion
Cryotherapy has been used as a local treatment for primary, locally advanced and 
mestastic tumour deposits. There is currently no way of accurately modelling the process 
of cryotherapy and cryoinjury in vitro, which in turn would help to study the molecular 
aspects of cryotherapy in cancer cells and identify possible synergistic agents. In this 
study the sensitivity of PC-3 and DU 145 prostate cancer cells to cryotherapy alone and in 
combination with TRAIL was investigated.
Clinical reports demonstrated that -40°C represent the ideal target temperature for a 
satisfactory prostate tissue ablation (Larson et ah 2000). It is therefore important to 
characterize the precise target temperature during clinical cryotherapy. The vascular 
injury which leads to ischemic necrosis has been implicated for increased sensitivity to 
cryotherapy in vivo. The limitation of these studies has been the lack of a representative 
model which simulates the clinical situation in order to design strategies to enhance the 
killing effect further.
In this study a novel in vitro cryotherapy model using Cryocare system™ which is used 
in the clinical practice was established. The model was robust and accurately reproduces 
the precise conditions of the current clinical cryotherapy. The apparatus allows cells to be 
treated at a range of temperature between 0 and -40°C and held at specific temperatures 
for as long as required. It was found PC-3 cells were slightly more sensitive to cryo­
injury compared to DU 145 cells; both cell lines survived low freezing temperature up to -
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40°C and a small proportion of resistant cells were evident and able to recover fully after 
treatment.
In an attempt to understand the behaviour of prostate cancer cells following exposure to 
sub-lethal freezing temperature, PC-3 cells were treated to -10°C (which represents the 
average temperature at the outer zone of the ice ball) and survival was assessed for 7 days 
after treatment. Cells treated in the presence and absences of freezing medium fully 
recoverd when returned to normal culture conditions. On the contrary, PC-3 cells which 
survived the first freeze-thaw cycle and recovered for 24 hour after treatment followed a 
different survival pattern after exposure to a second freeze-thaw cycle. After 7 days those 
cells failed to proliferate and viability continued to decline indicating that freezing may 
sensitize prostate cancer cells to a second freeze-thaw cycle. Gene expression profiling 
showed this was associated with up-regulation of genes which inhibit cell cycle 
progression. Interestingly IL-6 was up regulated following double freeze thaw cycle and, 
if expressed into urine after prostate cryotherapy, may represent a novel marker for 
successful double freeze. Further investigation in the role of IL-6 in cryoinjury in prostate 
cancer cells is necessary.
It was demonstrated that the principle mode of cell death after cryotherapy is by necrosis, 
in agreement with previous studies (Bischof et ah 1997). However, data also suggest that 
cells which initially escape necrotic death upon freezing may subsequently enter 
apoptosis, raising the possibility that combining an apoptosis-inducing agent with 
freezing could have a synergistic antitumour effect.
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Various studies investigated the role of apoptosis following freezing injury (Baust et ah 
2004) (Hollister et al. 1998) (Yang et al. 2003). It was demonstrated that prostate cancer 
cells exposed to temperature above -10°C die through apoptosis, whereas cells exposed to 
temperature below -15°C die through necrosis (Hollister et al. 1998). Apoptotic cells 
were also identified in the peripheral zone of the cryogenic lesion where complete 
ablation of prostate cancer was difficult to achieve (Baust and Gage 2005).
It is well known that prostate cancer cells can survive fi*eezing at -20°C (Klossner et al. 
2007). In prostate cryotherapy, it is technically difficult to achieve temperature lower 
than -20°C in all prostatic tissue as this may result in high percentage of complication. 
Therefore complete ablation of prostate cancer tissue some times fails and results in local 
disease recurrence. In an attempt to reduce the critical fi*eezing temperature and improve 
the outcome following prostate cryotherapy, several reports described the use of 
adjunctive therapy with cryotherapy in order to increase sensitivity of cancer cells to 
cryogenic injury and hence increase the efficacy of cryotherapy (Clarke et al. 2007) 
(Goel et al. 2007) (Clarke et al. 2004) (Clarke et al. 2001). The identification of apoptotic 
cells in the cryogenic lesion was the comer stone for the subsequent studies on the 
combined treatment. The use of chemotherapeutic agents prior to fi*eezing was reported 
to increase cell death following combination treatment (Clarke et al. 2004). TNF-a was 
also used to enhance cryoinjury in vivo (Goel et al. 2007) (Chao, He and Bischof 2004). 
TRAIL is an inducer of the extrinsic cell death pathway, and has previously been shown 
to kill prostate cancer cells (Nesterov et al. 2001). It emerged recently as a promising 
target for therapeutic intervention in cancer therapy (Wu, Ogawa and Kakehi 2004).
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Clarke et al (2007) investigated the effects of combination treatment of TRAIT, and 
cryotherapy on cell survival in vitro. They demonstrated that the synergistic effect of 
cryotherapy and TRAIL was primarily due to marked increase in apoptosis. They also 
demonstrated that TRAIL alone did not result in any activation of the apoptotic cascade.
We demonstrated that cells resistant to cryotherapy showed up regulation of TNF -a  
receptor superfamily, caspase 3 and caspase 8. Furthermore, cryotherapy down regulates 
AKT and upregulates phosphatase and tensin homology deleted on chromosome 10 
(PTEN) and BCL-2 associated x protein (Bax), which may enhance the sensitivity of 
prostate cells to TRAIL induced apoptosis (Yuan and Whang 2002) (Chen et a l 2001a). 
Therefore, the use of TRAIL seemed to be an appropriate therapeutic agent adjunctive to 
cryotherapy. Whilst DU 145 and PC3 cells are relatively insensitive to killing by TRAIL, 
it does nevertheless significantly increase apoptosis associated caspase activation and 
cleavage of the caspase target protein PARP. Despite this observation, a combination of 
TRAIL and freezing cells works synergistically with respect to cell killing. The high 
death rate following concomitant use of TRAIL and cryotherapy was mainly by necrosis. 
It seems likely in this case that TRAIL causes the rapid onset of apoptosis in cells that 
initially survive the fireezing event. One possible explanation of this phenomenon is the 
transition of apoptosis to necrosis which was referred to as secondary necrosis (Clarke et 
al 2004). Transcriptional changes upon freezing may underlie this mechanism, at least in 
part, as key anti-apoptotic genes are up regulated including BIRC4 and BIRC5. 
Furthermore, cryotherapy resulted in upregulation of BCL2, BCL2A1 and BCL2L2 
which negatively regulate apoptosis. Over all, microarray data confirm that cryotherapy
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alters the balance between the pro- and anti- apoptotic gene expression in favour of 
necrotic cells death.
3.6 Conclusion
In conclusion, data show that cryotherapy alone may fail to eradicate prostate cancer cells 
and combination with a sensitising agent may be needed to improve the long term clinical 
outcome. Targeted modulation of cell death signalling pathway could represent a new 
way to enhance cells death after freezing injury especially at the peripheral zone of ice 
ball. In this study we have demonstrated that combined treatment of TRAIL and 
cryotherapy represent a novel approach to increase the sensitivity to cryotherapy. As 
TRAIL is already under clinical evaluation as a cancer therapy, this combined approach 
may be feasible for locally advanced prostate cancer. Further research is necessary for 
better understanding of the molecular changes following combination treatment of 
TRAIL and cryotherapy.
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Chapter 4
Immune-regulatory effects of 
cryotherapy on human 
dendritic cells
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4.1 Introduction
4.1.1 Dendritic cells (DC)
Dendritic cells (DC) are bone marrow derived cells that are specialized in antigen 
processing and presentation. They play a central part in cellular immunity. They are 
located in the lymphoid and non lymphoid organs. Immature DC reside in the peripheral 
tissues sensing their microenvironment for antigens. They are highly endocytic with poor 
antigen presenting capacity. Upon maturation, DC undergo phenotypic and functional 
changes. They show increased expression of major histocompatibility complex (MHC), 
adhesion and costimulatory molecules (CD80 and CD86). In contrast, mature DC have 
increased antigen presenting capacity and are more capable of migration to local lymph 
nodes where they act as efficient antigen presenting cells (APC) and prime naïve antigen 
specific T cells (Banchereau and Steinman 1998). Moreover, mature DC secrete IL-12 
which stimulates Th cells differentiation into ThI effecter cells (Banchereau and 
Steinman 1998). DC activate NK cells and induce B cells differentiation (Ardavin, 
Amigorena and Reis e Sousa 2004).
DC maturation can be induced by different substances including LPS, bacteria and 
chemical allergen (Hulette, Ryan and Gerberick 2002). Both necrotic and apoptotic cells 
are able to trigger DC maturation (Megalli, Gursel and Veenema 1974) (Albert, Sauter 
and Bhardwaj 1998) (Ronchetti et al. 1999) (Rovere et al. 1998). Other studies have 
demonstrated that stressed tumour cells either by gamma irradiation or heat shock did not 
upregulate the expression of maturation markers on the surface of DC but they enhanced 
the ability of DC to elicit a long lasting immunity in vivo (Prasad et al. 2005). Den brok
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et al (2006) demonstrated that tumour debris created by radiofrequency and cryotherapy 
comprises an effective antigen source for local DC which was able to induce DC 
maturation and prime antigen specific immunity.
Immature DC internalize antigen through 2 distinct mechanisms, macropinocytosis which 
involves actin dependent formation of lamellipodia extensions and allows for continuous 
internalization of large volume of fluid (Falcone et a l 2006) and via manose receptors 
which deliver large numbers of antigens and provides some selectivity for non-self 
antigens (Sallusto et a l 1995). Once internalized, the antigens are transported to acidic 
endosomal compartment where they are processed and the resulting peptides form a 
complex with the newly synthesised MHC molecules which are expressed on the surface 
of DC (Thomas and Lipsky 1996). Simultaneously, they upregulate cell surface receptors 
that act as costimulatory receptors in T cell activation such as CD80 and CD86. Upon 
maturation, DC lose their ability to capture antigens and antigen processing capacity is 
diminished, this is associated with downregulation of MHC molecules. Mature DC 
upregulate CCR7 a chemokine receptor which make them more capable of migration to 
secondary lymphoid organs where they can prime naïve T cells via TCR and 
costimulatory molecules resulting in antigen specific immune response (Banchereau and 
Steinman 1998).
After they complete their antigen presenting function, DC are either removed by natural 
killer (NK) cells lysis or undergo apoptosis in the absence of appropriate stimulatory 
molecules like TNF-a and CD40 ligand (Ludewig et a l 1995) (Shah et a l 1986).
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4.1.2 DC and cancer
The key steps in developing anti cancer immune response is the presentation of tumour 
associated antigen (TAA) by APC, the recognition of this antigen by a peptide specific 
TCR and the expression of costimulatory molecules on the surface of APC (Satthapom 
and Eremin 2001). DC are the key APC which play an important role in antigen 
presentation in the tumour microenvironment (Huang et a l 1994). DC infiltrating the 
tumour microenvironment has been described in several human cancers and have been 
associated with increased survival. Coventry and Morton (2003) have analysed the CD la 
positive DC density in patients with primary breast cancer and its association with 
survival. They demonstrated that higher CD la DC density correlates with higher survival 
rate. Ambe et al. (1989) evaluated the prognostic value of tumour infiltrating DC in 
colorectal cancer patients. They demonstrated that increased number of DC located 
within the tumour is correlated with better prognosis. Similar findings were demonstrated 
in hepatocellular carcinoma (Cai et al. 2006), malignant melanoma (Ladanyi et al. 2007) 
and gastric carcinoma (Saito et al. 2007). There are limited numbers of reports of DC 
infiltrate in prostate cancer. Troy et al. (1998) evaluated DC populations in prostate 
cancer and adjacent normal tissue. DC were identified as CD45+, lin- and HLA-DR+ 
using double labelling. Activated DC were identified by CD83 and CMRF44 monoclonal 
antibodies. They demonstrated that the number of DC present in prostate cancer tissue 
represent only 9.4% of tumour infiltrating leukocyte and is less than that seen in normal 
tissue. Activated DC were found in small number in the tumour tissue and were absent in 
normal tissue. Langerhans cell (EC) distribution and HLA class-II molecules expression 
in prostate cancer specimens was evaluated (Bigotti, Coli and Castagnola 1991). EC were
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shown to be more prominent in low grade cancer and correlated directly to the expression 
of MHC class-II molecules. This may represent a good prognostic parameter in prostate
cancer.
4.1.3 DC and cancer immunotherapy
Tumour antigens are those antigens that are presented by the MHC I molecules on the 
surface of tumor cells. These antigens can sometimes be presented only by tumor cells 
and they are called tumor-specific antigens and result fi*om a tumor specific mutation. 
More common are antigens that are presented in the normal tissue and over expressed or 
aberrantly produced by tumour cells and they are called tumor-associated antigens. 
Identification of tumour antigen has facilitated the use of these antigens in cancer 
immunotherapy (Vuk-Pavlovic 2008). An efficient immunotherapy induces a specific 
immune response against TAA leading eventually to tumour regression and clinical 
response.
The ability of DC to process TAA and present them to T cells to induce tumour specific 
immune response renders them the ideal immune cells for tumour immunotherapy. 
Dendritic cell immunotherapy has been evaluated in numerous early phase clinical trials. 
DC generated from CD 14 progenitor or monocyte precursors, stimulated ex vivo to 
cancer antigens were successful in initiating tumour specific immune response and 
clinical responses were reported (Burch et ah 2000) (Murphy et al. 1999) (Tjoa et al. 
1999).
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Cancer immunotherapy faces 2 major challenges (i) most of TAA are self antigens and 
does not represent a rejection antigen in vivo (ii) tumours frequently develop various 
mechanisms to escape the immune recognition (Nouri-Shirazi et a l 2000). Cancer 
immunotherapy approach should overcome both problems to be successful in eliciting 
anti tumour immune response. In an attempt to find the optimal method of tumour 
antigen preparation and subsequent pulsing of DC as well as increasing the 
immunogenicity of tumour antigens, various DC loading strategies were attempted. A 
widely used method is to load DC with tumour specific peptide presented on restricted 
MHC molecule. DC pulsed with HLA-A2 restricted peptides derived from PSMA were 
employed in clinical trials (Murphy et a l 1996). Later studies have used whole protein 
like PSA and PAP which may present all the potential epitopes of a specific antigen 
(Barrou et a l 2004) (Small et a l 2000). Transfection of DC with mRNA encoding for 
TAA or RNA derived from tumour cells is another method of loading DC with tumour 
antigen (Su et al. 2005). More recently, whole tumour cell killed by various method or 
tumour lysate was used as a source of tumour antigen (Neidhardt-Berard et a l 2004) 
(Pandha et a l 2005) (Pandha et a l 2004). The use of whole tumour cells is attractive 
because it provides both MHC class-I and II peptide complex leading to the entire antigen 
repertoire of a tumour is processed and presented by the DC resulting in stimulation of 
both CD4 and CDS cells. Furthermore, whole tumour cells does not require the 
identification of immunogenic antigen neither HLA matching which give a wide 
flexibility in using it as a source of antigen in DC based cancer vaccine (Neidhardt- 
Berard et a l 2004).
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4.1.4 The effect of mode of cell death on DC maturation 
There are 2 mode of cell death, necrosis and apoptosis. The morphological features of 
necrosis include cell swelling, nuclear changes (karyolysis, pyknosis and karyorhexis) 
and cytoplasmic changes (eosinophelia, loss of structure and fragmentation) (Majno and 
Joris 1995). On the contrary, apoptosis or programmed cell death is a gene regulated 
process and morphologically is characterized by cell shrinkage, plasma membrane 
blebbing, chromatin condensation and DNA fragmentation (Majno and Joris 1995).
It has been shown that immature DC efficiently phagocytose apoptotic cells and cross 
present tumour antigen on MHC class-I to CDS T cells (Albert et a l 1998) (Albert, 
Sauter and Bhardwaj 1998). However, there is a controversy in the literature on the effect 
of apoptotic and necrotic cell death on DC maturation (Strome et a l 2002) (Ronchetti 
al 1999) (Schnurr et a l 2002) (Feng et a l 2002) (Jenne et a l 2000) (Inzkirweli et a l 
2007) (Prasad et a l 2005) (Sauter et al 2000) (Fields, Shimizu and Mule 1998) (Chen et 
al 2001b) (Kandil et a l 2005). Sauter et a l (2000) demonstrated that immature DC 
exposed to necrotic cells or their supernatant but not apoptotic cells were able to acquire 
mature phenotyope. DC matured by necrotic cells or their supernatant induced antigen 
specific CDS cells and enhanced cross presentation of antigens derived from apoptotic 
cells. This effect was only noticed when necrosis was induced by 5 freeze-thaw cycles 
which resulted in complete disruption of the cells. Supernatant of cells undergoing single 
freeze thaw cycle were ineffective in maturing DC. Similar results were noticed in other 
studies (Fields, Shimizu and Mule 1998) (Kandil et a l 2005). Strome et a l (2002) 
compared 3 methods of tumour cell preparation for DC loading, irradiation, boiling and
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freeze-thaw lysis. They demonstrated that irradiation is the most effective method for DC 
loading leading to the development of protective anti tumour immunity.
4.1.5 The effect of cryotherapy on DC maturation
Tumour destruction by cryotherapy results in release of large amounts of cryonecrotic 
tissue and tumour antigens. This may enhance the uptake of these antigens by local DC 
leading to naïve T cells activation and the development of tumour specific immune 
response (den Brok et al 2006). Ex vivo generation and loading of DC remains the 
preferable method in DC based vaccine therapy. However, efficient DC migration from 
subcutaneous injecting site to the regional lymph node remains questionable (Figdor et 
al 2004) (Steinman and Mellman 2004). Few studies have discussed the role of 
cryoablation of the primary tumour on DC activation and the development of tumour 
specific immune response, den Brok et a l (2006) studied the effect of in vivo tumour 
ablation by radiofrequency and cryotherapy on DC activation on the draining lymph 
nodes. They demonstrated that in situ tumour destruction by cryotherapy was more 
efficient than radiofrequency in loading DC with tumour antigen in the draining lymph 
nodes. Ex vivo generated and loaded DC with tumour antigen failed to reach the draining 
lymph nodes. Cryotherapy significantly upregulated CD80 and CD86 surface molecules 
in antigen positive DC. The effect was further augmented by regulatory T cells depletion. 
Two other studies investigated the effect of intratumoral administration of ex vivo 
generated DC combined with cryotherapy of the primary tumour (Machlenkin et al 
2005) (Udagawa et a l 2006). It was demonstrated that the combined treatment of 
intratumoral administration of immature DC and cryotherapy has induced tumour specific
128
immune response and Thl type CD4 cells (Machlenkin et a l 2005). Furthermore, it 
reduced the metastatic burden of the tumour and increased survival in experimental mice. 
Udagawa et al (2006) used DC stimulated with Bacillus Calmette-Guerin cell wall 
skeleton (BCG-CWS) injected into cryotreated tumour in animal model. There was a 
significant increase in tumour specific immune response for both treated and untreated 
tumour which was inoculated into the opposite site which resulted in tumour eradication
4.2 Study objectives
• To investigate the immunological effect of cryotreated prostate cancer cell on DC 
maturation.
• To assess the function of DC loaded with cryotreated tumour cells.
• To assess the molecular changes of DC following exposure to cryotreated tumour 
cells.
• To assess the mechanism through which cryotherapy affects the local immune 
environment.
4.3 Experiment design
Prostate cancer cell line (DU 145 and PC-3) were harvested, centrifuged and re-suspended 
in fresh culture medium at a density of 2x10^ cells / ml. One ml of cell suspension then 
placed in 1.5 ml eppendorf tubes and centrifuged at 10000 rpm for 1 minute. Cells were 
treated as described in chapter 2. Human DC was generated from blood monocytes and 
maintained with IL-4 and GM-CSF. Cryotreated tumour cells (treated at 0, -10 and - 
20°C), untreated tumour cells and tumour lysate (200pg/ml protein) were added at day 3
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to both immature DC and DC matured by LPS. DC: cancer cells ratio was 5:1. On day 7 
DC were harvested to proceed in the experiment (Figure 4.1)
The treated groups of DC includes
1- Immature DC used as a control (iDC)
2- DC matured with LPS (LPS).
3- DC loaded with untreated tumour cells with or without LPS (UT).
4- DC loaded with tumour lysate with or without LPS (Lys).
5- DC loaded with cryotreated tumour cells with or without LPS (-10).
Day 0 Day 3 Day 7
V V
Monocytes LPS
Untreated tumour cells 
Tumour lysate 
Cryotreated tumour cells
DC harvested 
stained and analysed
Figure 4.1 Study design of DC loading with untreated tumour cells, tumour lysate and 
cryotreated tumour cells.
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4.4 Results
4.4.1 Cryotreated prostate cancer cells induce upregulation of co-stimulatory 
molecules on cultured human DC.
Following 7 days in culture, the mean fluorescence intensity (MFI) of surface markers 
expression was measured and compared between 8 groups, immature DC (control) , DC 
matured with LPS (LPS), immature DC loaded with untreated whole tumour cells (UT), 
mature DC loaded with untreated whole tumour cells (UT+LPS), immature DC loaded 
with tumour lysate (Lys), mature DC loaded with tumour lysate (Lys+LPS), immature 
DC loaded with cryotreated whole tumour cells (-10) and mature DC loaded with 
cryotreated whole tumour cells (-10+LPS). Treatment with LPS induced up-regulation of 
costimulatory molecules and maturation markers (CD80, CD83, CD86, Class-II and 
CCR7 P<0.001) and down regulation of CD 14 and CD209 molecules (Figure 4.2). 
Exposure of DC to cryotreated tumour cells at -10°C resulted in 450 % increase in the 
expression of CD86 compared to the control (P<0.001). The effect of cryotreated tumour 
cells with LPS was stronger than LPS alone in up regulation of CD86 (P<0.001). Cells 
treated with tumour lysate with and without LPS showed similar response to cryotreated 
whole tumour cells. There was statistically significant up regulation of CD86 in the DC 
group loaded with cryotreated prostate cancer cells compared to cells treated with fresh 
untreated tumour cells (P<0.01) (Figure 4.3).
Up regulation of CD80 induced by cryotreated tumour cells was equivalent to LPS 
response (180% of the control). Furthermore, it resulted in far more stronger response in 
DC matured with LPS compared to all other treatment. There was no significant
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difference in the expression of CD83 molecules between the groups (P>0.05). 
Cryotreated tumour cells and tumour lysate induced more than 2 folds upregulation of 
surface expression of Class-II molecule compared to control DC (P<0.01). On the 
contrary Class-II expression was minimally up regulated by untreated whole tumour cells 
(P>0.05). DC loaded with cryotreated tumour cells showed a significant upregulation of 
CCR7 molecule compared to the control (P<0.05) and it was equivalent to LPS 
stimulated DC response. CD209 expression was significantly down regulated following 
exposure to tumour lysate and cryotreated tumour cells. The untreated whole tumour cells 
slightly decreased the expression of CD209 (P>0.05).
C C R 7-
C D 1a-
0) CD8o 4
3U0) CD 83-
o2 CD 209-
Q Class-II -
U C D 86-
C D IIc -
C D 14-
DCs
D C s+LPS
100 200 300 400 500 600 700
MFI
(% of control)
Figure 4.2 The effect of LPS on different CD molecules expression by dendritic cells, the 
graph showes that the isolated cells were phenotypically dendritic. There was significant 
increase in CD86, CD80 and Class-II surface expression upon maturation with LPS.
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Figure 4.3 The effects of LPS, untreated tumour cells, Tumour lysate and cryotreated 
tumour cells at -10°C on cell surface marker expression on DC. Cells were loaded at day 
3 with various agents and harvested at day 7. Cells were then washed, stained and 
analysed using FACS machine. The mean fluorescence intensity as a percent of control is 
plotted against treatment. [Control^ immature DC, LPS= DC matured with LPS, UT= 
DC loaded with untreated tumour cells +/- LPS, Lys= DC loaded with tumour lysate +/- 
LPS, (-10) = DC loaded with cryotreated tumour cells at -10°C +/- LPS.]
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4.4.2 Cryotherapy results in increased stimulatory cytokine expression in 
prostate cancer cells
mRNA level of immunostimulatory (IL-lp, IL-2, IL-6, IL-12p40, IL-15, IL-18, TNF-a 
and IFN-y) and immunoinhibitory (IL-10 and TGF-P) cytokines in response to 
cryotherapy was quantitatively assessed using RT-qPCR in 2 prostate cancer cell lines 
(PC-3 and DU145). The relative expression of each cytokine was calculated using the 2' 
method (Livak and Schmittgen 2001). Cells were cooled to 0, -5 and -10°C for 10 
minutes and recovered for 24 hours at 37°C. RNA was extracted from the cells and after 
reverse transcription a RT-qPCR reaction was established to detect GAPDH and cytokine 
mRNA expression (IL-ip, IL-2, IL-15, IL-18, IL-6, IL-12, TNF-a, IL-10, IL-1 and TGF- 
p). Both cell lines expressed IL-18, IL-ip and IL-15 at relatively high levels, while they 
expressed lower levels of IL-12, IL-6 and TGF-p and minimal levels of IL-2 and IL-10. 
IFN-y was not expressed by both cell lines (data not shown). mRNA expression for IL-2, 
IL-15 and IL-18 was significantly up-regulated in response to freezing injury with the 
highest expression being at -10°C (f<0.001). IL-6, IL-12 and TNF-a mRNA expression 
were clearly up-regulated at all treatment temperatures and predominantly at -5°C 
(P<0.001). In contrary, the immunoinhibitory cytokines (IL-10 and TGF-P) mRNA 
expression was down regulated upon fi*eezing, the change in expression was insignificant 
(P>0.05) except for IL-10 at -10°C (Figure 4.4). IL-1 is the only proinfiammatory 
cytokine tested which is reduced with freezing in DU 145 cells whereas in PC-3 cells the 
mRNA levels increased significantly at -10°C (data not shown).
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Figure 4.4 Cytokine gene expressions by RT-qPCR in DU 145 cells in response to 
freezing injury. Cells were treated for 10 minutes at 3 different target temperatures of (0, 
-5 and -10°C) and thawed in 55°C water bath to room temperature. Cells then incubated 
over night at 37°C, 5% C02. mRNA expression of the immunostimulatory cytokines was 
significantly up regulated upon freezing (P<0.001) whereas the immunoinhibitory 
cytokines were down regulated but the changes were insignificant except for IL-10 in 
cells cooled to -10°C (P<0.05). At least 3 independent experiments were performed.
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4.4.3 DC exposed to cryotreated whole tumour cells express high levels of 
immunostimulatory cytokines
Pro (IL-lp, IL-2, IL-6, IL-12, IL-15, IL-18, IFNy, TNF-a, and CCR-7) and anti (IL-10, 
TGFP) inflammatory cytokine gene expression was quantitatively assessed in the eight 
groups studied using RT-qPCR. Normalized gene expression was calculated and relative 
changes in gene expression were compared across different cell groups. DC exposed to 
cryotreated tumour cells expressed higher levels of IL-12p40, TNFa, IL-ip IFN-y and 
CCR7 (P< 0.001) compared to control DC. The increase in IL-15 and IL-18 mRNAs 
expression was statistically insignificant (Figure 4.5). Stimulation of DC with LPS and 
cryotreated tumour cells resulted in strong upregulation of most of immunostimulatory 
cytokines (IL-lp, TNFa, IFN-y, IL-12p40, CCR7, IL-6 and IL-15 P<0.001). 
Furthermore, cryotreated tumour cells provided stronger stimulus for DC to produce 
immunostimulatory cytokine (IL-ip, IFN-y, IL-12p40, TNFa and CCR7) than untreated 
tumour cells (P<0.01). IL-2 and IL-6 mRNA expressions were strongly upregulated in 
DC loaded with tumour lysate (P<0.001). Addition of LPS further increased IL-6 mRNA 
expression. Untreated tumour cells did not result in any significant change in the level of 
cytokines tested. DC loaded with LPS and untreated tumour showed increase expression 
of IL-lp, IL-12p40 and CCR7 (P<0.001). The changes maybe mainly due to LPS effect. 
mRNA levels of the Immunoinhibitory cytokines (IL-10 and TGF-P) were measured 
following various treatments. Although levels showed a downregulation trends upon 
loading DC with untreated tumour cells, tumour lysate and cryotreated tumour cells, the 
changes were statistically insignificant (P>0.05) (data not shown).
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Figure 4.5 Cytokine gene expressions by RT-qPCR. RNA was extracted from different 
groups of DC and reversed transcriped using cDNA synthesis kit. Fold change in gene 
expression was measure in comparison to iDC (control). DC loaded with cryotreated 
tumour cells showed statistically significant upregulation of IL-12p40, IFN-y, TNFa, IL- 
lp and CCR7 (P< 0.001). Further upregulation was noticed after the addition of LPS. 
cryotreated tumour cells provided stronger stimulus for the DC than untreated tumour 
cells. There was no significant changes in IL-10 and TGF-P levels (P>0.05). At least 3 
independent experiments were performed.
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4.4.4 Assessment of cytokine levels in supernatant from DC exposed to 
various stimuli
Cytokine secretion was evaluated in the supernatant collected from different groups of 
DC at different time intervals (Figure 4.6). five groups of DC were compared, immature 
DC (iDC), LPS stimulated DC (DC-LPS), DC loaded with untreated tumour cells (DC- 
UT), DC loaded with tumour lysate (DC-Lys) and DC loaded with cryotreated tumour 
cells (DC-10). Supernatants were collected at 2, 6, 24 and 72 hour post treatment. IL-6, 
IL-15, IL-12p70, IL-2 and IFN-y cytokines levels in the supernatant were assessed using 
Bio-Plex cytokine assay. Significant levels of IL-6 were detected in the supernatant of all 
groups. There was a significant reduction in IL-6 production upon exposure to 
cryotreated tumour cells compared to the control DC (P= 0.0028). Significant level of IL- 
15 was detected in the supernatant of DC pulsed with cryotreated tumour cells compared 
to the control DC (P<0.0001). Cryotreated tumour cells provided a stronger stimulation 
for DC to secrete IL-15 compared to LPS stimulation. IFN-y cytokines levels were 
significantly increase in DC loaded with cryotreated tumour cells compared to iDC 
(P=0.0212). There were no significant difference in IFN-y levels in the supernatant from 
DC loaded with cryotreated tumour cells and LPS stimulated DC. IL-12p70 cytokine 
levels were significantly reduced in the DC-10 group compared to iDC (P=0.0175). 
There was no significant change in IL-2 levels in the supernatant collected from different 
groups (P=0.0517).
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Figure 4.6 IL-6, IL-15, IL-2, IFN-y and IL-12P70 levels in supematent 72 hours 
following DC stimulation detected by Bio-Plex cytokine assay. There was a significant 
increase in IL-15 secretion by DC loaded with cryotreated tumour cells (P<0.001). IL-6 
levels showed a significant reduction (P=0.0028). IFN-y and IL-2 levels showed an 
increasing trend following exposure to cryotreated tumour cells (P=0.0212 and P=0.0517 
respectively). IL-12p70 reduced significantley (P=0.0175). At least 2 independent 
experiments were performed.
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4 .4 .5  D C  e x p o s e d  t o  c r y o t r e a t e d  c e l l s  a c q u i r e  p o t e n t  T  c e l l  s t i m u l a t o r y  
c a p a c i t y
We assessed the capacity of DC exposed to cryotreated tumour cells to prime naïve T 
cells in allogenic MLR. Human T cells were isolated from peripheral blood and 
stimulated in vitro by immature DC (iDC), DC mature with LPS (LPS), DC pulsed with 
tumour cells cooled at -10 (-10), tumour lysate (Lys) and untreated tumour cells (UT). 
The proliferative response was then measured. A strong stimulation of allogenic T cell 
proliferation was observed with DC that had been pulsed with cryotreated tumour cells 
compared to DC pulsed with tumour lysate and untreated tumour cells (P<0.001 and 
P<0.05 respectively). The stimulatory activity was higher in DC matured with LPS 
(P<0.05) (Figure 4.7).
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Figure 4.7 The effect of DC exposed to cryotreated tumour cells on T cell proliferation in 
MLR. Stimulator/effector ratio was 1:10. Following exposure to cryotreated cells, DC 
gained high stimulatory capacity on T cells proliferation compared to the control groups 
(P<0.001).
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4.4.6 Gene expression profile by gene microarray in DC loaded with 
cryotreated tumour cells
DC were exposed to LPS, untreated tumour cells, tumoue lystate and cryotreated tumour 
cells at day 3. Total RNA was then isolated at day 7 and cRNA for each sample was 
synthesised and labelled with Cy3 by a direct labeling method. The labelled cRNA was 
hybridized to the human 4x44 K cDNA chip (Invitrogen, Paisley, UK) that was scanned 
using Agilent’s microarray scanner (Agilent, Cheshire, UK) and gene expression profiles 
were analysed by Genespring GX 7.3.1 software. Expression patterns in treated DC were 
compared to immature DC which served as a control. Two independent experiments were 
performed. Total numbers of differentially expressed genes at the mRNA level were 50, 
59, 48 and 67 in LPS, UT, Lys and -10 groups respectivelywith more than twofold 
change in gene expression (Table 4.1). All reported genes were statistically significant 
(P<0.05).
Table 4.1 Total numbers of genes that were differentially expressed in different groups. 
Expression levels were measured relative to control (immature DC). At least 2 folds 
change in gene expression was included and all reported expression levels were 
statistically significant (P<0.05).
Group Up regulated Down regulated Total
DC+LPS 31 19 50
DC loaded with untreated 
tumour cells
48 11 59
DC loaded with tumour lysate 36 12 48
DC loaded with cryotreated 
tumour cells.
45 22 67
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IL-1 cytokine is secreted by innate immune cells and is a potent stimulator of DC 
maturation. It was demonstrated that ILIB represents a key cytokine for DC activation 
during early stages of inflammation. It stimulates CD40 ligand leading to increased 
cytokines secretion by activated DC. Furthermore, it induces higher levels of IFN-y 
secretion by activated T cells (Luff et al. 2002). It this study we demonstrated that DC 
loaded with cryotreated tumour cells showed more than 56 folds increase expression in 
IL-IB compared to the control. In addition there was more than 2 folds increase in CD40 
molecule expression. The other groups showed far more less expression levels of IL-IB 
and CD40 molecules. This is one mechanism that could be responsible for the activation 
of DC following exposure to cryotreated tumour cells.
Fas (TNF receptor superfamily, member 6) is a member of TNF family which induces 
apoptosis upon legation to its ligand. We demonstrated that Fas was upregulated 
approximately 35 folds in DC loaded with cryotreated tumour cells compared to the 
control DC. It was previously reported that DC express Fas receptor that is upregulated 
by LPS. It was also demonstrated that DC are resistant to Fas induced apoptosis by 
constitutive expression of FLICE-inhibitory protein (FLIP) (Rescigno et al. 2000). 
Several functions of Fas receptor have been identified in immune cells. DC can induce T 
cells apoptosis via Fas-FasL dependent mechanism (Reid, Penna and Adorini 2000). Fas 
signalling in early stages of immune response can lead to T cell activation and immune 
stimulation (Rescigno et al. 2000). Furthermore, Fas can induce phenotypical and 
functional DC maturation and increased secretion of TNFj^g and ILIB (Rescigno et al.
142
2000). Fas-FasL pathway is involved in cytotoxic killing of overian cancer cells by 
immature DC and in the development of tumour specific CTLs (Yang et a l 2001).
DC loaded with cryotreated cells showed 6 folds increase in CDKNIA (p21) expression 
compared to 4 folds in DC loaded with LPS and 5 folds in DC loaded with tumour lysate. 
It was demonstrated that p21 is required for DC maturation and function (Kramer et al
2002). Other genes involved in cell cycle regulation were also upregulated with 
cryotreated tumour cells such as CDKNIB (p27, Kipl) and CDKN2A (pl6).
Tumour necrosis factor receptor superfamily, member 1 lb (osteoprotegerin) was 4 folds 
up regulated in -10 group that was more than the up regulation in the LPS and tumour 
lysate group. It was demonstrated recently that DC express osteoprotegerin which is up 
regulated by DC maturation, TNF-a and ILIB. Furthermore it was demonstrated that 
osteoprotegerin expression was controlled by NF-kB and so it may play a role in 
regulating immune response (Schoppet et a l 2007).
Other genes which was up regulated in the -10 group is VEGF (3.83 folds), CXCR4 (3.46 
folds) and Bax (2.02 folds). VEGF may impair anticancer immune response via inhibition 
of DC maturation and differentiation (Osada et aï. 2008). CXCR4 is a chemokine 
receptor that is expressed in mature DC and is responsible for DC migration (Kabashima 
et a l 2007). Furthermore, it was found that CXCL12/CXCR4 interaction promotes 
thymic DC survival via altering the balance between key anti and pro apoptotic proteins 
and enhances its function (Hemandez-Lopez et a l 2008).
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A number of important genes involved in induction of apoptosis were downregulated in 
the -10 group such as Caspase 8 (0.426 folds) and BCL2 (0.455 folds). LCK protein 
tyrosine kinase play important role in T cell activation and proliferation. It was 
demonstrated that CD8a^ DC express LCK which bind to CD8a molecule and may 
induce DC-T cell activation (Hong, Webb and Wilkes 2007).
Table 4.2 List of genes co-regulated in dendritic cells upon loading with cryotreated 
tumour cells. Numbers represents fold change in gene expression compared to immature 
DC which served as a control.
Gene name Genbank Symbol Fold change
Upregulated genes
Growth differentiation factor 15 NM_004864 GDF15 270.8
Ras-related associated with diabetes [NM_004165 RRAD 108.2
Plasminogen activator, tissue NM_000930 PLAT 83.01
Interferon, alpha-inducible protein 27 NM_005532 IFI27 70.57
Interleukin 1, beta NM 000576 ILIB 56.94
Serine dehydratase NM 006843 SDS 49.46
Fas (TNF receptor superfamily, member 6) NM_000043 FAS 34.55
Met proto-oncogene (hepatocyte growth factor 
receptor)
NM_000245 MET 26.94
Rho family GTPase 3 NM 005168 RND3 24.94
Lymphocyte antigen 6 complex, locus K NM 017527 LY6K 19.48
Tumor necrosis factor (ligand) superfamily, 
member 10
NM_003810 TNFSFIO 16.3
Matrix metalloproteinase 1 (interstitial 
collagenase)
NM_002421 MMPl 12.95
Adrenomedullin NM 001124 ADM 12.12
Mdm2, transformed 3T3 cell double minute 2, 
p53 binding protein (mouse)
NM_002392 MDM2 10.21
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Proliferating cell nuclear antigen NM 002592 PCNA 9.842
Integrin, beta 3 (platelet glycoprotein Ilia, 
antigen CD61)
NM_000212 ITGB3 7.701
Fibronectin 1 NM 212482 FNl 6.23
Cyclin-dependent kinase inhibitor lA (p21, 
Cipl)
NM_000389 CDKNIA 5.821
Peroxisome proliferative activated receptor, 
gamma
NM_138711 PPARG 5.416
Interleukin 1, alpha NM 000575 ILIA 5.333
Cyclin-dependent kinase inhibitor 2A 
(melanoma, p i6, inhibits CDK4)
NM_058197 CDKN2A 5.014
Tumor necrosis factor receptor superfamily, 
member 1 lb (osteoprotegerin)
NM_002546 TNFRSFl
IB
4.374
Vascular endothelial growth factor NM 0010253 
66
VEGF 3.836
Chemokine (C-X-C motif) receptor 4 NM 0010085 
40
CXCR4 3.463
N-myc (and STAT) interactor NM 004688 NMI 3.213
Cadherin 1, type 1, E-cadherin (epithelial) NM 004360 CDHl 2.787
Cyclin-dependent kinase inhibitor IB (p27, 
Kipl)
NM 004064 CDKNIB 2.278
BCL2-associated X protein NM 138764 BAX 2.021
Signal transducer and activator of transcription 
l,91kDa
NM_139266 STATl 2.019
Down regulated genes
Baculoviral lAP repeat-containing 5 (survivin) NM 0010122 
71
BIRC5 0.135
Transcription factor 7 (T-cell specific, HMG- 
box)
NM_003202 TCF7 0.187
Fas ligand (TNF superfamily, member 6) NM 000639 FASLG 0.192
Lymphocyte-specific protein tyrosine kinase NM 005356 LCK 0.248
Cell division cycle 2, G1 to S and G2 to M. NM 001786 CDC 0.251
Zeta-chain (TCR) associated protein kinase 
70kDa
NM_001079 ZAP70 0.287
Cyclin A2 NM 001237 CCNA2 0.304
Amyloid beta (A4) precursor protein (protease 
nexin-II, Alzheimer disease)
NM_000484 APP 0.371
Ataxia telangiectasia mutated (includes 
complementation groups A, C and D)
NM_000051 ATM 0.379
Family with sequence similarity 64, member A NM 019013 FAM64A 0.418
Caspase 8, apoptosis-related cysteine protease NM 033356 CASP8 0.426
B-cell CLL/lymphoma 2 , nuclear gene 
encoding mitochondrial protein
NM_000633 BCL2 0.455
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4.5 Discussion
The aim of prostate cryotherapy is to destroy neoplastic tissue and preserve vital 
structures around the prostate i.e. the rectum and urinary bladder. A precise freezing 
process is therefore required to effectively destroy the cancerous tissue and preserve the 
surrounding structures. The freeze-thaw cycle induces a thermal gradient in the treated 
tissue with the peripheral tissue being exposed to the highest temperature in this gradient 
(Smith et al. 1999). Therefore, two well demarcated zones surrounding the cryo probe 
can be identified, an internal zone of coagulative necrosis (kill zone) and a peripheral 
zone of haemorrhage and metaplasia (damage zone) (Larson, et al. 2000). It is technically 
challenging to achieve lethal critical temperature in all the prostatic tissue as this will 
result in a high percentage of complications. Therefore complete ablation of prostate 
cancer tissue some times fails and results in local disease recurrence. In an attempt to 
overcome this issue and increase the success rate following prostate cryotherapy, several 
reports described an adjuvant therapy combined with prostate cryotherapy in order to 
increase the sensitivity of cells to cryogenic injury and increase the efficacy of 
cryotherapy (Clarke et al. 2004) (Clarke et al. 2007) (Goel et al. 2007). One approach 
was intratumoral administration of DC following cryoablation of the primary tumour or 
cryoimmunotherapy (Udagawa et al. 2006).
In this study the effect of cryotherapy of prostate cancer cells on DC maturation and 
function was addressed and the mechanism responsible for the DC stimulation by 
cryotherapy identified.
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DC are potent initiator of immunity, in their immature status, they have the ability to 
acquire, process and present antigens to naïve T cells. Upon maturation, DC express high 
levels of MHC and costimulatory molecules, produce large amounts of the 
proinfiammatory cytokine and induce T cell immunity (Lutz and Schuler 2002).
It was demonstrated that DC can be activated by endogenous signals such as stressed 
cells, virally infected or necrotic cells but not by normal or apoptotic cells (Gallucci, 
Lolkema and Matzinger 1999) (Sauter et a l 2000). Other studies demonstrated that both 
necrotic and apoptotic cells were able to trigger DC maturation and induce tumour 
specific immune response (den Brok et a l 2004) (Ronchetti et a l 1999). DC infiltrating 
the tumour microenvironment has been described in several human cancers and has been 
associated with increased survival (Bigotti, Coli and Castagnola 1991) (Coventry and 
Morton 2003).
The initial experiment was designed to evaluate the effect of untreated whole tumour 
cells, tumour cell lysate and cryotreated tumour cells on the surface expression of co 
stimulatory molecules on DC. Prostate cancer cells treated with cryotherapy were more 
effective in inducing DC maturation than tumour lysate and untreated tumour cells. 
Flowcytometric data revealed 4 folds increase in CD86 marker expression and more than 
double of class-II expression. Maturation was further increased by treating DC with LPS. 
The nature of maturation stimuli provided by cryotreated cells is not well identified. Two 
cytokines are important for DC maturation, TNF-a and IL-1 (3, both cytokines were not 
detected in the supernatant of necrotic tumour cells which induced DC maturation (Sauter
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et al. 2000). S alio et al. (2000) demonstrated that the stimulation was mainly as a 
consequence of mycoplasma contamination. Cell line used in this experiment tested 
negative for mycoplasma infection. Matzinger et al. (1994) proposed that stressed cells 
release alarm signals responsible for DC activation. Other studies demonstrated that non 
apoptotic cell death was associated with increased expression of heat shock proteins 
(HSP) which provided immune stimulatory signals and resulted in increased 
immunogenicity of the tumours (Melcher et al. 1998). Todryk et al. (1999) have shown 
that HSP70 expression by the tumour cells was associated with increased infiltration of 
DC into the tumour tissue and resulted in increased antigen uptake by immature DC. 
Significant expression of IL-2, TNF-a, IL-12 p40 and GM-CSF was detected at relatively 
high levels and may be implicated in DC stimulation.
In order to explore the mechanism by which cryotreated tumour cells stimulate 
maturation signal in DC, we evaluated cytokine gene expression by prostate cancer cells 
in response to cryotherapy. Immunostimulatory cytokines (IL-2, IL-15, IL-12p40 and IL- 
18) were significantly upregulated upon freezing at -10°C. TNF-a mRNA expression was 
significantly increased upon treatment at -5°C. Freezing injury resulted in up regulation 
of IL-IB in PC-3 cell line, in the contrary it is significantly down regulated in DU 145 cell 
line. Immunoinhibitory cytokines was significantly down regulated. These data suggest 
that cryotherapy creates immunostimulatory environment through increased production 
of proinfiammatory cytokines for the immune cells to function. These observations may 
be a key factor in enhancing DC maturation.
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To explore further the nature of these maturation signals on DC function, we examined 
cytokine gene expression by DC exposed to different maturation stimuli. DC exposed to 
cryotreated tumour cells showed increased expression of stimulatory cytokines (IL-lp, 
IL-12p40, IL-15, TNFa, IFN-y and IL-15) and chemotactic marker CCR7 compared to 
DC exposed to tumour lysate and untreated tumour cells. The expression was higher than 
LPS stimulated DC.
To evaluate further the functional effect of DC exposed to different cell type we tested 
these DC for their ability to induce T cell proliferation in an allogenic MLR reaction. DC 
exposed to cryotreated tumour cells resulted in heightened T cell proliferation activity in 
allogenic MLR reaction. This confirms that DC exposed to cryo-treated tumour cells are 
both phenotypically and functionally more active than DC stimulated by LPS. It was 
reported that complete fragmentation of tumour cells by multiple freeze-thaw cycles is 
required to induce DC maturation (Sauter et al. 2000). In our study, freezing temperature 
has no effect on the level of DC maturation, and temperature of -5,-10 and -20°C 
produced the same effect. Gene microarray data revealed that DC exposed to cryotreated 
tumour cells showed up regulation of important genes that are involved in DC maturation 
and function such as ILIB, Fas, CDKNIA (p21), osteoprotegrin and CXCR4. Genes 
responsible for apoptotic death pathway such as BCL2 and caspase 8 were 
downregulated.
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4.6 Conclusion
Overall, data suggest that the effect of cryotherapy is generally stimulatory to dendritic 
cells which may favour antitumour effects. Freezing injury stimulate DC in 2 different 
ways. First it provides a pool of antigen from the cryo-destructed tumour tissue and 
secondly by creating an immunostimulatory cytokine environment which enhance DC 
maturation. Therefore, the combination of cryotherapy and DC vaccine may represent a 
novel method to increase the efficacy of cryotherapy especially at the peripheral zones of 
the prostate where cells are exposed to sublethal temperature. Further in vivo study is 
necessary before applying this model in clinical trails.
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Chapter 5
The Role of the aquaporin 
water channels in prostate 
cancer cells resistance to 
freeze injury
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5.1 Introduction
The aquaporin (AQP) family of water channels are intrinsic membrane proteins that 
facilitate selective water and small solute movement across the plasma membrane 
(Verkman and Mitra 2000). They were initially characterised in human red blood and 
renal cells (Nielsen et ah 1993) (Preston et al. 1992). Subsequently, they were identified 
in mammals, plants, yeasts and arthropods. To date, 13 members of the aquaporin family 
have been identified in mammals (AQPO-12). Mammalian aquaporins are stratified into 
two subgroups, the first subgroup including AQPl, AQP2, AQP4, AQP5, AQP6 and 
AQP8 is highly selective for the passage of water across the plasma membrane. The 
second group is the aquaglyceroporins which include AQP3, AQP7, AQP9 and AQP 10; 
they permit the transport of small non ionic molecules such as glycerol, in addition to 
water (Ishibashi et al. 1994).
It is becoming more evident that aquaporins play a role in tumour pathogenesis. AQP3 
was found to be expressed in normal and malignant prostate tissue and may be involved 
in tumour initiation and development (Wang et al. 2007). Prostate tumour showed 
prominent expression of AQPl confined to capillary endothelium. Possible involvement 
of AQPl in tumour growth and angiogenesis was suggested and changes in AQPl 
expression may be involved in microvascular alteration during tumour angiogenesis 
(Mobasheri et al. 2005).
A few studies have reported on the relationship of aquaporin water channels and freeze 
tolerance. It was demonstrated that artificial over-expression of AQP3 in mouse oocytes
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increased survival after cryopreservation in glycerol based medium (Edashige et al.
2003). Gene expression analysis in bakers yeast revealed a correlation between freeze 
resistance and the expression of AQPl and AQP2 genes (Tanghe et al. 2002). Deletion of 
the respective genes has raised the sensitivity to fi'eeze injury whereas their over 
expression has improved fi-eeze tolerance. The role of AQPs in the freeze tolerance in 
Arthropods was also investigated (Izumi et al. 2006) (Philip et al. 2008): inhibition of 
AQPs by mercuric chloride (HgCb) results in significant reduction of survival after 
exposure to freezing injury even in the presence of cryoprotectant.
In this study we investigated the effects of the AQP inhibition in sensitising prostate 
cancer cell to cryotherapy. The expression of AQPs by DU 145 and PC-3 cells before and 
after freezing injury was determined using RT-qPCR. Changes in the expression of AQPs 
were determined at different time intervals post freezing using RT-qPCR and Western 
blot analysis. We have assessed the potential use of RNA interference technology as an 
adjunctive therapy to cryotherapy to enhance the antitumour efficacy.
5.2 Hypothesis
In this study, we hypothesized that AQPs play an important role in the ability of prostate 
cancer cells to survive freezing injury. Inhibition of AQPs on the cell surface will prevent 
the transport of water out of the cell during extracellular ice formation leading to 
retaining of adequate amount of water in the cytoplasm. Therefore, intracellular ice will 
form at higher freezing temperature leading to increase cell death.
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5.3 Material and methods
To test the role of AQPs in freeze tolerance, the expression of AQPl, AQP3 and AQP9 in 
prostate cancer was examined by RT-qPCR. These 3 aquaporines were shown to be 
expressed in prostate tissue. Prostate cancer cells were cooled to 0, -5 and -10°C for 10 
minutes and changes in the expression of AQP3 was examined by RT-qPCR and Western 
blot analysis. Prostate cancer cells were treated in the presence or absence of the 
aquaporin inhibitor mercuric chloride (HgCh) (Sigma-Aldrich, Pool, UK) at a 
concentration of 0.075 mM for 15 minutes. Cells are washed twice and treated with 
freezing at -10°C for 10 minutes and thawed in a 55°C water bath to room temperature. 
Cell survival was compared to the untreated cells, cells treated in the absence of HgCh 
and cells treated with HgCh without freezing using the MTS assay. To further investigate 
the role of AQP3 in freeze tolerance, AQP3 mRNA was blocked using small interference 
RNA (siRNA) and cell survival was assessed after freezing as described in the materials 
and methods.
Table 5.1 Definition of group of cells used in the study.
Group Description
Untreated Untreated tumour cells.
HgCh Cells treated with 0.075 mM HgCh.
Cryo(-lO) Cells cooled to -10°C for 10 minutes.
Combo Combination treatment of freezing and HgCh.
AQP3 siRNA Cells with blocked AQP3 mRNA using siRNA.
Control siRNA Cells exposed to control siRNA.
Mock transfection Cells exposed to transfection medium only.
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5.4 Results
5.4.1 Prostate cancer cells express AQPl, AQP3 and AQP9
Prostate cancer cells were cooled to 0, -5 and -10°C for 10 minutes. Following overnight 
recovery total RNA and protein was extracted and AQPl, AQP3 and AQP9 mRNA 
expression was assessed using RT-qPCR. AQPs expression in the untreated cells was 
compared to GAPDH mRNA expression. LNCaP and DU 145 cells expressed mainly 
AQP3 with very minimal levels of AQPl and AQP9. PC-3 cells expressed lower levels 
of all tested AQPs (figure 5.1). There was an overall increase in expression of all AQPs 
tested upon exposure to -10°C freezing temperature. PC-3 cells showed a significant 
increase in AQPs expression at -10°C (P<0.001). Whereas at -5°C only AQPl mRNA 
showed a significant increase in expression compared to untreated levels (P<0.01). AQPs 
expression in DU 145 cells slightly reduced at 0°C followed by significant rise in 
expression at -10°C (P<0.001). AQP3 mRNA expression gradually decreased upon 
exposure to 0 and -5°C but the changes were insignificant compared untreated DU 145 
cells. Cells cooled to -10°C showed approximately 3 folds increase in expression levels 
(P<0.001). AQPl mRNA expression significantly increased in DU 145 cells cooled to -5 
and -10°C (P<0.01). AQP9 mRNA levels did not change after exposure to cryoinjury 
(P>0.05). LNCaP cells showed similar trend to DU 145 cells. There was initial reduction 
in expression followed by more than 50 times increase expression in AQPl and AQP9 
(P<0.001) and to a lesser extent in AQP3 expression (P>0.05) compared to the untreated 
(figure 5.2). AQP3 mRNA and protein expression was evaluated 2, 8 and 24 hours post 
freezing in DU 145 and PC-3 cells using RT-qPCR and Western blot analysis. The results 
show that in the immediate post freeze period there are 5 and 50 fold increases in AQP3
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expression in DU 145 and PC-3 cells, respectively, followed by a gradual return to the 
untreated level (Figure 5.3). A response which may represents a protective mechanism 
exerted by the cells to face the osmotic stress associated with freezing injury.
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Figure 5.1. AQPl, 3 and 9 mRNA expression in prostate cancer cells analysed using RT-qPCR. 
The relative expression ratio was compared to GAPDH expression. AQP3 was prominently 
expressed in LNCaP and DU145 cells. In PC-3 cells lower levels of AQPs were detected.
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Figure 5.2 AQPl, AQP3 and AQP9 expressions in (A) PC-3, (B) DU 145 and (C) LNCaP 
cells in response to freezing. mRNA expression was measured as fold change compared to 
untreated cells. There is a significant increase in expression levels of the tested AQPs at -10°C 
in PC-3 cells, AQPl and AQP3 in DU 145 cells and AQPl and AQP9 in LNCaP cells.
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Figure 5.3 AQP3 mRNA expression by RT-qPCR (A and B) relative to untreated cells 
and protein expression by Western blot analysis (C and D) in DU 145 and PC-3cells over 
time intervals post freezing. In the Western blot analysis primary antibody against C-18 
terminus of human aquaporin 3 was used. The results show that in the immediate post 
freeze period there are 5 and 50 fold increases in AQP3 expression in DU145 and PC-3 
cells, respectively, followed by a gradual time dependent return to the untreated level. A 
response which may represents a protective mechanism exerted by the cells to face the 
osmotic stress associated with early phase of cryoinjury.
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5.4.2 Cryotherapy results in relocalisation of AQP3 into the plasma 
membrane.
It was demonstrated that AQP3 protein is expressed at the cytoplasm of the human 
prostate cancer cells (Wang et al. 2007). Transporter proteins need to be expressed at the 
plasma membrane to function. In this study we investigated the expression and 
localisation of AQP3 in prostate cancer cells in response to cryoinjury using 
immunofluorescence staining. Cryotherapy markedly redistributed AQP3 protein into the 
plasma membrane of prostate cancer cells. Figure 5.4 clearly show membrane expression 
of AQP3 in PC-3 cells. DU 145 cells showed similar finding (data not shown). Control 
wells incubated with dilution buffer showed no immunoreactivity (data not shown).
Figure 5.4 Immunofluorescence expression and localisation of AQP3 protein post cryotherapy. 
Cells were incubated with the primary antibody against AQP3 overnight at 4°C and then with 
the secondary Antibody (Donkey anti-goat IgG Antibody, Alexa Fluor ® 488 Conjugated, 
Invitrogen, Paisley UK) at room temperature for 1 hourlt are clear that AQP3 is expressed on 
the plasma membrane of PC-3 cells. Similar finding was seen in DU 145 cells. Original 
magnification X 600.
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5.4.3 Inhibition of the AQPs by mercuric chloride results in increase 
sensitivity of prostate cancer cells to breeze injury
Mercuric chloride is a universal inhibitor of AQPs which has routinely been used to test 
AQPs function in animal and plants cells. It has high affinity to reactive thiol moiety of 
cysteine residues within the AQPs causing covalent changes leading to inhibition of 
water transport function (Savage and Stroud 2007). In order to ascertain the effect of 
HgCb on prostate cancer cell survival, DU 145 and PC-3 cells were treated with various 
concentration of HgCb for 15 minutes and survival was assessed using the MTS assay. 
PC3 cells were very sensitive to HgCb treatment and more than 80% died at low 
concentration (0.04mM). DU 145 cells were more resistant to HgCb and the IC50 was 
0.15 mM (Figure 5.5). DU 145 cells were treated with 0.078 mM of HgCb for 15 minutes, 
cells then were exposed to freezing temperature for 10 minutes. Cell survival was 
assessed by the MTS assay and compared to the untreated cells, cells treated with HgCb 
or freezing alone. HgCb or cryotherapy treatment alone resulted in 40% and 80% 
reduction in cell survival respectively. The combination treatment resulted in significant 
reduction in cell survival and almost there was a complete loss of cell viability after 
treatment (P<0.001) (Figure 5.6). PC-3 cells were not suitable for the experiment as it 
was very sensitive to HgCb treatment. To determine whether the combination treatment 
is synergistic, the combination index (Cl) was calculated using CalcuSyn software 
(Biosoft, Cambridge, UK) that uses the median effect principle. Cl provides a 
quantitative measure of the degree of interaction between two or more agents (Chou and 
Talalay 1984). Cl for the combination treatment was 0.2 which denotes synergy between 
the two treatments.
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Figure 5.5 The effects of Mercuric chloride (HgCl]) on DU145 and PC-3 cell survival. 
DU 145 cells resistant to low concentrations of HgCli and more than 50% of cells 
survived 0.156mM concentration. PC-3 cells were sensitive to all concentrations tested 
and more than 80% were dead following exposure to 0.156mM.
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Figure 5.6 DU 145 cell survival following exposure to Mercuric chloride (HgCli), 
freezing (cryo (-10)) and combination of HgClz and freezing (Combo). HgCli and 
cryotherapy resulted in 40% and 80% reduction in cell survival respectively. The 
combination treatment of HgCb and cryotherapy resulted in almost 100% loss of cell 
survival (f<0.001). At least 3 independent experiments were performed.
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5.4.4 Inhibition of AQP3 using siRNA in prostate cancer cells
To further investigate the role of specific AQPs in protecting prostate cancer cell from 
cryoinjury, AQP3 silencing experiment was performed with lOOnM of AQP3 siRNA. 
AQP3 gene silencing was verified by a decrease in target mRNA and protein expression 
using RT-qPCR at day 3 and Western blot analysis at day 6 after inducing RNA 
interference (RNAi). A control siRNA was used in parallel to test the potential non 
specific effects of the short RNA duplex. Mock transfected cells are cells which were 
exposed to the transfection reagent without RNA duplex. To evaluate the toxic effect of 
transfection on overall viability, cell survival was assessed by the MTS assay at day 6 
after the addition of the siRNA.
The percentage of cell survival was above 80% in all groups indicating optimal 
transfection conditions with no toxic effect of the lipid complex on the treated cells 
(Figure 5.7). The results show that AQP3 mRNA levels were significantly decreased 3 
days following the treatment with siRNA and there was more than 90% reduction in 
AQP3 mRNA level (Figure 5.8). There was no significant change in AQP3 mRNA 
expression in cells treated with control siRNA and mock transfected cells. Western blot 
analysis showed a reduction in AQP3 protein levels at day 6 while protein expression 
levels were unaffected in cells treated with control siRNA and mock transfected cells 
compared with untreated cells, demonstrating the specificity of the results (Figure 5.8). 
Therefore the AQP3 silencing experiment using siRNA technology was conducted under 
optimal conditions achieving the maximum transfection efficiency and target specificity.
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Figure 5.7 DU 145 cells survival after transfection with siRNA. Cell survival was assessed 
using the MTS assay at day 6 after the addition of the transfection complex. There was no 
toxic effect of the transfection process on cell survival and cell survival in all groups was 
more than 80%.
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Figure 5.8 AQP3 mRNA and protein levels in (A) DU 145 and (B) PC-3 cells were assessed 
by RT-qPCR and Western blot analysis 3 and 6 days after AQP3 transfection respectively. 
AQP3 gene silencing was verified by a decrease in target mRNA expression at day 3 and 
protein expression at day 6 post transfection. There was more than 90% reduction in AQP3 
mRNA levels in cell treated with AQP3 siRNA (P<0.01). Multiple controls were used to 
verify the specificity of the treatment none showed any significant reduction in AQP3 
mRNA levels (P>0.05).
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5 .4 .5  A s s e s s m e n t  o f  c e l l  s u r v i v a l  i n  A Q P 3  k n o c k d o w n  c e l l s  c o m p a r e d  t o  
n o r m a l  c e l l s
AQPs inhibitor (HgCb) resulted in significant decrease in DU 145 cell viability following 
exposure to -10°C freezing temperature. To determine whether specific inhibition of 
AQP3 could increase cell sensitivity to cryotherapy and enhance cell death following 
exposure to cryo injury, AQP3 knocked down DU 145 and PC-3 cells were cooled to - 
10°C for 10 minutes and thawed in 55°C water bath to room temperature as described in 
materials and methods. Following exposure to cryo injury, cell viability was assessed by 
the MTS assay. Four groups were compared, normal cells (cryo -10), cells transfected 
with AQP3 siRNA (AQP3 siRNA), cells transfected with control siRNA (control siRNA) 
and mock transfected cells (mock transfection). All cell survival measurements were 
relative to the untreated cells and calculated as percentage survival. AQP3 knocked down 
DU 145 cells showed more than 90% reduction in cells survival following freezing at - 
10°C compared to 70% in normal cells and 75% in cells treated with control siRNA and 
mock transfected cells {P < 0.001) (Figure 5.9). Cells treated with control siRNA and 
mock transfected cells showed similar cell viability to normal cells after exposure to 
freezing at -10°C (P>0.05). Similar results are demonstrated in PC-3 cells. Increased 
sensitivity to cryo injury was specific to AQP3 knockdown cells suggesting that AQP3 
gene play a role in protecting prostate cancer cells from cryoinjury. Specific AQP3 
inhibition resulted in a significant reduction in cell survival but never resulted in 
complete loss of viability as compared to HgCk. This may indicate that other AQPs may 
be expressed in prostate cancer cells and play a role in protecting cells from cryoinjury.
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i  - i
Untreated Cryo (-10) AQP3 Control Mock
siRNA siRNA transfection
(B)
 i-.. m
Untreated Cryo (-10) AQP3 siRNA Control siRNA Mock
transfection
Figure 5.9 (A) DU 145 and (B) PC-3 cell survival following exposure to cryo injury. AQP3 
knocked down cells showed a significant reduction in cell viability compared to the other 
groups (P<0.001). All results are expressed as a percentage of a parallel untreated control. 
Control siRNA and mock transfected cells did not show any significant change in cells survival 
compared to normal cells.
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5.5 Discussion
Cryotherapy is one of the effective therapies for localised or locally advanced prostate 
cancer (Ismail, Pandha and Davies 2008). Clinical reports demonstrated that -40°C 
represents the ideal target temperature for a satisfactory prostate tissue ablation (Larson et 
al. 2000). It is difficult to achieve such a low temperature in areas close to the rectum, 
urinary bladder and neurovascular bundles as it may increase the rate of significant 
morbidity. Therefore, complete ablation of cancer tissue some times fails and results in 
disease recurrence. It is therefore important to characterize the precise target temperature 
during clinical cryotherapy in order to achieve complete tissue ablation and reduce the 
rate of complication. Various studies described the use of adjunctive therapy with 
cryotherapy to increase sensitivity of prostate cancer cells to cryotherapy. Different 
agents were used such as chemotherapy, radiotherapy, hyperthermia and apoptosis 
inducing ligands (Liu et al. 2004a) (Mir and Rubinsky 2002) (Clarke et al. 2007).
In this study, we identified inhibition of aquaporins as a further therapeutic target that 
may be synergistic with cryotherapy. During the initial phase of freezing, ice formation 
starts in the extracellular space creating hyperosmolar environment and leading to water 
escape from the intracellular to the extracellular space along the osmotic gradient. 
Intracellular hyperosmolarity will result in a reduction in the critical temperature of 
intracellular ice formation. Inhibiting the aquaporins, which are primarily responsible for 
controlling water transport across the plasma membrane, will lead to intracellular water 
retention and a subsequent increase in the critical temperature at which intracellular ice 
will form.
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In this study we provide strong evidence that AQPs protein can play a key role in 
modulating prostate cancer cell response to cryotherapy. AQP3 was expressed in both 
prostate cancer cell lines and it was used as a target in this study. Exposure to freezing 
temperature provided a strong stimulus for enhanced expression of AQP3 in an attempt to 
overcome the osmotic stress. AQP3 expression was increased by 150% and 1000% in 
DU 145 and PC-3 cells respectively upon freezing at -10°C. Similar up regulation upon 
exposure to mild hypothermia was reported in previous studies (Fujita et ah, 2003).
Cryotherapy increases the expression of AQP3 through two mechanisms. Firstly, by 
creating hyperosmolar environment at the extracellular space that leads to increase 
expression of AQP3 (Bell et ah, 2009). Secondly we found 5 fold increase in Mitogen 
Activated Protein Kinase 14 (MAPK14) expression in prostate cancer cells upon 
exposure to -10°C freezing temperature (chapter 6). Bell et ah (2009) demonstrated that 
MAPK 14 is involved directly in regulating AQP3 expression in response to 
hyperosmotic stress. Therefore up regulation of AQP3 can be considered as part of a 
protective physiological stress response to the osmotic changes at the initial phase of 
cryoinjury. AQP3 is a transporter protein that needs to be expressed in the cell 
membrane to function. Wang et ah (2007) demonstrated that AQP3 is expressed in the 
cytoplasm of prostate cancer cells. Based on our finding from immunofluorescence 
staining, we clearly showed that cryoinjury results in relocalisation of AQP3 from the 
cytoplasm to the plasma membrane which may reflect the direct involvement of AQP3 in 
the intracellular osmotic changes associated with cryoinjury.
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Previous studies have reported on the relationship of aquaporin water channels and freeze 
tolerance. Forced over-expression of AQP3 in mouse oocytes increased survival after 
cryopreservation in a glycerol-based medium (Edashige et al., 2003). Gene expression 
analysis in baker’s yeast revealed a correlation between freeze resistance and the 
expression of AQPl and AQP2 genes (Tanghe et al., 2002). Deletion of the respective 
genes has raised the sensitivity to cryoinjury. It was also demonstrated that high level of 
freeze tolerance in arthropods was significantly reduced when the expression of the AQP 
was inhibited by HgCb even in the presence of glycerol as a cryoprotectant (Izumi et ah, 
2006) (Philip al, 2008).
Based on these observations we examined the role of the AQPs in freeze tolerance of 
human prostate cancer cells. DU 145 cells and PC-3 cells were frozen in the presence or 
absence of mercuric chloride (HgCb) a universal inhibitor of the AQPs (Niemietz and 
Tyerman, 2002). Low dose (0.075mM) of HgCli had a minimal effect on DU 145 cell 
survival suggesting that HgCb was not toxic to unfrozen cells. To test the role of AQPs 
in freeze tolerance of prostate cancer cells, DU 145 was fi*ozen in the presence or absence 
of HgCli. Cells exposed to combined treatment were more seriously damaged by freezing 
at -10°C compared to cells exposed to cryotherapy alone. These findings indicate that 
AQPs play a crucial role in freeze tolerance of human prostate cancer cells. The use of 
HgCli inhibits water transport through the AQP water channels during the extracellular 
ice formation which is essential for freeze tolerance (Philip et al. 2008). Izumi et al. 
(2006) suggested that freezing stress requires control of water and solutes across the 
plasma membrane and cell survival of freezing depends on portion of intracellular water
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replaced by cryoprotectant. In this study the main aim is to increase the efficacy of 
cryotherapy, therefore no cryoprotectant was used.
To further characterise the role of the AQPs in fireeze tolerance of human prostate cancer 
cells, RNA interference technology was used to inhibit AQP3, a new approach which was 
used recently to study the effect of silencing of a gene of interest and thus to analyze its 
function (Nicchia et a l 2003). Results demonstrate that AQP3 silencing experiment was 
conducted under optimal conditions and all cells treated maintained their viability above 
80% at the end of experiment. AQP3 inhibition by siRNA was specific and highly 
efficient in treating human prostate cancer cells in vitro and the inhibition was confirmed 
by 3 independent Western blot and RT-qPCR experiments. Cells which lack specific 
AQP3 function showed increased response to cryoinjury compared to normal cells. These 
data provides compelling evidence that expression of AQP3 on the plasma membrane is 
essential to protect human prostate cancer cells from cryoinjury, suggesting a specific 
functional role of the AQP in cancer cells biology.
These important findings suggest that AQP3 inhibition by pharmacological blockers 
might provide a new therapeutic approach for sensitising human prostate cancer cells to 
cryotherapy. Since AQPs inhibitors are not at present available as pharmacological agents 
that can be used clinically, AQP3 inhibition studies using siRNA technology using a 
virus victor will be very useful to examine the hypothesis in vivo.
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5.6 Conclusion
In conclusion the results presented in this study indicate that prostate cancer cells express 
AQP3 which may play a role in the physiological process such as water transport. 
Furthermore, the expression of AQP3 increases with decreasing temperature. It was also 
demonstrated a direct involvement of AQP3 in human prostate cancer cells resistance to 
cryo injury. Inhibition of AQP3 by siRNA increases sensitivity of prostate cancer cells to 
freeze injury. Further research in the clinical application of AQPs inhibitors is crucial.
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Chapter 6
Characterization of the 
molecular features of prostate 
cancer cells treated with 
cryotherapy by gene 
microarray
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6.1 Introduction
Prostate cancer is recognized as one of the most common non-dermatological male 
cancer in the UK accounting for almost 1 in 4 of all new male cancers (Cancer research 
UK 2007). Radical prostatectomy and extemal-beam radiotherapy remain the two major 
techniques for the treatment of prostate cancer with acceptable results although they may 
be associated with varying degrees of morbidity (Arai et a l 1996) (Kupelian et a l 2004) 
(Aus et a l 2005) (Lim et a l 1995). In the early 1960s, cryotherapy emerged as a 
minimally invasive alternative treatment for localized or locally advanced prostate 
cancer. Cryotherapy was abandoned because of high rates of significant complication 
especially urethral sloughing and rectourethral fistula. In 1990s, cryotherapy was revived 
following 2 major advances. Firstly, the development of gas-driven cryosystems based on 
the Joule-Thompson effect resulted in more efficient tissue destruction. Secondly, 
improved monitoring of the procedure by real time ultrasound scan (Onik et a l 1993). 
These technical advances in addition to the use of a urethral warming catheter markedly 
reduced the complication rates and led to dramatic improvement in clinical outcome (Han 
et al 2003a). As a result, prostate cryotherapy has re-emerged as an alternative minimally 
invasive treatment option for prostate cancer. Recent clinical case series reported 
biochemical disease free survival rates ranging between 20-70% for salvage treatment, 
and 40-90% for the primary cryotherapy (Ismail, Pandha and Davies 2008) (Mouraviev 
and Polascik 2006).
Cryotherapy results in necrotic cell death, both via mechanical disruption of the cells 
through ice formation, osmotic related changes and post-thaw ischemia (Bischof et a l
174
1997). There is little information available on the molecular changes in prostate cancer 
cells following exposure to freezing injury. Several studies investigated the changes in 
apoptotic genes in response to freezing injury in an attempt to develop new therapeutic 
strategies to increase the efficacy of cryotherapy.
It was demonstrated that cryotherapy results in an increase in Bcl-2 protein levels 12 
hours after freezing prostate cancer cells. Whilst, Bax level remains near to the control 
levels (Clarke et al. 2004). Data from colorectal cancer cells showed no change in Bcl-2 
and Bax levels following cryotherapy (Yang et al. 2003). The role of caspases in 
cryoinjury was also investigated (Stroh et al. 2002). It was demonstrated that the freeze- 
thaw cycle is associated with caspase 3 activation in hematopoietic progenitor cells. 
Inhibition of caspase 3 activation improved cell survival following freezing injury. Over 
expression of Bcl-2 protein provided further protection against cryoinjury suggesting the 
involvement of the intrinsic mitochondrial apoptotic pathway in cryoinjury associated 
cell death. Similar results were demonstrated by Hollister et al. (1998) in prostate cancer 
cells and Hanai et al. (2001) in colon cancer cells. Yang et al. (2003) investigated the role 
of tumour suppressor gene p53 and its down stream regulator in the control of
cryotherapy induced apoptosis in colorectal cell lines. They demonstrated that p53 was 
not upregulated after cryotherapy. The protein expression was increased 4
hours after cryotherapy in p53 mutant cells suggesting that cryotherapy induced apoptosis 
is a p53 independent mechanism. Furthermore, it was demonstrated that despite Bax 
protein levels were not changed in response to freezing, there was a significant
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redistribution of Bax into the mitochondria which was associated with a significant 
reduction in mitochondrial membrane potential 2 hours after cryoinjury.
The role androgen receptor (AR) expression in prostate cancer cells in response to 
freezing was investigated (Klossner et al. 2008). Androgen sensitive cells (LNCaP) were 
more sensitive to freezing injury than androgen resistant cells (PC-3). Transfection of 
PC-3 cells with AR increased their sensitivity to freezing to the same level of LNCaP 
cells. AR levels decreased significantly following exposure to freezing injury implying 
the possible role of AR in freeze resistance status.
In this study the expression patterns of the differentially regulated genes in response to 
cryotherapy are reported and the significant biological and molecular functions are 
identified.
6.2 Study objectives
• To better understand the precise molecular features of prostate cancer cells 
following exposure to freezing injury.
• To identify the up and downregulated genes upon exposure to freezing 
temperatures which are involved in cancer cell resistance to cryotherapy.
• To identify candidate genes whose products could serve as molecular targets for 
development of adjuvant therapy in conjunction to cryotherapy.
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6.3 Study design
DU 145 cells were treated with cryotherapy in the presence or absence of freezing 
medium (10% DMSO) as described in material and methods to a temperature of -10°C 
and thawed in a 55°C water bath to room temperature. Cells then recovered at 37°C for 
24 hour. Total RNA was isolated using RNeasy ® Plus mini kit (Qiagen, UK) according 
to the manufacturers’ protocol. cRNA for each sample was synthesised by using One- 
Color Low RNA Input Linear Amplification Kit PLUS (Invitrogen, Paisley, UK) and was 
labeled with Cy3 by a direct labelling method. Following purification by RNeasy ® Plus 
mini kit, cRNA was fragmented by incubation in the fragmentation buffer at 60°C for 30 
minutes. The fragmented and labelled cRNA was hybridized to the human 4x44 K cDNA 
chip (Invitrogen, Paisley, UK). After washing the slides was scanned using Agilent’s 
microarray scanner (Agilent, Cheshire, UK) and gene expression profiles were analysed 
by Genespring GX 7.3.1 software. Expression patterns in treated cells were compared to 
untreated cells which served as a control. Go ontology classification was performed using 
a web based tool for functional profiling (G. Profiler) (Reimand et a l 2007).
6.4 Results
6.4.1 Overview of the differentially regulated genes in the different groups
Gene expression profile of DU 145 cells treated with cryotherapy was assessed using 
cDNA microarray technique. Two independent experiments showed 202 differentially 
expressed genes at the mRNA level with more than twofold change in gene expression. 
All reported genes were statistically significant (R<0.05). Among these genes, 168 genes 
were upregulated and 34 genes were downregulated. For cells cooled to -10°C in the
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presence of freezing medium, a total of 194 were differentially expressed with 168 
upregulated and 26 genes downregulated. Exposure to freezing medium alone resulted in 
upregulation of 55 genes and downregulation of 6 genes (Table 6.1). Figure 6.1 shows 
the scattered blot of the normalised expression data using genespring GX software. Data 
in red are the upregulated genes and data in blue are the downregulated genes.
After clustering based on biological function, it was found that cryotherapy upregulated 
genes which are involved mainly in cell cycle regulation, cell death, signal transduction, 
transport, immune response, response to stimulus and transcription. On the other hand, 
cryotherapy downregulated genes that are related mainly to metabolism, cell death, signal 
transduction and response to stimulus (Table 6.2).
Table 6.1 Total numbers of differentially expressed genes among different tested groups 
compared to untreated DU 145 cells.
[UT= untreated DU 145 cells, FM=cells exposed to freezing medium, -10=cells treated 
with cryotherapy at -10°C and -10(FM) = cells treated with cryotherapy at -10°C in the 
presence of freezing medium].
Group Upregulated genes Downregulated genes
UT v s .-10 168 34
UT vs. -IO(FM) 168 26
UT vs. FM 55 6
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Up regulated genes Down regulated genes
Figure 6.1 Statistically significant co-regulated genes in the tested groups. (A) A scatter blot 
shows significantly up and down regulated genes in DU 145 cells treated with cryotherapy in 
the presence or absence of freezing medium. (B) Venn graphs show total numbers of genes 
in the different groups.
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Table 6.2 Total number of differentially up or downregulated genes according to 
biological function in the treated groups compared to untreated cells. Genes regulating 
cell cycle, cell death metabolism response to stimulus and signal transduction have been 
regulated with cryotherapy.
Group No in category -10 -10(FM) FM
Up Down Up Down Up Down
Cell growth 245 2 2 3 - - 1
Angiogenesis 108 3 - 3 - - -
Cell differentiation 820 6 - 7 - - -
Metabolism 12150 91 11 92 - 22 4
Transcription 3517 33 2 32 1 8 -
Death 844 25 7 28 4 6 5
Immune response 1148 17 4 20 4 6 2
Transport 4061 19 6 19 4 3 2
Cell cycle 1151 28 5 28 2 6 4
Signal transduction 4419 61 10 61 6 16 4
Response to 
stimulus 2874 43 12 45 7 14 4
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6.4.2 Unsupervised clustering approach to identify gene expression patterns 
among different groups
Gene clustering helps to identify co-regulated genes and may demonstrate that a set of 
genes effectively differentiate across different treatment groups. Genes are frequently 
clustered according to their expression patterns. Genes with similar expression patterns 
may share the same biological and molecular function and therefore tend to cluster 
together. As data on the gene expression profile following cryotherapy are not available, 
clustering in this study was performed using unsupervised method. The unsupervised 
clustering methods depend on the clustering algorithm and distance metric was used (Do 
and Choi 2008). In this study both hierarchical and self organizing feature maps (SOFM) 
were used to analyse the data.
Hierarchical clustering has been used widely to analyse gene microarray output data. 
Cluster algorithms are designed to divide genes or conditions into groups that have 
similar expression patterns. In gene tree, genes are represented on the left and groups are 
represented with branches on the top of the tree structure. The length of the branch 
between 2 genes indicates how correlated their expression patterns are the shorter the 
distance the higher the correlation is. Standard correlation was used in this study which 
measures the directional similarity of 2 expression profiles. A correlation coefficient of 1 
indicates perfect correlation, 0 indicates no correlation and -1 means that they are anti 
correlated.
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SOFM transform the input microarray data into groups of similar properties. Genes are 
plotted on a one or two dimensional discrete map. Genes or experiments that are plotted 
near each other are more strongly related than data points that are far apart (Do and Choi 
2008). In this study a two dimensional 4x3 grid with iteration of 10000 was used to 
classify genes with similar expression patterns.
6.4.2.1 Hierarchical clustering
Gene expression profiles were compared among 4 groups, untreated DU 145 cells (UT), 
DU145 cells exposed only to freezing medium (FM), cells cooled to -10°C (-10) and cells 
cooled to -10°C in the presence of freezing medium (-IO(FM)). Figure 6.2 shows the 
gene expression patterns related to the 4 groups tested. The most notable property of the 
clustered data was that untreated groups clustered together and showed similar gene 
expression patterns. On the other hand, groups treated with cryotherapy showed similar 
gene expression patterns. Gene up and down regulation in (-10) group were more 
prominent than the -10(FM) group which reflects the cryoprotectant effect of the freezing 
medium. A central feature of the cluster image (Figure 6.2) is that larger group of the 
clustered genes showed increased expression following exposure to freezing compared to 
the untreated control. Conversely, smaller group showed reduced expression. 
Significantly co-regulated genes were classified into 6 clusters, 4 clusters of upregulated 
genes, one cluster of downregulated genes and one cluster of genes upregulated in the - 
10(FM) group.
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(-10) -IO(FM) FM UT
Figure 6.2 A dendrogram of an unsupervised hierarchical clustering analysis of the 
significantly regulated genes across four tested groups. Cells exposed to freezing with 
and without freezing medium showed similar expression profile and cluster together. The 
protective effect of freezing medium is noticeable.
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Cryotherapy downregulated important genes involved in specific biological functions 
including, genes control response to stimulus (12 genes), death genes (7 genes), genes 
responsible for cell proliferation (7 genes) and signal transduction (10 genes), cell 
communication (15 genes) and biological process regulation (17 genes). These genes are 
also subjected to cluster analysis according to cellular components. Downregulated genes 
were mainly responsible for transcription and translation of extracellular components 
proteins. After clustering based on the molecular function, cryotherapy downregulated 
genes that are involved mainly in protein and receptor binding (Figures 6.3 and 6.4). 
Each of the downregulated genes was mapped to specific KEGG pathway database which 
is a collection of graphical diagrams (KEGG pathway maps) representing molecular 
interaction networks in various cellular processes. Freezing resulted in downregulation of 
important genes involved in the prostate cancer pathway, focal adhesion pathway, 
apoptosis and P53 signalling pathway. Among the genes which are inhibited by 
cryotherapy are interleukin 1 alpha (IL-la) and interleukin 1 beta (IL-ip), interleukin 4 
(IL-4), protein kinase B (AKTl/PKB), tumour protein 53 (TP53) and protein tyrosine 
kinase 2 beta (PTK2B).
IL-la and IL-lp are proinflammatory cytokines. By binding to their receptors, they 
activate transcription factors such as NF-kB and activator protein 1 (AP-1) leading to a 
cascade of events which are involved in cell survival, proliferation and angiogenesis 
(Lindmark et al. 2005). IL-1 mRNA expression has been described in androgen 
independent prostate cancer cell lines (DU 145 and PC-3) and it was correlated to the 
expression of neuroendocrine markers and the inhibition of androgen sensitive cell
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growth (Hoosein 1998). Over expression of IL-la was correlated to increased cell 
proliferation in benign prostatic hyperplasia and prostate cancer (Ricote et ah 2004). The 
absence of IL-ip expression was a characteristic feature of prostate cancer (Ricote et al. 
2004). IL-4 cytokine is produced by T cells, mast cells and macrophages. It plays a 
central role in cell mediated immunity and inflammatory responses (Giver et al. 2007). 
The potential role of IL-4 in the activation of androgen receptor was investigated in 
prostate cancer cells. Serum levels of IL-4 are elevated in patients with hormone 
refractory prostate cancer which imply the role of IL-4 in the development of androgen 
independent state (Takeshi et al. 2005). It was demonstrated that IL-4 increases androgen 
sensitivity of LNCaP cells leading to enhanced cell growth both in the absence and the 
presence of very low doses of androgen (Lee et al. 2008). Furthermore, LNCaP cells 
transfected with IL-4 were more resistant to anti-androgen treatment compared to normal 
cells (Lee et al. 2008). AKTl is an essential member of serine/threonine kinase family 
which is an important mediator of cell survival, growth and metabolic signalling. It 
constitutes an important component of the Phosphoinositide 3-kinases (PI3K) signalling 
pathway. Phosphoinositide 3, 4, 5 triphosphate (PIP3) results in the activation and 
recruitment of AKT to the cell membrane. Activated AKT promotes cell survival and 
growth and protects cells from apoptosis (Cinar et al. 2007). In addition AKT activation 
has been implicated in the development of cancer and may be involved in the resistance 
of cancer cells to conventional therapies (Zhang et al. 2007). TP53 gene is responsible for 
encoding transcription factor p53 in response to various oncogenes and DNA damage. Its 
major role is to protect cells against oncogenesis via the induction of cell cycle arrest, 
DNA repair and apoptotic cell death (Ventura et al. 2007). Loss of wild type p53 function
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play a role in tumour initiation, growth and resistance to conventional therapies (Ventura 
et a l 2007) (Snyder et al 2004) (Bajgelman and Strauss 2006). The role of tumour 
suppressor gene p53 in the control of cryotherapy induced apoptosis in colorectal cell 
lines was investigated (Yang et a l 2003). They demonstrated that cryotherapy has no 
effect on p53 protein expression suggesting that cryotherapy can induce apoptosis is a 
p53 independent mechanism. It was also demonstrated that DU 145 cells express a 
temperature sensitive p53 mutant gene which denotes that p53 protein will have normal 
function under hypothermic conditions (Bajgelman and Strauss 2006). In this study, we 
demonstrated that p53 gene is downregulated in response to cryoinjury, whereas its down 
stream regulator was upregulated more than 5 folds.
Table 6.3 Downregulated genes in DU 145 cells upon exposure to -10°C. Genes involved 
in important biological processes such as response to stimulus, biological regulation and 
cell communication functions.
Gene name Genbank Symbol Fold change
Interleukin 1 alpha NM_000575 ILIA 0.19
Interleukin 1 beta NM_000576 ILIB 0.028
Interleukin 4 NM_000589 IL4 0.149
Protein kinase B NM_005163 AKTl/PKB 0.256
Tumour protein 53 NM_000546 TP53 0.458
Protein tyrosine kinase 2 beta NM_173174 PTK2B 0.211
Tumour necrosis factor ligand superfamily 
member 10
NM_003810 TNFSFIO 0.108
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reg u la tio n  of b io log ical q u a lity  C2) 
reg u la tio n  of b io log ical process C2>
reg u la tio n  of m u ltic e llu la r  organismal process C3) 
reg u la tio n  of ch o les tero l absorp tion  C4) 
negative reg u la tio n  of b io lo g ica l process C3> 
negative reg u la tio n  of c e l lu la r  process C4) 
reg u la tio n  of developmental process C3)
negative reg u la tio n  of developmental process C4) 
reg u la tio n  of programmed c e ll  death C4) 
reg u la tio n  of apoptosis  C5)
negative reg u la tio n  of programmed c e l l  death  C5) 
negative reg u la tio n  o f apoptosis C6> 
p o s itiv e  reg u la tio n  of b io lo g ical process C3) 
p o s itiv e  reg u la tio n  of m etabolic process C4> 
p o s itiv e  reg u la tio n  of c e l lu la r  process C4)
p o s itiv e  reg u la tio n  of c e l lu la r  m etabolic process C! 
reg u la tio n  of signal transduc tion  CD
p o s itiv e  reg u la tio n  of sig n a l transduc tion  C2) 
reg u la tio n  of b io sy n th e tic  process CD
reg u la tio n  of c e l lu la r  b io sy n th e tic  process C2) 
p o s itiv e  reg u la tio n  of b io sy n th e tic  process C2)
p o s itiv e  reg u la tio n  of c e l lu la r  b io sy n th e tic  process C3)
c e ll  communication CD 
signal transduc tion  C2)
in tr a c e l lu la r  s ig n a lin g  cascade C3> 
p ro te in  kinase cascade C4) 
c e l l - c e l l  s igna ling  C2)
term domain and name
1334
825
530
80:0005576
80:0044421
80:0005615
e x tra c e llu la r  region CD
e x tra c e llu la r  region p a r t  C2) 
e x tra c e l lu la r  space C3)
2.66e-05 872
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Q Q6.T
21 21 80:0005515
80:0008034
80:0005102
80:0008083
term domain and name
p ro te in  binding CD
lip o p ro te in  binding C2) 
recep to r binding C2)
growth fa c to r  a c t iv i ty  C3)
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P-value T Q Q&T t6fH ID t6rm domain and nam6
1 1 1 1 1 1 1 1 1 1 i 1 1 1 i n i 1.326-03 56 18 3 KEGG:05223 k6 Non-small C6ll lur^ cancor (1)
T U T U  1 1  I I 1 1 1 n i l 3.55e-04 89 18 4 KEGG:05215 k6 Prostata cancar (1)
n  1 1 I I 1 1 1 1 n T m m 1.09e-03 197 19 5 KEGG:04510 k6 Focal adhesion (1)
I I 1 1 1 1 1 1 1 1 1 1 1 1  m 1.06e-03 52 18 3 KEGG:05213 k6 Endometrial cancer (1)
. 1 1 I I  m i l l M  1 1 1.35e-03 135 17 4 KEGG:04650 k6 Natural k ille r cell mediated cytotoxicity (1)
]  r r m i  1 1 1 4.68e-04 42 17 3 ŒGG:05219 k6 Bladder cancer (1)
n i l  11 m l.OOe-03 30 2 KEGG:05010 k6 Alzheimer's disease (1)
n  1 1 1 1 1 1 1 T T m 7.33e-05 68 16 4 KEGG:04U5 k6 p53 signaling pathway (1)
_ U . l . . L . L L I . . l  1 1 9.836-05 64 IB 4 KEGG:05214 k6 Glioma (1)
m n n n 1.996-04 263 7 4 KEGG:04060 k6 Cytokine-cytokine receptor interaction (1)
1 1 1 1 1 1 1 1 1 1 I I 11 m 9.446-04 50 IB 3 KEGG:04150 k6 mTOR signaling pathway (1)
m T I T l T I  1 1 j j l l l l l  #  i Q 1.316-06 86 21 6 KEGG:C4210 k6 Apoptosis (1)
1 1 1 I I I I  a  I I 1 1 1  1 1 1 1.406-04 70 18 4 KEGG:C@218 k6 Melanoma (1)
NM.000230
NH.000518
NH.000579
NH.000589
m.000039
M1.000927
m.000576
m.002332
NH.000618
M1.173174
W1.003246
Nn.000029
NH.080548
NH.003810
NI1.000051
NH.000546
Nn.002746
NI1.0Ô5163
M1.00Ü01
NM.001045
M1.000575
LEP
CCR5
IL4
fPOAl
ABCBl
ILIB
LRPl
IGFl
PTK2B
Leptin precursor (Obesity factor) (Obese protein). [Soiree:Uniprot/SWISSPK)T;Acc:P41159]
Hemoglobin s ita rit beta (Hemoglobin beta chain) (Beta-globin). [Source:Uniprot/SWlSSPR0T;ftec:P68871]
C-C chemokine receptw t^ s  5 (C-C CKR-5) (CC-CKR-5) (CCR-5) (CCR5) (HlV-1 fusion cireceptor) (CIEMR13) (C0195 antigen). ISourceUniprot/SillSSPROT;Acc;P51681: 
lnterleukin-4 precursor (lL-4) (B-cell stimulatory factor 1) (BSF-1) (Lymphocyte stimulatory factor 1) (Binetrediin) (Pitr^inra) [Source:Uniprot/Sli)lSSPROT;ft( 
ftpolipoprotein ft-1 precursor (Apo-Al) (ApoA-1) [Contains: Apolipoprotein A-1(1-242)1. [Source:Uniprot/SWlSSPROT;Acc:P02647]
Hultick-ug resistance protein 1 (EC 3.6.3.44) (flTP-binding cassette sub-family B member 1) (P-glycoprotein 1) (CD243 ertigen). [Surce:Uniprot/StilSSPROT;ftcc:Pt 
lnterleukin-1 beta precursor (IL-i beta) (Catabolin). [Source:Uniprot/SWlSSPR0T;Acc:P015841
Low-density lipoprotein receptor-related protein 1 precursor (LRP) (Alpha-2-macroglobulin receptor) (A21R) (Apolipoprotein E recptor) (APOER) (CD91 antigen) 
Insulin-like growth factor lA precurscr (IGF-IA) (Somatomedin C) (Mechano growth factor) (HGF). [Source:ikiiprot/SWlSSPROT;Acc:P0.3431 
Protein tirosine kinase 2 beta (EC 2.7.10.2) (Focal acSiesion kinase 2) (FMK 2) (Proline-rich tyrosine kinase 2) (Cell adhesion .inase beta) (CAK beta) (Calc; 
TffiSl Thrombospondin-1 precursor. [Source:Uniprot/SWlSSPROT;Acc:P079961
%T Angiotensinogen precursor (Serpin A8) [Contains: Angiotensin-1 (Angiotensin 1) (Ang 1); Angiotensin-2 (Angiotensin 11) (Ang ll);Angiotensin-3 (Angiotensin 1:
PTPN6 Tyrosine-protein phosphatase non-receptor t^ e  6 (EC 3.1.3.48) (Protein-tyrosine phosphatase 10 (PTP-IC) (Hematopoietic cell pntein-tyrosine phosphatase) (!
TNFSFKTumor necrosis factor ligand superfamily member 10 (TNF-related apoptosis-inckicii^ ligand) (Protein TRAIL) (Apo-2 ligand) (Apo-2) (CD253 antigen). [Source:Ut
ATM Serine-protein kinase ATM (EC 2.7.11.1) (Ataxia telangiectasia mutated) (A-T, mutated). [Source:Uniprot/SWlSSPR0T;Acc:Q133151
TP53 Cellula- tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53) (Antigen NY-CO-13). [Source:Uniprot/SUlSSPR0T;Acc:P046371
MAPK3 Mitogen-activated protein kinase 3 (EC 2.7.11.24) (Extracellular signal-regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinse) (MAP kinase 1) (MAPK 1) '
AKTl RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (RAC-PK-alpha) (Protein kinase B) (PKB) (C-AKT). [Source:Uniprot/SWlSSPBTpAcc:P317491
ACTB Actin, cytoplasmic 1 (Beta-actin). [Source:Uniprot/SWlSSPR0T;Acc:P607091
SLC6A4 Sodium-dependent serotonin transporter (5HT transporter) (5HTT). [Source:Uniprot/SWlSSPR0T;Acc:P316451
ILIA lnterleihin-1 alpha precursor (lL-1 alpha) (Hematopoietin-1). [Source:Uniprot/SWlSSPROT;Acc:P015831
Figure 6.4 Functional classification of the significantly downregulated genes following 
freezing. Term size (T) represents total number of genes annotated to a given function, 
query size (Q) is the total number of genes analysed by the user and intersection size 
(Q&T) is the number of genes in Q that are commonly represented in T.
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Freezing of DU 145 cells in the presence of freezing medium resulted in the increased 
expression of a limited number of genes that are not significantly changed upon exposure 
to either freezing or freezing medium alone. A total of 17 genes were upregulated (Figure 
6.3B). Those gene share biological functions including cell differentiation, cell 
communication and signal transduction. After clustering based on molecular function, it 
was demonstrated that genes mainly involved in protein binding and molecular 
transducer activity were up regulated. The genes with altered expression encodes mainly 
for plasma membrane proteins which of the cellular components (Figure 6.5). Specific 
genes which were up regulated include signal transducers and activators of transcription 1 
(STATl), STATS, insulin-like growth factor binding protein 3 (IGFBP3), integrin beta 1 
(ITGBl), ITGB2 and interleukin 6 (IL-6).
IL-6 is a pro and anti-inflammatory cytokine which regulates growth and differentiation 
of various types of cancers. It was demonstrated that IL-6 is over expressed in androgen 
independent cancer cells (Lou et a l 2000). Increased cell growth and proliferation 
induced by IL-6 is mediated through the janus kinase-signal transducers and activators of 
transcription (JAK-STAT) signalling pathway which transmits IL-6 signals from the cell 
surface to the nucleus (Ni et a l 2000). In this experiment, it was found that the 
combination of freezing and freezing medium resulted in a 5 fold up regulation of IL-6 
compared to the untreated control. Freezing or freezing medium alone resulted only in 
double and 3 times increased expression respectively. The combination of freezing and 
freezing medium also resulted in increased expression of 2 genes that are involved in the 
regulation of the JAK-STAT signalling pathway (STATl and STAT3). Previous studies
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showed that activated STATS is critical for the growth of prostate cancer cells and the 
inhibition of STATS resulted in suppression of the growth of human prostate cancer cells 
(Ni et al. 2000). Downregulation of ITGB2 was identified during malignant 
transformation from PINs to prostate cancer and may be involved in early stages of 
carcinogenesis (Ashida et al. 2004). It was demonstrated here that both ITGBl and 
ITGB2 genes were upregulated in the -10(FM) group. While ITGB2 was over expressed 
to a lesser extent in the other groups, ITGBl expression remains constant. Insulin-like 
growth factor binding protein 3 (IGFBP3) was over expressed in the -IO(FM) group and 
but it was downregulated in the (-10) group. IGFBP-3 exerts antiproliferative and 
proapoptotic effects on prostate cancer cells. The role of IGFBP3 in the modulation of 
prostate cancer cell proliferation is unknown. Serum levels of IGFBP-3 were found to be 
associated with the risk of prostate cancer (Massoner et al. 2008).
Table 6.4 List of genes that were upregulated in the -IO(FM) group.
Gene name Genbank Symbol Fold change
Signal transducers and activators of 
transcription 1
NM_139266 STATl 4.5
Signal transducers and activators of 
transcription 1
NM_213662 STAT3 2.17
Insulin-like growth factor binding protein 3 NM_001013398 IGFBP3 2.73
Integrin beta 1 NM_133376 ITGBl 2.9
integrin beta 2 NM_000211 ITGB2 4.82
Interleukin 6 NM_000600 IL6 4.95
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7.75e-06 42 17 3 60:0007259 BP JAK-STAT cascade (1)
2.52e-05 62 17 3 60:0018212 BP peptidyl-tyrosine modification (1)
4.53e-05 761 17 6 60:0006468 BP protein amino acid phosphorylation (1)
2.29e-05 60 17 3 60:0018108 BP peptidyl-tifosine phosphorylation (2)
2.27e-05 1032 17 7 60:0002376 BP iimune system process (1)
3.74e-06 3335 17 12 60:0032502 BP developmental process (1)
3.36e-06 831 16 7 60:0016265 BP death (2)
1.50e-06 1892 17 10 60:0048869 BP cellular developmental process (1)
1.50e-06 1892 17 10 60:0030154 cell differentiation (2)
3.82e-07 1309 16 9 60:0048468 cell development (1)
3.36e-06 831 16 7 60:0008219 BP cell death (2)
2.40e-06 790 16 7 60:0012501 BP programmed cell death (3)
2.26e-06 783 16 7 60:0006915 BP apoptosis (4)
2.55e-05 71 15 3 60:0048747 BP muscle fiber development (2)
6.70e-05 98 15 3 60:0007519 BP skeletal muscle development (1)
2.55e-05 71 15 3 60:0048741 BP skeletal muscle fiber development (2)
l.lOe-05 995 16 7 60:0050793 BP regulation of developmental process (1)
5.31e-06 827 17 7 60:0008283 cell proliferation (1)
l.lOe-05 4479 17 13 60:0007154 BP cell communication (1)
3.86e-05 4136 17 12 60:0007165 BP signal transduction (2)
9.03e-05 45 6 2 60:0019221 BP cytokine and chemokine mediated signalir^ pathway (1)
5.64e-06 1213 17 8 60:0048518 BP positive regulation of biological process (1)
2.83e-06 1106 17 8 60:0048522 BP positive regulation of cellular process (2)
3.06e-06 258 17 5 60:0008284 BP positive regulation of cell proliferation (1)
P-value T Q Q&T term ID term domain and name
5.22e-05 1923 15 8 60:0044459 CC plasma membrane part (1)
3.18e-05 89 13 3 60:0042611 CC fWC protein complex (1)
P-value T Q Q&T term ID term domain and name
4.95e-05 7345 11 11 60:0005515 MF protein binding (1)
7.02e-06 2844 17 11 60:0060089 MF molecular transducer activity (1)
7.02e-06 2844 17 11 60:0004871 MF signal transducer activity (2)
;5.14e-U 154 17 7 60:0005057 MF receptor signaling protein activity (3)
' 5.51e-07 4 6 2 60:0005062 MF hematopoietin/interferon-class (D200-domain) cytokine recep
5.46e-05 12 17 2 60:0004716 f f receptor signaling protein tyrosine kinase activity (4)
P-value T Q Q&T term ID term domain and name
5.21e-05 73 15 4 KE60:05212 ke Pancreatic cancer (1)
5.46e-04 146 14 4 KE66:04514 ke Cell acSiesion molecules (CAMs) (1)
5.74e-04 56 15 3 KE66:05223 ke Non-small cell lung cancer (1)
4.04e-04 135 14 4 KE66:04650 ke Natural k ille r cell mediated cytotoxicity (1)
Eukaryotic translation initiation factor 5B (eIF-5B) (Translation initiation factor lF-2). [Source:Uniprot/StllSSPR0T;Acc:060841]
Signal transducer and activator of transcription 3 (Acute-phase response factor). [Source:Uniprot/SlillSSPR0T;Acc:P40763]
l-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma 1 (EC 3.1.4.11) (Phosphoinositide phospholipase C) (PLC-gamna-1) (Phospholipase C-gamm. 
Apolipoprotein E precursor (Apo-E). [Source:Uniprot/SUlSSPR0T;Acc:PO2649]
HLA class 1 histocompatibility antigen, B-7 alpha chain frecursor (MHC class 1 antigen B*7). [Source:Uniprot/SWlSSPR0T;Acc:P018891 
Signal transducer and activator of transcription 1-alpha/beta (Transcription factor lSGF-3 ccmponents p91/p84). [Source:Uniprot/SWlSSPR0T;Acc:P422241 
Insulin-like growth factor-binding protein 3 precursor (lGFBP-3) (IBP- 3) (IGF-bindir^ protein 3). [Source:Uniprot/SillSSPR0T;Acc:P17936]
RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Raf- 1) (C-RAF) (cRaf). [Source:Uniprot/SWlSSPfiOT;Acc:P040491 
Cell division protein kinase 2 (EC 2.7.11.22) (p33 protein kinase). [Source:Uniprot/SWlSSPR0T;Acc:P249411
Amyloid beta A4 protein precurscr (APP) (ABPP) (Alzheimer disease amyloid protein) (Cerebral vascular amyloid peptide) (CVAP) (Protease nexin-11) (PN-. 
Integrin beta-1 precursor (Fibronectin receptor subunit beta) (Integrin VLA-4 subunit beta) (CD29 antigen). [Source:Uniprot/SWlSSPR0T;Acc:P055561 
MHC class 1 HLA-J antigen (Fragment). [Source:Uniprot/SPTRErBL;Acc:Q30175]
HLA class 11 histocompatibility antigen, DRBl-1 beta chain precursor (MHC class 1 antigen DRBlfl) (DR-1) (DPI). [ Source : Un i prot/SWISSPROT;Acc : P042291 
Integrin beta-2 precursor (Cell surface adhesion glycoproteins LFA- l/CR3/pl50,95 subunit beta) (Complement receptor C3 subunit beta) (CD18 antigen). . 
Receptor tyrosine-protein kinase erbB-2 precursor (EC 2.7.10.1) (pl85erbB2) (C-erbB-2) (NEU proto-oncogene) (Tyrosine kinase-type cell surface recepto. 
lnterleukin-6 precursor (lL-6) (B-cell stimulatory factor 2) (BSF-2) (Interferon beta-2) (Hybridoma growth factor) (CTL differentiation factor) (CDF).. 
Tyrosine-protein kinase Lyn (EC 2.7.10.2). [Source:Uniprot/SWlSSPR0T;Acc:P079481
Figure 6.5 Functional profile of genes upregulated upon exposure freezing in the presence of 
freezing medium.
NM.0159C4 E1F5B
NM.213662 STAT3
NM.002660 PLC61
m.000041 APOE
NM.005514 HLA-B
NM.139266 STATl
NM.001013398 16FBP3
NM_(W2880 RAFl
NM.001798 C0<2
NM.000484 APP
NM.133376 1T6B1
BC089454 H.A-J
NM.002124 W.A-DR!
NM.000211 1T6B2
NM.001005862 E%B2
NM.000600 1L6
NM.002350 LYN
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Unsupervised hierarchical clustering analysis of gene expression patterns across the 4 
tested groups revealed 4 distinct clusters of upregulated genes which have different 
expression patterns. Cluster 1 (Figure 6.6) showed enrichment for sets of genes involved 
in distinct functional categories such as macromolecules metabolic process, cellular 
metabolic process (mainly nucleic acid metabolism) and cell cycle process. Cluster one 
includes caspase 3 (CaspS), toll like receptor 2 (TLR2), Interleukin 18 (IL-18), 
retinoplastoma associated protein (RBI) and myc proto-oncogen protein (MYC) (Figure 
6.7).
In Cluster 2 (Figure 6.8) the total number of upregulated genes was 28. This cluster is 
dominated by genes encoding proteins responsible for regulation of biological process 
(18 genes), regulation of cellular process (18 genes), cell death (10 genes), cell 
differentiation (13 genes) and intracellular signalling pathway (11 genes) (Figure 6.9). 
When the molecular function was examined, genes in this cluster were found to be 
involved in protein C terminus binding. Pathway analysis revealed the representation of 
genes in cluster 2 within important biological pathway including prostate cancer pathway, 
epidermal growth factor receptor (ErbB) pathway and focal adhesion pathway. Genes in 
this cluster include epidermal growth factor receptor (EGFR), beta catenin (CTNNBl), 
cell division control proteins 2 and 42 (GDC), cyclin-dependent kinase inhibitor IB 
(CDKNIB) and transcription factor E2F1.
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Cluster 1
ll
Figure 6.6 Gene cluster 1 which was over 
expressed in the (-10) group. Cluster 1 enriched 
for genes involved in cellular metabolic process 
specifically nucleic acid metabolism.
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5.12e-05 7179 18 15 60:0043170 BP macromolecule metabolic process (1)
2.17e-07 721 14 7 60:0007049 BP cell cycle (1)
2.68e-07 432 14 6 60:0022402 BP ce ll cycle process (2)
4.09e-05 350 11 4 60:0022403 BP ce ll cycle phase (3)
1.78e-05 283 11 4 60:0000279 BP M phase (4)
2.31e-05 80 14 3 60:0007050 BP ce ll cycle «-rest (3)
1.21e-04 44 7 2 60:0022411 BP ce llu lar competent disassembly (1)
2.43e-05 20 7 2 60:0006921 BP cell s tructure disassembly during apoptosis (2)
4.52e-05 8405 18 16 60:0044237 BP ce llu lar metabolic process (1)
3.58e-06 4076 18 13 60:0006139 BP nucleobase, nucleoside, nucleotide and nucleic acid metabolic
2.01e-06 910 15 7 60:0006259 BP ONft metabolic process (3)
7.00e-05 107 15 3 60:0006310 BP DNA recombination (4)
7.70e-06 8 10 2 60:0006312 BP mitotic recombination (5)
5.20e-05 20 10 2 60:0007131 BP meiotic recombination (5)
4.16e-05 26 7 2 60:0006308 BP ONA catabolic process (4)
2.15e-05 13)1 15 7 60:0006996 BP organelle organization and biogenesis Cl)
8.04e-05 36 7 2 60:0006997 BP nuclear organization and biogenesis (2)
2.43e-05 20 7 2 60:0030262 BP apoptotic nuclear changes (3)
1.54e-05 16 7 2 60:0006309 BP ONA fragmentation during apoptosis (4)
5.80e-05 4703 17 12 60:0050789 BP regulation of biological process Cl)
1.05e-04 401 5 3 60:0051239 BP regulation of m ulticellular organismal process C2)
7.37e-06 187 14 4 60:0002682 BP regulation of immune system process C2)
2.40e-05 1213 16 7 60:0048518 BP positive regulation of biological process C2)
5.30e-05 374 11 4 60:0051094 BP positive regulation of developmental process C3)
3.05e-05 478 16 5 60:0009893 BP positive regulation of metabolic process C3)
3.04e-05 4430 17 12 60:0050794 BP regulation of ce llu lar process C2)
5.22e-05 105 14 3 60:0050865 BP regulation of ce ll activation C3)
5.22e-05 105 14 3 60:0002694 BP regulation of leukocyte activation C4)
4.12e-05 97 14 3 60:0051249 BP regulation of lymphocyte activation C5)
2.06e-05 77 14 3 60:0050863 BP regulation of T ce ll activation C6)
2.23e-05 529 14 5 60:0042127 BP regulation of ce ll pro liferation  C3)
6.29e-06 52 14 3 60:0032944 BP regulation of mononuclear ce ll pro liferation  C4)
6.29e-06 52 14 3 60:0050670 BP regulation of lymphocyte p ro liferation  C5)
3.05e-06 41 14 3 60:0042129 BP regulation of T ce ll p ro liferation  C6)
2.75e-06 10 5 2 60:0046006 BP regulation of activated T ce ll p ro liferation  C7)
6.84e-05 330 14 4 60:0051726 BP regulation of ce ll cycle (3)
9.80e-06 201 14 4 60:0045786 BP negative regulation of ce ll cycle C4)
1.30e-04 66 5 2 60:0030155 BP regulation of ce ll adhesion (3)
1.31e-05 1106 16 7 60:0048522 BP positive regulation of ce llu lar process (3)
9.86e-05 260 7 3 60:0043068 BP positive regulation of programmed ce ll death (4)
5.60e-05 215 7 3 60:0012502 BP induction of programmed ce ll death (5)
2.78e-05 469 16 5 60:0031325 BP positive regulation of ce llu la r metabolic process (4)
4.51e-05 100 14 3 60:0043086 BP negative regulation of ca ta ly tic  ac tiv ity  (1)
1.07e-05 62 14 3 60:0051348 BP negative regulation of transferase ac tiv ity  (2)
1.02e-05 61 14 3 60:0033673 BP negative regulation of kinase ac tiv ity  Cl)
1.02e-05 61 14 3 60:0006469 BP negative regulation of protein kinase ac tiv ity  (2)
9.64e-05 258 7 3 60:0043065 BP positive regulation of apoptosis (1)
5.53e-05 214 7 3 60:0006917 BP induction of apoptosis (2)
1.05e-04 41 7 2 60:0008629 BP induction of apoptosis by in trace llu la r signals (3)
4.32e-05 14 14 2 60:0030888 BP regulation of B ce ll pro liferation  (1)
2.14e-05 10 14 2 60:0050869 BP negative regulation of B ce ll activation (1)
2.14e-05 10 14 2 60:0045736 BP negative regulation of cyclin-dependent protein kinase ac tiv ity
5.69e-05 16 14 2 60:0042130 BP negative regulation of T ce ll pro liferation  Cl)
2.86e-06 4 14 2 60:0030889 BP negative regulation of B ce ll p ro liferation  Cl)
3.16e-05 827 16 6 60:0008283 BP cell pro liferation  Cl)
3.23e-07 73 16 4 60:0032943 BP mononuclear ce ll p ro liferation  C2)
4.46e-05 252 16 4 60:0001775 BP ce ll activation Cl)
2.81e-05 224 16 4 60:0045321 BP leukocyte activation Cl)
1.77e-05 199 16 4 60:0046649 BP lymphocyte activation C2)
3.23e-07 73 16 4 60:0046651 BP lymphocyte pro liferation  C3)
6.66e-06 53 14 3 60:0042098 BP T cell p ro liferation  C4)
4.77e-06 13 5 2 60:0050798 BP activated T ce ll p ro liferation  C5)
1.66e-04 1 3 1 60:0042891 BP antib io tic  transport Cl)
1.66e-04 1 3 1 60:0042892 BP chloramphenicol transport C2)
2.69e-05 21 7 2 60:0008637 BP apoptotic mitochondrial changes Cl)
1.17e-05 14 7 2 60:0001836 BP release of cytochrome c from mitochondria C2)
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NM.004346 CASP3
NM_000201 ICAMl
NM.003264 TLR2
NM.013448 BAZIA
NM.001562 1L18
NM.001014763 ETFB
NM.002467 MYC
NM_001813 CENPE
NM.012415 RAD54B
NM.005732 RAD50
NM.000321 RBI
NM.000946 PRIMl
NM_024094 NP_076999
NM.058197 CDKN2A
NM.020159 SMARCADl
NM.000194 HPRTl
NM.007152 2NF195
NM.004688 NMI
P-value T Q Q&T term ID term domain and name
5.58e-05 2851 15 9 00:0044422 CC organelle part (1)
5.46e-05 2843 15 9 60:0044446 CC in trace llu la r  organelle part (2)
3.60e-06 993 15 7 60:0044428 CC nuclear pa rt (3)
1.44e-05 532 12 5 60:0005694 CC dromosome (1)
P-value T Q Q&T term ID term domain and name
2.14e-05 10 14 2 60:0004861 MF cyclin-dependent protein kinase inh ib ito r ac tiv ity
1.66e-04 1 3 1 60:0001875 MF lipopolysaccharide receptor ac tiv ity  (1)
1.66e-04 1 3 1 60:0051076 MF 6ram-positive bacteria l binding (1)
P-value T Q Q&T term ID term domain and name
7.36e-05 42 14 3 KE66:05219 ke Bladder cancer (1)
4.35e-04 76 14 3 l€66:05220 ke Chronic myeloid leukemia (1)
l.O le-03 135 2 2 KE66:04650 ke Natural k i l le r  ce ll mediated cyto toxicity  (1)
3.55e-03 15 1 1 KE66:05050 ke Dentatorubropa11ido1uysi an atrophy (DRPLA) (1)
P-value T Q Q&T term ID term domain and name
5.53e-04 1 1 1 REAC:202969 re Caspase mediated cleavage of beta-catenin (1)
5.53e-04 1 1 1 REAC:202966 re Caspase mediated cleavage of HlP-55 (1)
Caspase-3 precursor (EC 3.4.22.56) (CASP-3) (Apopain) (Cysteine protease CPP32) (Yama protein) (CPP-32) (SREBP cleavage ac tiv ity  1) (SCA- 
In te rce llu la r adhesion molecule 1 precursor (lCAM-1) (Major group rhinovirus receptor) (CD54 antigen). [Source :Un i prot/SWISSPROT; Acc:P053 
T o ll-like receptor 2 precursor (Toi1/interleufcin 1 receptor-like protein 4) (CD282 antigen). [Source:Uniprot/SUISSPR0T;Acc:0606031 
Bromodomain adjacent to  zinc finger domain protein lA (ATP-utilizing chromatin assembly and remodeling fac to r 1) ChACFl) (ATP-dependent c 
Interleukin-18 precursor (lL-18) (Interferon-gamma-inducing facto r) (IFN-gamma-inducing fac to r) (In terleukin-1  gamma) (IL-1 gamma) (Iboct 
Electron tran sfe r flavoprotein subunit beta (Beta-ETF). [Source:Uniprot/SWlSSPR0T;Acc:P38U7]
Myc proto-oncogene protein (c-Myc) (Transcription facto r p64). [SourcelUniprot/SWISSPROT;Acc:P011061 
Centromeric protein E (CENP-E). [ Source :lln i prot/SW I SSPROT ; Acc : Q02224]
DNA repair and recombination protein RAD54B (EC 3 .6 .1 .-)  (RAD54 homolog B). [Source :Un i prot/SW1SSPROT; Acc:Q9Y6201 
DNA repair protein RAD50 (EC 3 .6 .- .- )  (hRAD50). [Source :Un i prot/SWISSPROT;Acc:092878]
Retinoblastoma-associated protein (PPUO) (P105-RB) (RB). [Source:Uniprot/SUlSSPR0T;Acc:P064003
DNA priraase small subunit (EC 2 .7 .7 .-)  (DNA primase 49 kOa subunit) (p49). [Source:L)niprot/SWlSSPROT;Acc:P496421
defective in s is te r  chromatid cohesion homolog 1 [Source:RefSeq_peptide; Acc:NP_076999]
Cyclin-dependent kinase inhib ito r 2A, isoform 4 (pl4ARF) (pl9ARF). [Source:Uniprot/SWlSSPR0T;Acc:Q8N7261
SWl/SNF-related m atrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1 (EC 3 .6 .1 .-)  (ATP- dependent 
Hypoxanthine-guanine phosphoribosyltransferase (EC 2 .4 .2 .8) (HGPRT) (HGPRTase). [Source:Uniprot/Sli)lSSPROT;Acc:P00492]
Zinc finger protein 195. [Source :Un i prot/SW1SSPROT; Acc:0146281
N-myc-interactor (Nmi) (N-myc and STAT in te rac to r) . [Source :Uniprot/SWISSPROT; Acc:0132871
Figure 6.7 Functional profile o f  up regulated genes located in cluster 1.
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Figure 6.8 Gene cluster 2 which was over 
expressed in the (-10) group. Cluster 2 
enriched for genes involved in regulation of 
biological and cellular processes.
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■  i l  | a_23_P29495 (CTNNB: FLJ25606; FU37923; DKFZp68...
■  ■ H a_23_P138507 (CDK1; CDC28A; MGC111195; DKFZp6... 
m  H a_23.P11507 (FLJ10362; DKFZP564I052; DKFZp313N...
■  I  ■  ■ a_24_P42633 (G25K; CDC42Hs)
■  ■  ■  | a_23_P123343 (CML66; FU14991) 
m  | a_23_P42935 (BRAF1; RAFB1; B-raf 1; MGC126806; M... 
m  | a_23_P148798 (UCH37; CGI-70)
■  H  | a_23_P19313 (GTF2D; SCA17; TFIID; GTF2D1; MGC11...
■  ■  ■  ■ a_23_P213661 (FLJ21506: K1AA0433)
■  ■  I  | a_23_P166716 (FLJ20432)
■  ■  ■  | a_23.P133284 (FU11159)
m  | a_23_P23765 (CENPR; NRIF3; TAP20; CENP-R; HSU3... 
m  | a_23_P56865 (MrDb; FLJ33908)
■  ■  ■  |A _ 23_ P 98 431  (UPS; PBGD; PBG-D)
■  H  | a_23_P122052 (LOC493869; UNQ847) 
m  | a_23_P99027 (CFG; NS1; SHP2; BPTP3; PTP2C; PTP-... 
m  |A _ 23_ P 20 799 9  (APR; NOXA)
■  H  |A _ 2 3 _ P 6 7 0 4 2  (MOS; HMCS; FLJ20733) 
m | A _ 2 4 _ P 8 1 8 4 1  (KIP1; MEN4; CDKN4; MEN1B; P27KIP1) 
m  |A _ 2 3 _ P 4 8 6 3 7  (HIF1A)
m  |A _ 2 3 _ P 8 0 0 3 2  (RBP3; E2F-1; RBBP3)
1 1  | a_23_P98183 (CTLO; HRAS1; K-ras; N-ras; RASH1; c-b... 
- [ # 0 1 1  ■  | a_23_P59677 (RINT-1; DKFZp667H2324)
H  | a_23_P109143 (CJD; GSS; PrP; ASCR; PRIP; PrPc; CD... 
■  U t ) E 1 A _ r 6 0 _ a 2 0  
0 H + ) E 1 A _ r 6 O _ a 9 7
1 1  |A _ 23_ P 14 50 2 4  (BAR; B2AR; ADRBR; ADRB2R; BETA2... 
1 1  |A _ 23_ P 12 08 8 3  (HO-1; bK286B10)
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1.09e-05 4703 28 18 K):0050789 BP regulation of biological process (1)
8.70e-09 1285 28 13 00:0048519 BP negative regulation of biological process (2)
8.51e-06 995 28 9 00:0050793 BP regulation of developmental process (2)
9.02e-07 371 28 7 00:0051093 BP negative regulation of developmental process (3)
4.1Se-05 1213 28 9 00:0048518 BP positive regulation of biological process (2)
4.37e-06 4430 28 18 00:0050794 BP regulation of cellular process (2)
1.29e-05 555 28 7 00:0043067 BP regulation of programmed cell death (3)
1.20e-05 549 28 7 00:0042981 BP regulation of apoptosis (4)
4.00e-09 1205 28 13 00:0048523 BP negative regulation of cellular process (3)
3.24e-05 253 28 5 00:0043069 negative regulation of programmed cell death
3.06e-05 250 28 5 00:0043066 BP negative regulation of apoptosis (5)
1.99e-05 1106 28 9 00:0048522 BP positive regulation of cellular process (3)
2.52e-Û5 6 25 2 00:0031576 BP G2/M transition checkpoint (1)
2.52e-05 6 25 2 00:0031572 BP G2/M transition DNA damage checkpoint (2)
2.28e-05 1433 28 10 00:0048513 BP organ development (1)
2.75e-05 256 5 3 00:0001501 BP skeletal development (2)
2.84e-06 3335 28 16 00:0032502 BP developmental process (1)
1.65e-07 831 28 10 00:0016265 R) death (2)
8.46e-07 1892 28 13 00:0048869 BP cellular developmental process (1)
8.46e-07 1892 28 13 00:0030154 BP cell differentiation (2)
1.21e-06 1309 28 11 00:0048468 BP cell development (1)
1.65e-07 831 28 10 00:0008219 BP cell death (2)
1.28e-06 790 28 9 00:0012501 BP programmed cell death (3)
1.19e-06 783 28 9 00:0006915 apoptosis (4)
8.53e-06 1598 28 11 00:0007242 BP intracellular signaling cascade (1)
P-value T Q Q&T term 10 term domain and name
8.51e-05 4742 7 7 00:0005634 CC nucleus (1)
P-value T Q Q&T term 10 term domain and name
5.58e-05 59 24 3 00:0008022 MF protein C-terminus binding (1)
5.53e-05 1 1 1 00:0008434 MF vitamin 03 receptor activ ity (1)
1.15e-04 62 5 2 00:0003690 MF double-stranded ONA binding (1)
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L i  j  m  1 1 1 B 7.37e-05 84 10 3 KEGG:05210 ke Colorectal cancer (1)
r r  i m  i ■ 2.21e-05 76 8 3 KEGG:04520 ke Adherens junction (1)
[ 1 .1 .  m  1 1 B  B  1 1 1 1 1T i l l  M  ' B 2.47e-05 73 23 4 KEGG:05212 ke Pancreatic cancer (1)
[ I  I m  11 1 1 B  1 1 1 1 1 I I  I I  M  B B 2.17e-05 64 24 4 KEGG:05214 ke Glioma (1)
[ I I  m  11 J O i ■ 1.12e-03 210 10 3 KEGG:04810 ke Regulation of actin cytoskeleton (1)
!'! ' 1 m  1_ L L B _ 1 _ L 1 . I I M i l l  3 3 1 1 6.16e-08 89 24 6 KEGG:05215 ke Prostate cancer (1)
L 1 ..1 .1 B  I B I M I N I 1 I B 9.46e-04 113 19 3 KEGG:04670 ke Leukocyte transendothelial migration (1)
Œ 1 . . . B . . I  1. M B  1 1  1 1 .1 M l  M  1 B B 1.27e-05 56 24 4 KEGG:05223 ke Non-small cell lung cancer (1)
1 I I  B 1 1 B I ! M i l l I I  B 2.30e-04 70 19 3 KEGG:05120 ke Epithelial cell signaling in Helicobacter pylori infection
I I I  1 f l  1 1 1 B l 1 I I  1 1 M i l  1 1 B 7.5^-05 31 24 3 KEGG:05216 ke Thyroid cancer (1)
1 1 1 1 B 1J Ê 9.46e-04 54 8 2 KEGG:05131 ke Pathogenic Escherichia coli infection -  EPEC (1)
i 1 1 B  B ■ 1.64e-03 100 6 2 KEGG:04540 ke Gap junction (1)
1.1 I B  1 1 I I  B I I  I I  1 ■ f l ...M  I 1 B B 3.94e-06 42 24 4 KEGG:05219 ke Bladder cancer (1)
|" "[ I B M I I  B  I I  I I  1T T M  I B  a 7.66e-05 88 24 4 l€œ:04012 ke ErbB signaling pathway (1)
m " B  T l 1 1  B 4.18e-04 28 10 2 KEGG:04320 ke Dorso-ventral axis formation (1)
m  B B  1 B  B ■ 2.21e-05 197 10 4 KEGG:04510 ke Focal adhesion (1)
1 1 1 B B  1TTB“n T  I T n  1 I I  M  B 9.40e-06 52 24 4 KEGG;05213 ke Endometrial cancer (1)
□ 1 1  1 B  1 9.46e-04 54 8 2 KEGG:05130 ke Pathogenic Escherichia coli infection -  EHEC (1)
m i  111 I I  B  I I  I I  1 l l  3  1 3 3 3 1.18e-06 76 24 5 KEGG:05220 ke Chronic myeloid leukemia (1)
m [ [ B : i i T T B  I T  1 1 1 1 M  M  1 3 3 3.10e-05 70 24 4 KEK:05218 ke Melanoma (1)
M l  1 1 1 1 B  B  1 I I  I I I I  3  M  I 3 2.92e-05 69 24 4 KEGG:05211 ke Renal cell carcinoma (1)
P-value T g Q&T term ID term domain and name
Œ i . . f l _ I . [ . 1 . 1 . 1 1  LI .  1 1 1 1 1 B 1.02e-04 4 19 2 REAC:177924 re Dephosphorylation of Gabl by S
m B 1 1 5.49e-05 6 8 2 K%:183002 re betaPIX pushes ClIfôS away from
1:1 I B M “B l ' T T T T r r r n a m r r B 6.55e-05 37 24 4 REfC:177929 re Signaling by EGFR (1)
M  1 B 1 1T T M T T T r r 1 1 B 1.02e-04 4 19 2 REAC:177944 re Activation of SW2 through the binding to phospho-Gabl (1)
MJ...B 1 I I I  I I  I I  1 1 1 1 1 B 1.02e-04 4 19 2 ŒAC =177926 re Dephosphorylation of PAG by SHP2 (1)
M ' T B  1 1J i 5.49e-05 6 8 2 REfC =183084 re Cbl escapes Cdc42-mediated irtiibition by down-regulating th
r T T B ' T  1 1 1  T !■ ■!■■■]■■■!■■■ !■■!■I T B 1.02e-04 4 19 2 REAC=177935 re SHP2 dephosphorylates J yr  992 on EGFR (1)
m.001017535 VDR
«.017906 PAKllPl
«.022451 N0C3L
«.005228 EGFR
«.001904 CTMJBl
«.001786 CDC2
«.015534 ZZZ3
«.044472 CDC42
«.032869 MJOCDl
«.004333 BRff
«.015984 UCHL5
«.003194 TBP
«.015216 HISPPDl
«.017819 RG9MTD1
«.018343 R10K2
«.014288 ITGB3BP
«.006773 DDX18
«.000190 » es
«.002834 PTPNll
«.021127 PMAIPl
«.017947 MOCOS
«.004064 CDKNIB
«.005225 E2F1
«.005343 WAS
«.021930 RINTl
«.000311 PRNP
«.000024 A0RB2
«.002133 HHOXl
Vitamin D3 receptor (VDR) (1,25-dihydroxyvitainin 03 receptor). [Source:Uniprot/SMISSPR0T;Acc:P11473]
p21-activated protein kinase-interacting protein 1 (PAKl-interacting protein 1) (PW/PLC-interacting protein 1) (hPIPl) (WD repeat protein & 
Nicleolar complex protein 3 homolog (N0C3 protein homolog) (N0C3-like protein) (Nucleolar coi#)lex-associated protein 3-like protein) (Factor 
Epidermal growth factor receptor precirsor (EC 2.7.10.1) (Receptor tyrosine-protein kinase ErbB-1). [Source:Un:.prot/SWISSPR0T;flcc:P005331 
Catenin beta-1 (Beta-catenin). [SourcelUniprot/SWISSPROT;Acc:P352221
Cell division control protein 2 homolog (EC 2.7.11.22) (EC 2.7.11.23) (p34 protein kinase) (Cyclin-dependent kinase 1) (CDKl). [Source:Unipn 
Zinc finger ZZ-type-containing protein 3. [Source:Uniprot/SWlSSPR0T;Acc:Q8IYH51
Cell division control protein 42 homolog precursor (G25K GTP-binding protein). [Source:Uniprot/SUlSSPR0T;Acc:Pt>0953]
NudC domain containing 1 [Source :RefSeq_peptide;Acc :NP_U62581
B-Raf proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (p94) (v-Raf murine sarcoma viral oncogene iiomolog 81). [Source:Uniprot/Si 
Ubiquitin carboxyl-terminal hydrolase i s o z ^  L5 (EC 3.4.19.12) (UCH- L5) (Ubiquitin thioesterase L5) (Ubiquitin C-terminal hydrolase UCH37) 
TftTft-box-bindir^ protein (TATfl-box factor) (TATA-binding factor) (TATA sequence-binding protein) (Transcription initiation factor TFIID TBP : 
Histidine acid phosphatase domain containing 1 [Source:RefSeq_peptide;Acc:NP_056031I 
RW (guanine-9-) methyltransferase domain containing 1 [Source:RefSeq_peptide;Acc:W_060289I 
Serine/threonine-protein kinase RI02 (EC 2.7.11.1) (RIG kinase 2). [Source:Unifrot/SWISSPR0T;Acc:Q9BVS4]
Centromere protein R (CENP-R) (Nuclear receptor-interacting factor 3) (Integrin beta-3-binding protein) (Beta3-endonexin). [Source:Uniprot/9 
ATP-dependent RNA helicase 00X18 (EC 3.6.1.-) (DEAD box protein 18) (Myc-regulated DEAD box protein) (MrDb). [Source:Uniprot/SWISSPROT;Acc:0 
Porphobilitwgen deaminase (EC 2.5.1.61) (Hydroxymethylbilane synthase) (HUBS) (Pre-uroporphyrinogen synthase) (PBG-D). [Source:Uniprot/SWIS3 
Tyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48) (Protein-tyrosine phosphatase 2C) (PTP-2C) (PTP-10) (SH-PTP3) (SH- PTP2) (SH 
Phorbo 1-12-myristate-13-acetate-induced protein 1 (PMA-induced protein 1) (Immediate-early-response protein APR). [Source:Uniprot/SWISSPROT; 
Molybdenum cofactor sulfurase (EC 4 .4 .-.-) (MoCo sulfurase) (MOS) (HMCS). [Source:Uniprot/SWISSPR0T;Acc:Q96EN8I 
Cyclin-dependent kinase inhibitor IB (Cyclin-dependent kinase inhibitor p27) (p27Kipl). [Source :Un i prot/SWISSPROT;Acc:P46527I 
Transcription factor E2F1 (E2F-1) (Retinoblastoma-binding protein 3) (RBBP-3) (PRB-binding protein E2F-1) (PBR3) (Retinoblastoma-associated 
GTPase Was precursor (Transforming protein p21) (p21ras) (H-Ras-1) (c-H-ras) (Ha-Ras). [Source :Uniprot/SWISSPt!0T;Acc:P01112]
RAD50-interacting protein 1 (RA050 interactor 1) (Protein RINT-1) (HsRINT-1). [SourcelUniprot/SWISSPROT;Acc:Q6NUQ11 
Major prion protein precursor (PrP) (PrP27-30) (PrP33-35C) (ASCR) (C0230 antigen). [Source:Uniprot/SWISSPR0T;Acc:P041561 
Beta-2 adrenergic receptor (Beta-2 adrenoceptor) (Beta-2 adrenoreceptor). [Source:Uniprot/SWISSPROT;Acc:P07550:
Heme oxygenase 1 (EC 1.14.99.3) (HO-1). [Source:Uniprot/SWISSPR0T;Acc:P096011
Figure 6.9 Functional profile of upregulated genes located in cluster 2.
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Gene expression profile in cluster 3 was dominated by upregulation of genes which 
regulate cell differentiation, cell communication and cellular response to stimulus (Figure 
6.10). A total of 22 genes were upregulated. Nineteen out of the 22 genes (87%) are 
involved in protein binding. Mapping genes to the biological pathway revealed 4 genes 
are involved in the cell cycle pathway including glycogen synthase kinase-3 beta 
(GSK3B), mothers against decapentaplegic homology 3 (SMAD3), Gl/S-speciflc cyclin 
D1 (CCNDl) and protein DBF4 homology (activator of S kinase) (DBF4). Other genes 
which are significantly upregulated in cluster 3 include interleukin 10 (IL-10), C-X-C 
chemokine receptor type 4 (CXCR4) matrix metalloproteinases 9 (MMP9) and 
baculoviral lAP repeat-containing protein 5 (survivin) (BERC5) (Figure 6.11).
Matrix metalloproteinases are group of enzymes that can degrade extracellular matrix and 
they are involved in tumour cells proliferation and migration (Birkedal-Hansen et al. 
1993). It was demonstrated that increased expression of MMPl plays an important role in 
the invasive properties of prostate cancer cells (Pulukuri and Rao 2008). Cryotherapy 
resulted in more than 50 times up regulation of MMPl genes compared to untreated cells 
and may enhance tumour invasiveness by destruction of the extracellular matrix and 
basement membrane. MMP9 was over expressed 12 times the control levels.
IL-10 is an anti inflammatory cytokines which is produced mainly by monocytes and to a 
lesser extent by activated T lymphocytes (Guedez et a l 2001). It was previously 
demonstrated that expression of IL-10 in prostate tissue was significantly increased with 
the progression from normal tissue to PIN and prostate cancer (Cardillo and Ippoliti
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2006). Stearns et al. (1999) demonstrated that tissue inhibitor of metalloproteinase 1 
(TIMP-1) mRNA levels were significantly induced by the treatment of prostate cancer 
cells with IL-10 which may indicate a role for IL-10 in MMPl inhibition. IL-10 gene 
expression patterns showed a significant rise (more than 40 times) following fireezing 
whereas in the presence of fi-eezing medium there was only 2 times rise in expression 
level.
Cluster 4 included important genes which are mainly involved in regulation of 
programmed cell death. Among genes in this cluster are MMPl, tumour necrosis factor 
alpha (TNF-a), transcription factor 7 (TCF7) and vascular endothelial growth factor A 
precursor (VEGFA) (Figure 6.12).
TNF-a is a proinflammatory cytokine that can induce a strong immune response. It 
activates TNF receptor on the cell surface to the initiate extrinsic apoptotic pathway. It 
was recently demonstrated that serum levels of TNF-a in patients who underwent 
prostate cryotherapy showed significant rise 4 weeks following the treatment (Si, Guo 
and Hao 2008). Similar results were demonstrated here as TNF-a expression levels 
increased more than 5 times that of the control levels, which may reflect the 
immunostimulatory effect of cryotherapy on prostate cancer cells. We also demonstrated 
that the level of expression of TNF- a was dependent on the freezing temperature. 
Cooling DU 145 cells to -5°C resulted in at least 5 folds increase in expression level of 
TNF- a compared to -10°C (chapter 4).
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g # A _ 2 3 _ P 2 5 1 3 4 2  (GSK3B)
0 |A _ 2 3 _ P 1 1 O 8 5 1  (TERT) 
g A _ 2 3 _ P 3 5 9 2 4 5  (HG FR; AU TS9; R C C P 2)
^  A _ 2 3 _ P 1 3 6 9 0 9  (N SBP1 )
H |A _ 2 3 _ P 2 1 2 6 1 7  (TFR; CD 71; T FR 1; TRFR) 
2 3 _ P 2 4 1 0 4  (ATF; UFA; URK; u-PA )
|A _ 2 3 _ P 1 0 4 6 8 9  (NFKB3; M G C 131774)  
|a _ 2 3 _ P 2 0 2 5 4 0
|A _ 2 4 _ P 5 6 3 8 8  (H IFI; M O PI; PASDB; HIF-1alph{ 
|A _23_P4B 936 (MADH3; JV 1B-2; S m ad  3; H S P C  
A _ 2 3 _ P 1 2 2 2 1 6  {M 6C 105112)
A _ 2 3 _ P 1 0 2 0 0 0  (FB22; HMB9; LAP3; L O RI: NP> 
A _23 _ P 1 4 4 0 5 4  (MAY1; M GC4990B; nPK C -delta  
A _23_P 1331  (F U 4 2 4 8 5 )
A _ 2 3 _ P 2 5 2 0 6 2  (N R 1C 3; PP A R G 1; PPA R G 2)  
|A _23_P4987B  (F U 1 0 1 5 6 ; FL J10491 )  
l 2 3 _ P 1 2 6 7 3 5  (CSIF; TGIF; IL-10; 1L10A; M G C ' 
|A _2 3 _ P 2 4 8 7 0  (IN; LHR; M C56; MDU2; MDU3; V 
L 2 3 _ P 2 0 4 9 4 7  (HID; KID; PPK ; 0X 26; DFNA3; I 
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Figure 6.10 Two related gene clusters 
(cluster 3 and 4) that were over 
expressed in cryotherapy group
,T_ssH RR 5
A_23_P7582 
TCF-1; MGC47735
A_23_P81805
VPF; VEGF; VËGF-A; MGC70609
A_23_P308603
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8.23e-06 1276 18 8 G0:0065008 BP regulation of bio logical quality  (1)
3.30e-05 252 15 4 G0:0001775 BP ce ll ac tivation  (1)
2.23e-05 73 15 3 G0:0032943 BP mononuclear c e ll p ro life ra tio n  (1)
2.08e-05 224 15 4 G0:0045321 BP leiAocyte ac tiva tion  (1)
1.31e-05 199 15 4 G0:0046649 BP lyt^ihocyte ac tivation  (2)
2.23e-05 73 15 3 G0:0046651 BP lymphocyte p ro life ra tio n  (3)
5.90e-05 66 22 3 G0:0000187 BP ac tivation  of MAPK a c tiv i ty  (1)
3.05e-05 4479 19 13 G0:0007154 BP ce ll communication (1)
1.60e-05 4136 15 11 G0:0007165 BP signal transduction (2)
2.50e-05 10 15 2 00:0032615 »> interleukin-12 production (1)
l.U e-0 4 1 2 1 00:0046827 BP positive regulation  of pro te in  export from nucleus (1
2.33e-05 3946 18 12 00:0032501 BP m ultice llu lar organismal process (1)
5.61e-05 1285 22 8 00:0048519 BP negative regulation  of biological process (1)
1.38e-08 3335 22 16 00:0032502 BP developmental process (1)
2.79e-05 831 22 7 00:0016265 BP death (2)
7.44e-07 2279 18 11 00:0048856 BP anatomical s tru c tu re  development (2)
1.74e-05 1906 18 9 00:0048731 BP system development (3)
1.48e-06 1433 22 10 00:0048513 BP organ development (3)
1.98e-07 1892 22 12 00:0048869 BP c e llu la r  developmental process (1)
1.98e-07 1892 22 12 00:0030154 BP ce ll d if fe re n tia tio n  (2)
6.40e-05 1309 22 8 00:0048468 BP ce ll development (1)
2.79e-05 831 22 7 00:0008219 BP ce ll death (2)
2.01e-05 790 22 7 00:0012501 BP programmed ce ll death (3)
3.76e—06 1213 22 9 00:0048518 BP positive regulation  of bio logical process (1)
1.75e-06 1106 22 9 00:0048522 BP positive  regulation  of c e llu la r  process (2)
4.93e-08 995 22 10 00:0050793 BP regulation of developmental process (1)
2.98e-05 555 22 6 00:0043067 BP regulation of programmed ce ll death (2)
P-value T Q Q&T term ID term domain and name
1.66e-04 1 3 1 00:0003721 MF telom eric template RNA reverse tran sc rip tase  a c tiv i t i
5.53e-05 1 1 1 00:0004229 nF gelatinase B a c tiv i ty  (1)
l .l le -0 4 1 2 1 00:0004696 MF glycogen synthase kinase 3 a c tiv ity  (1)
2.89e-06 7345 22 19 00:0005515 MF prote in  binding (1)
P-value T Q Q&T term ID term domain and name
1.33e-03 127 10 3 KE0G:0436O ke Axon guidance (1)
5.27e-04 113 20 4 KE0G:04110 ke Cell cycle (1)
l.O le-05 84 21 5 KE00:05210 ke Colorectal cancer (1)
NM.004994 MMP9
NM_002093 0SK3B
NM.198253 TERT
NM_000245 MET
NM.003234 TFRC
NM_002658 PLAU
NM_002658 PLAU
NM.181054 HIFIA
NM_005902 SMAD3
NM.002317 LOX
NM_001008540 CXCR4
NM.006254 PRKCD
NM_005203 C0L13A1
NM_138711 PPARO
NM.019013 FAM64A
NM_000572 ILIO
NM.000610 CD44
NM_004004 0JB2
NM_005574 LM02
M64349 COOl
NM_006716 DBF4
NM_001012271 BIRC5
NM_002006 FGF2
Matrix metaIloproteinase-9 precursor (EC 3.4.24.35) (MW-9) (92 kOa type IV collagenase) (92 kOa gelatinase) 
Glycogen synthase kinase-3 beta (EC 2.7.11.26) (GSK-3 be ta ). CSource:Uniprot/SWISSPR0T;Acc:P49841I 
Telomerase reverse tran sc rip tase  (EC 2 .7 .7 .49) (Telomerase ca ta ly tic  subunit) (HEST2) (Telomerase-associated 
Hepatocyte growth fac to r receptor precursor (EC 2.7.10.1) (HGF receptor) (S catter fac to r receptor) (SF recep 
Transferrin receptor pro tein  1 (TfRl) (TR) (TfR) (T rfr) (CD71 antigen) (T9) (p90) [Contains: Transferrin  red  
Urokinase-type plasminogen ac tiva to r precursor (EC 3.4.21.73) (uPA) (U-plasminogen ac tiv a to r)  [Contains: Urol 
Urokinase-type plasminogen ac tiv a to r precursor (EC 3.4.21.73) (uPA) (U-plasminogen ac tiv a to r)  [Contains: Urol 
Hypoxia-inducible fac to r 1 alpha (HIF-1 alpha) (HIFI alpha) (ARNT- in teracting  p ro te in) (Member of PAS prote 
Mothers against decapentaplegic homolog 3 (SMAD 3) (Mothers against DPP homolog 3) (Mad3) (hMAO-3) (JV15-2) 
Protein-lysine 6-oxidase precursor (EC 1 .4.3.13) (Lysyl oxidase). [Source :Un i prot/SWISSPROT;Acc:P283001 
C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (Stranal c e l l -  derived fac to r 1 receptor) (SOF-1 receptor) 
Protein kinase C delta  type (EC 2.7.11.13) (nPKC-delta). [Source :Un i prot/SWISSPROT; Acc:0056551 
Collagen alpha-K X lII) chain (COLXlIIAl). [Source:Uniprot/SWISSPROT;Acc:Q5TAT61 
Peroxisome p ro life ra to r-a c tiv a ted  receptor gamma (PPAR-gamma). [Source:Uniprot/SWISSPROT;Acc:P372311 
Protein FAM64A. [Source :Uniprot/SWISSPROT;Acc:Q9BSJ61
lnterleukin-10 precursor (IL-10) (Cytokine synthesis inhib itory  fac to r) (CSIF). [Source:Uniprot/SWISSPROT;Ad
CD44 antigen precursor (Phagocytic glycoprotein I)  (PGP-1) (HUTCH-I) (E x tracellu la r matrix receptor-111) (ECl
Gap junction beta-2 protein (Comexin-26) (Cx26). [Source:Uniprot/SWISSPROT;Acc:P290331
Rhombotin-2 (LIM domain only protein 2) (Cysteine-rich protein TTG-2) (T -cell tran slocation  pro te in  2 ) . [Soui
G l/S-specific cyclin-Dl (PRADI oncogene) (BCL-1 oncogene). [Source :Un i prot/SWISSPROT;Acc:P243851
Protein DBF4 homolog (A ctivator of S phase Kinase). [Source :Un i prot/SWISSPROT; Acc:Q9UBU7]
Baculoviral lAP repeat-containing protein 5 (Apoptosis inh ib ito r survivin) (Apoptosis inh ib ito r 4 ) . [Soiree:! 
Heparin-binding growth fac to r 2 precursor (HBGF-2) (Basic fib ro b las t growth fac to r) (BFGF) (P rosta trop in ). [:
Figure 6.11 Functional profile of up regulated genes located in cluster 3.
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1
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3.24e-05 20 8 2 G0:0032844 BP regulation of homeostatic process (1)
4.79e-06 8 8 2 G0:0032845 negative regulation of homeostatic process (2)
8.44e-05 32 8 2 G0:0034103 BP regulation of tissue remodeling (1)
2.05e-05 16 8 2 G0:0034104 BP negative regulatiwi of tissue remodeling (2)
8.44e-05 32 8 2 G0:0046850 regulation of bone remodeling (2)
2.05e-05 16 8 2 G0:0046851 BP negative regulation of bone remodeling (3)
1.84e-05 178 6 3 00:0009967 BP positive regulation of signal transduction (1)
5.57e-05 555 8 4 60:0043067 BP regulation of programmed cell death (1)
5.34e-05 549 8 4 60:0042981 BP regulation of apoptosis (2)
9.54e-05 34 8 2 60:0002377 BP immunoglobulin production (1)
6.44e-05 28 8 2 60:0000060 BP protein import into nucleus, translocation (1)
9.54e-05 34 8 2 60:0043388 BP positive regulation of DNA binding (1)
8.44e-05 32 8 2 60:0051091 BP positive regulation of transcription factor activity
5.11e-05 25 8 2 60:0051092 BP activation of NF-kappaB transcription factor (3)
6.44e-05 28 8 2 60:0045787 BP positive regulation of cell c;^le (1)
2.92e-05 19 8 2 60:0045840 BP positive regulation of mitosis (1)
P-value T Q Q&T term ID term domain and name
4.65e-05 530 8 4 60:0005615 CC extracellular space (1)
P-value T Q Q&T term ID term domain and name
5.72e-04 42 5 2 KE66:05219 ke Bladder cancer (1)
NM.000559 HBGl A-gamma globin [Source:RefSeq_peptide;ftcc:NP_000550]
NI1_002421 MMPl Interstitial collagenase precursor (EC 3.4.24.7) (Matrix metalIoproteinase-1) (MMP-1) (Fibroblast collagenase) [Contains: 22 kOa i.
NM.000594 TNF Tumor necrosis factor precursor (TNF-alpha) (Tumor necrosis factor ligand si^wrfamily member 2) (TNF-a) (Cachectin) [Contains: Turn.
NM.003202 TCF7 Transcription factor 7 (T-cell-specific transcription factor 1) (TCF- 1) (T-cell factor 1). [Source:Uniprot/SWISSPROT;Acc:P36402]
NM_00i025370 VEGFA Vascular endothelial growth factor A precursor (VEGF-A) (Vascular permeability factor) (VPF). [Source:Uniprot/SlilISSPR0T;Acc:Pi5692.
NM_005417 SRC Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (p60-Src) (c- Src) (pp60c-src). [Source:Uniprot/Sli)ISSPR0T;Acc:P12931]
NM_005733 KIF20A Kinesin-Iike protein KIF20A (Rabkinesin-6) (Rab6-interacting kinesin- like protein) (GG10.2). [Source:Uniprot/SWISSPROT;Acc:095235.
NM.000660 TGFBl Transforming growth factor beta-1 precursor (TGF-beta-1) [Contains: Latency-associated peptide (LAP)]. [Source:L)niprot/Sli)ISSPROT;A.
Figure 6.12 Functional profile of up regulated genes located in cluster 4.
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Table 6.5 List of genes that were upregulated in cells cooled to -10°C. Hierarchical 
clustering was used to cluster genes into 4 clusters according to their expression profile. 
Genes with similar expression pattern may share the same biological and molecular 
function.
Gene name Genbank Symbol Fold change
Cluster 1
Toll like receptor 2 NM_003264 TLR2 4.14
Caspase 3 NM_004346 Casp3 6.52
Caspase 8 Casp8 2.04
Interleukin 18 NM_001562 IL18 2.69
Retinoblastoma associated protein NM_000321 RBI 5.83
Myc proto-oncogen protein NM_002467 MYC 6.2
Cluster 2
Epidermal growth factor receptor NM_005228 EGFR 8.96
V-raf murine sarcoma viral oncogene 
homolog Bl
NM_004333 BRAF 3.16
Catenin beta 1 NM_001904 CTNNBl 3.08
Cell division control protein 2 NM_001786 CDC2 5.0
Cell division control protein 42 NM_044472 CDC42 5.4
Cyclin-dependent kinase inhibitor IB (p27, 
Kipl)
NM_004064 CDKNIB 2.0
Cyclin-dependent kinase inhibitor lA (p21, 
Cipl)
NM_000389 CDKNIA 5.03
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Cyclin-dependent kinase inhibitor 2A NM_058197 CDKN2A 5.81
E2F transcription factor 1 NM_005225 E2F 4.54
Cluster 3
Glycogen synthase kinase 3 beta NM_002093 GSK3B 3.024
Mothers against DPP homolog 3 NM_005902 SMAD3 4.53
cyclin D (cyclin Dl) M64349 CCNDl 2.28
Matrix metalloproteinases 9 NM_004994 MMP9 12.67
Interleukin 10 NM_000572 ILIO 44.38
Baculoviral TAP repeat containing protein 5 NM_001012271 BIRC5 4J8
C-X-C chemokine receptor type 4 NM_001008540 CXCR4 4.04
Cluster 4
Matrix metalloproteinases 1 NM_002421 MMPl 52.49
Tumour necrosis factor alpha NM_000594 TNF 5.53
Fas (TNF receptor superfamily member 6) NM_000043 FAS 2.49
CD40 antigen (TNF receptor superfamily, 
member 5)
NM_001250 CD40 2.06
Tumour necrosis factor receptor superfamily, 
member lA
NM_001065 TNFRSIA 2.70
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6.4.2.2 Self organizing feature maps
SOFM was constructed using 4x3 grids with iteration of 10000. In SOFM clustering a 
gene will always be most similar to a gene in its immediate neighbourhood than a gene 
farther away. The analysis showed 12 types of expression alteration (Figure 6.13). 
Among those, cluster 2.2, 3.2 and 3.3 included genes showing typical upregulation in -10 
and -IO(FM) groups. Clusters 1.4, 2.4 and 3.4 included genes showing upregulation in the 
-10 group only. These genes were also subjected to cluster analysis according to 
biological function. The upregulated genes are mainly involved in signal transduction 
(intracellular signalling pathways and protein kinase cascade) and regulation of cellular 
process mainly cellular proliferation. Total numbers of the differentially expressed genes 
were equally distributed across biological process, molecular function and cellular 
component (Figure 6.14).
1.1 (40 genes)
I) (FM)
Treatm ent type  
10{FM> UT
2.1 (4 genes)
I (FM)
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Figure 6.13 Two-dimensional SOFM of the differentially expressed genes. 4x3 grids with iteration of 
10000 were used to classify genes. Cluster 2.2, 3.2 and 3.3 included genes showing similar gene 
expression. Clusters 1.4,2.4 and 3.4 show a similar gene expression profile.
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Table 6.6 Differentially up regulated genes in DU 145 treated with cryotherapy to -10°C
classified according to gene function
Function Name Genbank Symbol Foldchange
Cell growth Cell division cycle 42 (GTP 
binding protein, 25kDa)
NM_044472 CDC42 5.401
SHC (Src homology 2 domain 
containing) transforming 
protein 1
NM_003029 SHCl 2.09
Angiogenesis Fibroblast growth factor 2 NM_002006 FGF2 4.46
Interleukin 18 (interferon- 
gamma-inducing factor)
NM_001562 IL18 2.699
V-erb-b2 erythroblastic 
leukemia viral oncogene 
homolog 2, neuro/glioblastoma 
derived oncogene homolog 
(avian)
NM 001005 
862
ERBB2 2.001
Cell
differentiation
BCL2-associated X protein. NM_138764 BAX 4.657
Fibroblast growth factor 2 NM 002006 FGF2 4.46
Interleukin 6 (interferon, beta 
2).
NM_000600 IL6 2.468
Peroxisome proliferative 
activated receptor, gamma.
NM_138711 PPARG 2.123
Metabolism Matrix metalloproteinase 1 NM 002421 MMPl 52.49
Heme oxygenase (decycling) 1 NM 002133 HMOXl 26.68
Matrix metalloproteinase 9 NM 004994 MMP9 12.67
Epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian), 
transcript variant 1
NM_005228 EGER R967
Cyclin-dependent kinase 9 
(CDC2-related kinase)
NM_001261 CDK9 6.66
Heat shock 90kDa protein 1, 
alpha
NM_005348 HSPCA 3.157
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Transcription V-jun sarcoma virus 17 
oncogene homolog (avian)
NM_002228 JUN 2T28
El A binding protein p300 NM 001429 EP300 13.09
V-myc myelocytomatosis viral 
oncogene homolog
NM_002467 MYC 8J52
N-myc (and STAT) interactor NM 004688 NMI 6.202
Retinoblastoma 1 NM 000321 RBI 5.834
Breast cancer 1, early onset (), 
transcript variant BRCAlb
NM_007295 BRCAl 5J#3
Poly (ADP-ribose) polymerase 
family, member 1
NM_001618 PARPl 5.219
Integrin beta 3 binding protein 
(beta3 -endonexin)
NM_014288 ITGB3BP 4.02
SMAD, mothers against DPP 
homolog 4 (Drosophila)
NM_005359 SMAD4 3.989
SMAD, mothers against DPP 
homolog 2 (Drosophila), 
transcript variant 1
NM_005901 SMAD2 3.09
Catenin (cadherin-associated 
protein), beta 1
NM 001904 CTNNBl 3.08
Apoptosis Caspase 3, apoptosis-related 
cysteine protease
NM_004346 CASP3 6.524
Tumor necrosis factor (TNF 
superfamily, member 2)
NM_000594 TNF 5.532
Breast cancer 1, early onset, 
transcript variant BRCAlb
NM_007295 BRCAl 5.283
Cyclin-dependent kinase 
inhibitor lA (p21, Cipl)
NM 000389 CDKNIA 5.039
BCL2-associated X protein. NM 138764 BAX 4.657
Baculoviral lAP repeat- 
containing 5 (survivin)
NM 001012 
271
BIRC5 4389
Tumor necrosis factor receptor 
superfamily, member lA
NM_001065 TNFRSFIA 2.707
Fas (TNF receptor 
superfamily, member 6)
NM_000043 FAS 2.492
CD40 antigen (TNF receptor 
superfamily member 5)
NM_001250 CD40 2.061
Caspase 8, apoptosis-related 
cysteine protease
NM_033356 CASP8 2.048
Immune response Mitogen-activated protein 
kinase 14
NM_001315 MAPK14 5.512
Nuclear receptor subfamily 3, 
group C, member 1
NM_000176 NR3C1 4.894
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Macrophage migration 
inhibitory factor
NM_002415 MIF 4.694
Spleen tyrosine kinase NM 003177 SYK 4.167
Toll-like receptor 2 NM 003264 TLR2 4.142
Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 (pl05)
NM_003998 NFKBl 3.678
Interleukin 18 (interferon- 
gamma-inducing factor)
NM_001562 IL18 2^89
Interleukin 6 (interferon, beta 
2)
NM_000600 IL6 2.468
Transport Gap junction protein, beta 2, 
26kDa (connexin 26)
NM_004004 GJB2 14.32
Collagen, type XIII, alpha 1 NM 005203 C0L13A1 10.17
Rad5 0-interacting protein 1 NM 021930 RINT-1 6.07
Hypoxia-inducible factor 1, 
alpha subunit (basic helix- 
loop-helix transcription factor)
NM_181054 HIFIA 5.475
Transferrin receptor (p90, 
CD71)
NM_003234 TFRC 4.706
Cell cycle Cyclin-dependent kinase 9 NM 001261 CDK9 6.66
Cyclin-dependent kinase 
inhibitor 2A (melanoma, p i6, 
inhibits CDK4), transcript 
variant 3
NM_058197 CDKN2A 5.816
Proliferating cell nuclear 
antigen
NM_002592 PCNA 5.615
Cyclin-dependent kinase 
inhibitor lA (p21, Cipl) 
transcript variant I
NM_000389 CDKNIA 5.283
Mitogen-activated protein 
kinase 1
NM_138957 MAPKl 3.281
Cyclin A2 NM 001237 CCNA2 2.287
Cyclin-dependent kinase 
inhibitor IB (p27, Kipl)
NM_004064 CDKNIB 2.005
Cell
communication
Gap junction protein, beta 2, 
26kDa (connexin 26)
NM_004004 GJB2 14.32
CD44 antigen NM 000610 CD44 8.77
Met proto-oncogene 
(hepatocyte growth factor 
receptor)
NM_000245 MET 6.064
Plasminogen activator. NM 002658 PLAU 5.926
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urokinase
Endothelin 1 NM 001955 EDNI 5.924
SMAD, mothers against DPP 
homolog 3
NM_005902 SMAD3 4.531
Chemokine (C-X-C motif) 
receptor 4
NM 001008 
540
CXCR4 4.04
Ras homolog gene family, 
member A
NM_001664 RHOA 3.684
Cell adhesion CD44 antigen NM 000610 CD44 8.77
Spleen tyrosine kinase NM 003177 SYK 4.167
Integrin beta 3 binding protein 
(beta3 -endonexin)
NM_014288 ITGB3BP 4.02
Integrin, alpha V (vitronectin 
receptor, alpha polypeptide, 
antigen CD51)
NM_002210 ITGAV 3.913
Cadherin 1, type 1, E-cadherin 
(epithelial)
NM_004360 CDHl 3.405
Catenin (cadherin-associated 
protein), beta 1
NM_001904 CTNNBl 3.08
Intercellular adhesion 
molecule 1 (CD54), human 
rhinovirus receptor
NM_000201 ICAMl 2.655
Integrin, beta 2 (antigen CD 18 
(p95), lymphocyte function- 
associated antigen 1; 
macrophage antigen 1 (mac-1) 
beta subunit)
NM_000211 ITGB2 2.07
Response to 
stimulus
Gap junction protein, beta 2, 
26kDa (connexin 26)
NM_004004 GJB2 14.32
Hypoxia-inducible factor 1, 
alpha subunit (basic helix- 
loop-helix transcription factor)
NM_181054 HIFIA 5.475
Superoxide dismutase 1 NM 000454 SODl 4.707
Exonuclease 1 NM 003686 EXOl 4.596
Fibroblast growth factor 2 
(basic)
NM_002006 FGF2 4.46
Nitric oxide synthase 2A NM 000625 N0S2A 4.324
Cyclin A2 NM 001237 CCNA2 2.287
Peroxisome proliferative 
activated receptor, gamma
NM 138711 PPARG 2.123
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Table 6.7 Differentially down regulated genes in DU 145 treated with cryotherapy to
10°C classified according to gene function.
Function Gene name Genbank Symbol Foldchange
Cell growth Tumor protein p53 NM 000546 TP53 0.458
Insulin-like growth factor 
binding protein 3.
NM 00101339 
8
IGFBP3 0.474
Cell
differentiation
Interleukin 4. NM_000589 IL4 0.149
Metabolism Leptin NM_000230 LEP 0.148
Apolipoprotein A-I NM 000039 APOAl 0.153
Coagulation factor II (F2) NM 000506 thrombin 0.155
Mitogen-activated protein 
kinase 3
NM_002746 MAPK3 0.361
Transcription Ataxia telangiectasia mutated NM_000051 ATM 0.389
Apoptosis Interleukin 1, beta NM_000576 ILIB 0.0286
Tumor necrosis factor (ligand) 
superfamily, member 10
NM_003810 TNFSFIO 0.108
Interleukin 1, alpha NM_000575 ILIA 0.19
PTK2B protein tyrosine kinase 
2 beta
NM_173174 PTK2B 0.211
V-akt murine thymoma viral 
oncogene homolog 1
NM_005163 AKTl 0.256
Immune response Interleukin 1, beta NM_000576 ILIB 0.0286
Tumor necrosis factor (ligand) 
superfamily, member 10
NM_003810 TNFSFIO 0.108
Interleukin 4 NM_000589 IL4 0.149
Transport Solute carrier family 6 
(neurotransmitter transporter, 
serotonin), member 4
NM_001045 SLC6A4 0.0452
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ATP-binding cassette, sub­
family B (MDR/TAP), member 
1
NM_000927 ABCBl 0.248
Low density lipoprotein-related 
protein 1 (alpha-2- 
macroglobulin receptor)
NM_002332 LRPl 0.303
Cell cycle Mitogen-activated protein 
kinase 3
NM_002746 MAPK3 0.361
Cell
communication
Interleukin 1, beta NM_000576 ILIB 0.0286
PTK2B protein tyrosine kinase 
2 beta
NM_173174 PTK2B 0.211
Chemokine (C-C motif) 
receptor 5
NM_000579 CCR5 0.262
Cell adhesion PTK2B protein tyrosine kinase 
2 beta
NM J73174 PTK2B 0.211
Thrombospondin 1 NM 003246 THBSl 0.286
Intracellular 
signaling pathway
Insulin-like growth factor I 
(somatomedin C)
NM_000618 IGFl 0.0546
Tumor necrosis factor (ligand) 
superfamily, member 10
NM_003810 TNFSFIO 0.108
Response to 
stimulus
Interleukin 1, beta NM_000576 ILIB 0.0286
Insulin-like growth factor 1 
(somatomedin C)
NM_000618 IGFl 0.0546
Tumor necrosis factor (ligand) 
superfamily, member 10
NM_003810 TNFSFIO 0.108
Interleukin 4 NM 000589 IL4 0.149
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Chapter 7
Final Discussion
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Prostate cancer is a significant health problem in the UK. The widespread use of PSA 
testing has led to more and more patients being diagnosed with this condition, but at the 
same time we are realising not all cases need active treatment i.e. some cancers may be 
observed carefully and treated if signs of progression (so-called active surveillance). 
Although the accepted treatment modalities do cure the majority of patients with early 
disease, there are still significant numbers with locally recurrent disease after 
radiotherapy, and these men may eventually succumb to metastatic prostate cancer. 
Therefore curative treatments at the point of local recurrence are urgently needed.
Prostate cryotherapy is a potential solution to this problem and is localised application of 
freezing temperature resulting in situ tissue ablation. In the last decade, cryotherapy has 
emerged as minimally invasive alternative treatment for localized or locally advanced 
prostate cancer. With better understanding of the biological effect of freezing and the 
introduction of the gas-driven systems, the procedure has been optimized to improve 
patient outcomes and reduce complication. Compared to salvage radical prostatectomy, 
the results of salvage cryotherapy are more promising and are associated with less 
morbidity. However the molecular and immunological basis of this form of cryotherapy 
is incompletely understood. New insights into the biology of freeze-associated tumour 
cell kill would allow optimisation and improvement of this technique, either alone or in 
combination with other agents. The aim of this thesis was to develop a robust and 
reproducible model of freeze injury which would allow the definition of molecular 
changes in prostate cancer cells after exposure to cryotherapy. Insights into these changes
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led to the evaluation of a sensitising agent, TRAIL, but which could form the basis of any 
combination approach.
In clinical cryotherapy cells are exposed to variable thermal history during the freezing 
process. Cells adjacent to the cryo probe are exposed to the lowest freezing temperature 
and cells distant from the cryo probe are exposed to the highest temperature. Cells in 
between are exposed to various ranges of freezing temperature. The limitation of the 
previous in vitro studies has been the lack of a representative model which simulates the 
clinical situation, and in particular exact mimics of the freeze temperatures used. In this 
project a novel in vitro model was established using cells packed at the bottom of a 
microtube and exposed to the advancing ice ball until they reached the final treatment 
temperature. The model is simple, robust, with extremely reproducible. The limitations 
are that it does not exactly mimic clinical prostate cancer due to absence of non-cancer 
cells and architecture; however, the model allows recovery of RNA and protein post­
treatment for analysis and is convenient and easy to use in the laboratory setting. During 
the treatment, cells are exposed to the expanding ice ball; therefore cells experience a 
similar thermal history to prostate cells during clinical cryotherapy. Argon gas used in the 
model allows a consistent and smooth drop in temperature. Furthermore, the freezing 
process is tightly controlled in response to temperature measurements. The model 
provides real time monitoring of the sample temperature throughout the treatment time.
The critical temperature required for complete ablation of the prostate tissue is not well 
defined, and some reports suggest that -40C is needed. It is well known that the
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temperature at the edge of the ice ball is 0°C and a few millimetres from the centre of the 
cryo probe is the -40°C point. Therefore, the inner zone of the ice ball, where the 
temperature is < -40°C is considered to be the lethal zone of the ice ball. Tissues within 
the lethal zone typically undergo coagulative necrosis whereas the peripheral tissue will 
be damaged by freezing and show inflammation and haemorrhage. Glandular epithelial 
tissue in the damage zone is capable of proliferation which could presumably increase the 
risk of treatment failure.
Various reports demonstrated incomplete glandular ablation after salvage cryotherapy. In 
order to achieve complete ablation of prostate tissue the ice ball should be allowed to 
extend few millimetres beyond the prostatic capsule to allow the lethal zone to cover all 
prostatic tissue. This is technically difficult and may result in high percentage of 
complication. Although the urethral warming catheter is used to maintain the integrity of 
the urethral mucosa and prevent urethral damage during freezing, it may also allow 
periurethral cancer to survive. Total cryotherapy without the use of urethral warming 
catheter increased the success rate of the procedure but with more complications.
In order to improve the outcome following prostate cryotherapy, the cryo sensitivity of 
prostate tissue at the peripheral and periurethral zone of the prostate should increase to 
ensure effective tissue destruction at higher temperatures. Radiotherapy, chemotherapy 
and hyperthermia all have been used as an adjunctive to cryotherapy with limited success. 
Prostate cancer is slow growing and some cells are in the S phase of cell cycle making 
cells resistant to chemotherapy. Prostate cancer cells express membrane associated death
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receptors such as TNF-a, TRAIL and Fas ligand. These receptors have emerged recently 
as promising targets for therapeutic intervention in cancer therapy. It was demonstrated 
that TRAIL is capable of inducing apoptosis in a wide variety of cancer cells including 
prostate cancer; however, normal cells are resistant to TRAIL induced apoptosis even 
though they express high levels of TRAIL receptors. Furthermore, TRAIL has no 
systemic toxic effect unlike TNF-a and FAS ligand both of which induces severe toxicity 
when administered systemically. Therefore, TRAIL represents a promising anticancer 
agent to modulate cell death signalling pathways in prostate cancer. In this study, it was 
demonstrated that cryotherapy induces apoptosis in human prostate cancer cells upon 
exposure to sublethal freezing temperature. It was demonstrated that whilst DU 145 and 
PC3 cells are relatively insensitive to killing by TRAIL, it does nevertheless significantly 
increase cellular activity related to apoptosis such as caspase activation and cleavage of 
the caspase target protein PARP. Interestingly, adding TRAIL to human prostate cancer 
cells after freezing resulted in only a minimal change in cell survival. Whereas pre­
treatment with TRAIL then freezing resulted in enhanced cell death and almost a 100% 
loss of viability was noticed at -10°C. Therefore, a combination of TRAIL and freezing 
cells works synergistically if sequenced correctly, despite necrotic death still being the 
predominant mechanism. It seems likely in this case that TRAIL causes the rapid onset of 
apoptosis in cells that initially survive the freezing event.
We hypothesised that cryotherapy induces transcriptional changes which further 
augments the extrinsic apoptotic signal of TRAIL on human prostate cancer cells. Gene 
microarray analysis of cells resistant to cryotherapy showed upregulation of TNF -a
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receptor superfamily, caspase 3 and caspase 8 which make cells more sensitive to 
TRAIL. Therefore, the use TRAIL seemed to be appropriate as a therapeutic agent 
adjunctive to cryotherapy. It was also demonstrated that cryotherapy down regulates 
AKT and upregulates phosphatase and tensin homology deleted on chromosom 10 
(PTEN) and BCL-2 associated x protein (Bax), both of which may enhance the sensitivity 
of prostate cells to TRAIL induced apoptosis.
AKT which is a serine/threonine kinase that regulates cell survival and growth through a 
phosphatidylinositol-3 kinase (PI3K) dependent mechanism. It was demonstrated that 
high levels of constitutive active AKT is directly correlated to TRAIL resistance. The 
tumour suppressor PTEN inhibits PI3K function and completely suppresses constitutive 
AKT function in prostate cancer cells. PTEN expression sensitized prostate cancer cells 
to death receptor mediated apoptosis induced by TRAIL. Processing of Bax by caspase 8 
leads to the formation of t-Bax which integrates into the outer mitochondrial membrane 
leading to loss of mitochondrial membrane potential and the release of cytochrome c and 
ultimately enhancing the extrinsic apoptotic signal. All these changes may play a role in 
sensitising prostate cancer cells to the combination therapy of TRAIL and cryotherapy.
The immunological consequences of cryoinjury were also investigated in an attempt to 
evaluate their potential utility to enhance tumour cell kill. The effects of cryotherapy of 
human prostate cancer cells on the differentiation and function of monocyte derived DC 
were investigated and the mechanisms responsible for DC stimulation were identified. 
Cryotreatment affected the phenotypic expression of a wide range of DC surface markers.
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The most marked changes were observed in CD86 and CD80. The upregulation in these 
molecules on the surface of immature DC after exposure to cryotreated tumour cells was 
identical to that observed after LPS stimulation which signifies the strength of the 
stimulus. A marked increase was also observed in the migratory marker CCR7 and MHC 
class II molecules demonstrating the stimulatory effect of the cryotreated prostate cancer 
cells on DC. Similar effects were seen in the LPS mature DC after exposure to the same 
stimulus. Expression of CD209 (DC-SIGN), a molecule involved in regulating the 
adhesion process or involved in DC trafficking and T-cell synapse formation, was 
significantly reduced following exposure to LPS and cryotreated cells. Therefore, the 
overall effects of cryotherapy were stimulatory to the DC. In an MLR, freezing of 
prostate cancer cells was stimulatory, whilst, tumour lysate and untreated tumour cells 
exerted inhibitory effect. The immunostiulatory effect of cryotherapy in MLR was more 
prominent at lower freezing temperatures as treatment at -20°C produced significant 
proliferation of Tcells.
Cytokines are the hormonal messengers which can modulate immune response. They can 
be functionally devided into 2 groups, the pro and anti inflammatory cytokines. DC 
modulate their local immune environment via the secretion of IL-12 in response to 
antigenic stimulation leading to T cell differentiation into Thl cells. Exposure of DC to 
cryotreated cancer cells resulted in a marked increase in secretion of IE-15 (P<0.001) and 
to a lesser extent IFNa and IL-2 (P>0.05), and a marked reduction in IL-6 secretion 
(P<0.01). The overall response was again stimulatory toward inducing a Thl response. 
Overall, results suggest that the effect of cryotherapy is immunostimulatory.
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The nature of the maturation stimuli provided by cryotreated cells is not well identified. 
Two cytokines are important for DC maturation, TNF-a and IL-lp. Neither cytokines 
was detected in the supernatant of necrotic tumour cells which induced DC maturation. It 
was proposed that stressed cells release alarm signals responsible for DC activation 
including HSP70, IL-2, TNF-a, IL-12 P40 and GM-CSF. In this study, we identified a 
significant increase in immunostimulatory cytokine expression upon exposure to freezing 
temperature. mRNA levels of IL-2, IL12, IL-15, IL18, and TNFa were significantly 
increased after treatment at -10°C. Overall, we demonstrated that freezing injury has 
immunostimulatory effects which may favour tumour eradication. Freezing stimulates 
DC in two different ways. First it provides an effective source of antigen for DC from the 
cryo-destructed tumour tissue and secondly, it creates an immunostimulatory cytokine 
environment that enhances DC maturation.
Molecular analysis of freeze injured cells indicated a potential to exploit the observed 
changes in aquaporin water channels in human prostate cancer cells. It was demonstrated 
that AQP3 in particular is expressed in prostate cancer cells. The expression levels 
increased upon exposure to freezing which may represent a protective response by the 
tumour cells to counteract osmotic stress which result from extracellular ice formation.
Previous studies demonstrated that AQP3 is expressed in PC-3 and DU 145 cells while 
AQPl is expressed in the tumour micro vasculature. In this project we demonstrated that 
AQP3 is expressed in all three prostate cancer cell lines tested. The expression levels of
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AQP3 changed in response to cryoinjury. There was a significant increase in AQP3 
mRNA and protein expression levels in the immediate post freeze period followed by 
reduction to the untreated level by 24 hours post freezing.
It was demonstrated in previous studies that aquaporins have an important function in the 
freeze tolerance of arthropods. In this study we demonstrated that the freeze tolerance of 
human prostate cancer cells was significantly reduced when the aquaporin channels were 
blocked with mercuric chloride. An increase in cell death was observed when cells were 
treated in the presence of HgCli. To further investigate the function of the AQPs in 
prostate cancer cell response to freeze injury, AQP3 was chosen as a target for small 
interference RNA. The effects of specific inhibition of AQP3 using siRNA on cell 
viability after exposure to freezing injury were examined. The results show that DU 145 
cell viability was significantly reduced by freezing at -10°C after AQP3 inhibition. 
Compared to HgCli, response to freezing was less prominent. This may be due to the 
higher affinity of mercuric chloride for a range of aquaporins. siRNA only targets one 
AQP and therefore, some form of protection may be provided by other undetected AQPs 
on the cell surface. To evaluate the role of AQPs in increasing resistance to cryoinjury, 
further studies are required to ensure that inhibition of other aquaporins such as AQP9 
and AQPl increase the sensitivity of human prostate cancer cells to cryoinjury. Cells that 
are sensitive to freezing injury may become more resistant after artificial expression of 
AQPs protein into their plasma membrane. In vivo experiments are essential to further 
evaluate the potential use of AQPs inhibitors as pharmacological agents prior to 
cryotherapy.
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In conclusion, there is a need to improve the efficacy of cryotherapy as treatment for 
locally advanced or locally recurrent prostate cancer. During freezing tissues are exposed 
to various damaging stresses, starting with osmotic stress during extracellular ice 
formation followed by intracellular ice formation and subsequently microciculatory 
failure a few hours later. The ideal temperature for tissue destruction was identified to be 
<-40°C. This study has sought to advance understanding on the effects of cryoinjury on 
human prostate cancer cell biology. After designing a robust and reproducible model of 
cryo injury, three specific aspects were examined in detail. The first described 
modulation of gene regulated cell death using the apoptosis-inducing ligand TRAIL prior 
to cryotherapy. The second described the immunostimulatory effect of cryotherapy on 
monocyte derived DC which may enhance tumour eradication after treatment. The main 
advantage of the cryoimmunotherapy will be to treat remote sites of tumour metastasis. 
The third is a novel description of the role of the AQPs expression in prostate cancer 
cells. Modification of the specific molecular pathways was successful in increasing the 
sensitivity of prostate cancer cells to cryoinjury. Further studies on the importance and 
utility of the findings from these three aspects are required. In particular modelling the 
cryotherapy in murine models, using local response, induction of antitumour immunity 
and overall survival endpoints. Furthermore, identification of an AQP inhibitor which 
may be used clinically would be extremely desirable. Finally randomised clinical trials 
comparing cryotherapy, concomitant therapy with cryotherapy versus observation are 
urgently needed.
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Introduction
Prostate cancer is the most commonly diagnosed malignancy in the UK representing 24% 
of male cancers diagnosed; the death rate from prostate cancer is significant at 3% of all 
male deaths\ In many cases the disease has a long period of asymptomatic growth before 
developing into locally advanced or metastatic disease with symptoms, this period is a 
window of opportunity for men who have early prostate cancer diagnosed by PSA 
screening, digital rectal examination, the use of PSA and its derivatives or use of more 
recently described markers such as PC A3.
There are several existing options for the control of early prostate cancer including radical 
prostatectomy (RP), utilising open surgical, laparoscopic or robotic techniques, external 
beam radiotherapy (EBRT), and brachytherapy (BXT) using either low dose rate or high 
dose rate techniques. More recently prostate cryotherapy has become available and new 
technologies including High Intensity Focussed Ultrasound (HIFU) and interstitial 
treatment with photosensitisers and laser radiation are evolving into clinically relevant 
entities.
Despite the range of technologies employed to target early prostate cancer none has 
become the definitive treatment for the most common of male malignancies. This is due 
to the fact that all have significant drawbacks, as well as advantages, over both each other 
and conservative therapy for early prostate cancer. The literature on radical treatment for 
early prostate cancer has few randomised trials. In this difficult intellectual terrain we 
describe the current and future place of prostate cryotherapy.
Aims of Treatment for Early Prostate Cancer
The aims of treatment for organ confined prostate cancer are to prevent progression from 
early disease to metastatic, locally advanced disease or symptomatic disease within the 
patient’s lifetime or as a cause of a shortened lifespan via the mechanisms described in 
figure 1. Its additional aim should be to achieve this without causing new symptoms or 
disease in the patient. Though an aim of screening has been to detect a higher percentage 
of prostate cancer before locally advanced disease or metastasis occurs in order to deliver 
the highest chance of cure there are a nmiiber of modalities which may be used in locally 
advanced as well as organ confined disease, albeit with lower success rates.
The late Dr Whitmore as director of urology at the Memorial Sloane Kettering Cancer 
Centre noted, of existing treatments for prostate cancer ‘When cure is possible is it 
necessary and when it is necessary, is it possible?’. This question is equally valid today 
and the value of cryotherapy may lie mainly in the group of men with significant primary 
or recurrent disease in whom the possibility of cure remains a challenge.
Figure 1. Possible patterns of prostate cancer progression
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Cryotherapy has been applied to all the stages of non-metastatic prostate cancer described 
in the grey shaded area of Figure 1. This chapter will describe current results of 
cryotherapy treatment as well as the theory underpinning the technique and possible areas 
for future development.
The History and Development of Cryosurgery for Prostate Cancer
The history of prostate cryotherapy was recently reviewed by Ahmed et a f. Whilst 
modem cryotherapy is a relatively recent and constantly evolving technique the 
recognition that cold could be used to treat tumours is not novel. Therapeutic cryotherapy 
started with the work of Dr James Amott from Brighton, UK. In the I840’s he described 
the use of ice slush for topical anaesthesia and to treat tumours including cervical cancer 
using a wide speculum to achieve freezing. He made an important conclusion following 
his observation on the use of cryotherapy in the treatment of cancer “Congelation 
arresting the accompanying inflammation, and destroying the vitality of the cancer cell, is 
not only calculated to prolong life for a great period, but may not improbably, in the early 
stage of the disease, exert a curative action” He published his work in the Lancet in 1850 
and his cryotherapy apparatus was shown in the Great Exhibition in London in 1851^
Topical applications of ice slush were not suitable for reliably achieving adequately 
reduced temperatures in the -20 to -40 range and although gas liquefaction by adiabatic 
expansion systems for cooling were invented in the I870’s, delivery systems were not 
developed until the late I890’s. The early I900’s saw an increase in availability of liquid 
nitrogen which led to the possibility of topical treatment of superficial lesions either by 
direct application of liquid nitrogen or application of a cooled metal probe.
It was not until 1961 that the neurosurgeon, Irving Cooper and engineer, Arnold Lee 
developed a vacuum insulated needle delivery system for liquid nitrogen. This allowed 
an iceball to be formed at the needle tip and variants of this system were used to treat 
benign and malignant conditions at a variety of sites including malignant brain tumours' .^ 
Gonder  ^ used a transurethral probe with digital rectal monitoring to freeze the prostate 
using liquid nitrogen. This process was complicated by a high incidence of urethral 
sloughing and recto-urethral fistulae .^
The modem renaissance of prostate cryosurgery was heralded by several developments. 
The description by Onik et al of transrectal ultrasound guided cryotherapy in 1993  ^using 
dual liquid nitrogen cryoprobes heralded the era of modern cryotherapy. The availability 
of more accurate thermocouples^ and the urethral warming catheter^ led to reductions in 
the significant complications of urethral sloughing and rectal fistulae which had been 
encountered in early cryotherapy.
Lastly the progression from single or dual-probe, liquid-nitrogen based systems to the 
current multi-probe argon-helium systems has led to better control of the cooling phase, 
ability to actively warm the probe, and reduced trauma as an effect of reduced probe size. 
Currently available systems utilise the Joule-Thompson effect. This is characterised by a 
change in temperature, produced in this scenario at the probe tip, when high pressure gas 
is released to a lower pressure, and exits via the outer lumen of the probe. The 
temperature at the probe tip may be reduced or increased depending on the physical 
properties of the gas chosen. Rapid cooling to temperatures as low as -I86°C may be 
achieved using Argon; Helium produces warming to temperatures of up to 40°C. Figure 
2 illustrates the iceball generated during probe testing on a modem device.
Two systems are currently in widespread use. Galil Medical introduced their third 
generation cryotherapy system (Seednet™) in the late 1990s. They developed ultra thin 
17-gauge needle probes which allowed more uniform coverage of the prostate. In 2003, 
Endocare introduced their fourth generation cryotherapy system (Cryocare™ CS), which 
superseded their previous argon-helium system, introduced in the mid 1990’s.
The latest developments of the technique resulted from the constant improvement in the 
quality of transrectal ultrasound images due to the evolution of high definition multi- 
planar ultrasound arrays over the last 20 years. This has led to an ability to more 
accurately monitor the iceball (which can be seen as a hyperechoic rim with acoustic 
shadowing^) and more accurately place the thermocouples used for temperature 
monitoring.
This evolution in the technique, with evidence of a significant reduction in complications 
as advances in technology occured^ does mean that care is necessary in interpreting the 
published results of prostate cryotherapy.
Figure 2. Iceball generated during cryoprobes testing prior to procedure.
Mechanism of tissue injury in prostate cryotherapy
The aim of prostate cryotherapy is to destroy neoplastic tissue and preserve vital 
structures around the prostate including the bladder, rectum and ideally the neurovascular 
bundles. This requires precise freezing process to achieve the maximum tissue ablation 
within the prostate without damage to the critical structures.
In modern prostate cryotherapy, several cryoprobes are used and cells are exposed to 
variable thermal parameters depending on their location from the freezing probe. Larson 
et a f  reported 2 areas of tissue damage surrounding the cryotherapy probe. Areas near to 
the probe undergo coagulative necrosis, at a greater distance from the probe tissue will 
undergo squamous metaplasia and haemorrhage which will be replaced by 
polymorphonuclear leukocytes infiltrate^®. The mechanism of cell death by cold injury 
has been investigated for many years. It is well known that 2 mechanisms are responsible 
for cell death: direct injury caused by ice formation and indirect ischemic effect caused by 
microvascular changes. During freezing extra-cellular ice forms at a temperature range 
between -7 and -20°C. A hyperosmolar extracellular environment draws water from the 
cells and lead to cell dehydration and shrinkage (the solute effect injury). At even lower 
temperatures (<-15 °C), ice will extend to the intracellular space^\ Homogenous 
intracellular ice crystals are noticed at temperature lower than -40°C which is almost 
always lethal to the cells ^ ^
During thawing, extracellular space is hypotonic and water will enter the cells which will 
augment the solute effect and results in cell rupture. Microvascular effects start with 
vasoconstriction and tissue anoxia during the freezing phase which results in tissue 
necrosis. This is followed by vasodilatation, increased vascular permeability and tissue
oedema during thawing phase which will contribute to the solute effect cell injury. 
Following freezing, blood vessels will show endothelial cell damage and micro-thrombus 
formation and complete cessation of circulation will follow in few hours^ .^ Apoptotic cell 
death was identified in the peripheral zone of the cryolésion where cells are exposed to 
sub-lethal freezing temperature^^.
Physical parameters in prostate cry otherapy
Several physical parameters appear to influence the biological tissue changes described 
above. These include the freezing rate, temperature nadir, thawing rate, duration of 
freeze and number of freeze cycles.
Freezing rate
Rapid freezing is essential for intracellular ice formation and is associated with higher 
rate of cell death^ '^ . However, there was no agreed definition of rapid freezing. In vitro 
studies demonstrated that intracellular ice formation can be achieved with freezing rate 
between 3-50 °C/minute^^ whilst Tatsutani et af^  demonstrated that a freezing rate of 
25°C/minute is essential for intracellular ice formation and complete cell death. Factors 
affecting the freezing rate include how far is the tissue from the centre of the ice ball, 
vascularity and water content of the treated organ^ .^
Target temperature
The critical temperature that results in complete ablation of the prostate tissue is not well 
defined. Early reports demonstrated a temperature of -20°C or less is essential to kill the 
cells^  ^ More recently, studies have shown that -40°C is required for complete 
destruction of prostate tissue^ ®. Larson et al? reported on 6 prostate cancer patients who
underwent prostate cryotherapy using single cryotherapy probe followed by radical 
prostatectomy as a definitive treatment. They identified critical temperature required to 
achieve uniform coagulative necrosis was -41.4°C in the double freeze cycle compared to 
-61.7°C in the single freeze cycle though clearly further tissue changes might have 
occurred if a greater time had been allowed to elapse between cryotherapy and 
prostatectomy.
Thawing rate
Thawing phase is important mechanism that results in cell destruction during the freeze- 
thaw cycle. During thawing phase cells are exposed to different damaging mechanisms 
including solute effect, ice crystal recrystallization and reperfusion injury^ \  It was 
demonstrated that slow thawing rates are associated with a significant increase in cell 
death compared to active thawing^®. Slow thawing exposes tissues to prolonged time of 
osmotic imbalance, oxidative stress and growth of ice crystals and hence is associated 
with increased cell death^.
Duration of freezing
Although the optimum duration of freezing is not yet well defined, it is well known that 
the length of exposure to freezing temperatures affects cell viability post cryotherapy^^. 
Early reports suggested that duration of freezing is less important when the tissue is 
treated to a temperature less than -40°C as a smaller amount of water remain unfrozen^\ 
Klossner et al. demonstrated that prostate cancer cells held at the critical temperature of 
-40°C for 2 minutes showed the maximum ablative level (- 93%) compared to cells 
which just reached the critical temperature (24%).
Repetition of the freeze-thaw cycle
The importance of double freeze-thaw cycle for complete ablation of prostate tissue has 
been identified in an in vivo study .^ The volume of necrotic tissue significantly increased 
from 4% to 13% following double freeze-thaw cycle. A recent report demonstrated 
enhanced lethal effect of cryotherapy following the second freeze-thaw cycle^ .^ The 
mechanism behind increased cell death following the second freeze-thaw cycle is not well 
understood. Cellular disruption and loss of cell membrane integrity following the first 
freeze cause increase thermal conductivity during the second freeze which results in faster 
and more extensive tissue freezing during the second freeze-thaw cycle""*. In addition 
extended exposure to cold injury or cancer cells sensitization may occur following the 
first freeze'*^ .
10
Patient Groups Amenable to Total Cryosurgical Ablation of the Prostate 
Primary Therapy -  Organ Confined Disease
Organ confined prostate cancer remains amenable to cryotherapy today although 
incre^ing competition from other treatment options means that this treatment is 
infrequently used for primary treatment in the UK, compared with radiotherapy and 
radical prostatectomy. Guidance was issued from the UK National Institute of Clinical 
Excellence (NICE), based on their literature review which was prepared in 2004^ ^^ . This 
stated that in view of the current scarcity of evidence on the efficacy and safety of 
primary cryotherapy, it was not recommended for men with localised prostate cancer 
other than in the context of controlled clinical trials comparing their outcomes with those 
of more established interventions.
The Cochrane review group considered cryotherapy for localised prostate cancer in 
2007^  ^ and their findings supported these conclusions. The American urological 
association has stated that there is insufficient published data to perform a meta-analysis 
of the results of cryosurgery for early prostate cancer and include this modality in the 
2007 guidelines on the management of clinically localised prostate cancer" .^
Best practice guidelines from the AUA on prostate cryotherapy suggest that although 
there is a scarcity of evidence that short term outcomes for intermediate and high risk 
organ confined disease may be similar to those from radiotherapy at follow up 
durations<8 years^ .^ The latest publications detailed in the results section include patients 
with 10 year follow up.
II
Primary Therapy -  Locally Advanced Disease
Cryotherapy has also been used to treat locally advanced prostate cancer. However a 
recent randomised controlled trial in T2c-T3b (bilateral organ confined, capsular 
penetration or seminal vesical invasion) by Chin et has suggested that biochemical 
disease free survival was poorer in men who underwent cryotherapy as their primary 
treatment modality than in those who underwent primary EBRT. Clearly the subgroup of 
patients with capsular penetration and a contraindication to EBRT may wish to consider 
cryotherapy as primary therapy. In the UK the National Institute of Clinical Excellence 
has recommended that cryotherapy for locally advanced disease is offered only as part of 
clinical trials.
Salvage Therapy after External Beam Radiotherapy or Brachytherapy
The failure rates for contemporary EBRT in biochemical control of organ confined 
prostate cancer range from 24-85% depending on the risk profile of the assessed group 
and the planning and delivery of radiotherapy^^'^\ Due to the widespread use of EBRT 
often at lower radiation doses than are used currently, this group of patients is potentially 
the largest group of patients who are suitable for prostate cryotherapy. The workload of 
such patients who may require cryotherapy is also higher, in part due to the relative lack 
of other established modalities which are recognised as effective in the treatment of 
locally recurrent disease after radiotherapy.
Patient Selection for Primary Cryotherapy
Guidelines by the American Urological Association and the National Institute for Clinical 
Excellence in the UK detail appropriate investigations to confirm staging prior to local 
ablative therapy in patients with pathologically confirmed prostate cancer^  ^ Use of
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established staging nomograms (Roach^" or Partin^^) should be considered and the 
possibility of lymph node sampling considered if the chance of LN involvement is 
>15%^ .^ As in patients undergoing primary treatment a prostate volume of more than 40 
cc"* requires 3 months cytoreductive hormone therapy in order to facilitate the procedure 
and reduce the risk to the surrounding structures"*^ .
Patient selection for salvage cryotherapy
Rising serum prostate specific antigen (PSA) level is usually the first sign of treatment failure 
in prostate cancer. The PSA may fluctuate in the first 18 months following radiotherapy^^. If 
there is a persistent rise in PSA which fulfils the Phoenix definition of biochemical failure 
(nadir PSA+2.0mmol/dl) then staging investigations for salvage therapy may be instigated^^. 
These investigations are suitable for salvage in both EBRT salvage and low and high dose 
brachytherapy salvage patients.
The possibility of lower urinary tract infection should be excluded. Restaging pelvic MRI 
scan and bone scan is mandatory to exclude patients with metastatic disease prior to prostrate 
biopsy. Prostate biopsy is mandatory to confirm local recurrence. Saturation prostate biopsy 
(20-40 cores) is more sensitive than transrectal biopsy (10 cores) in detection of recurrent 
cancer in irradiated patients^ .^ Cytoreductive androgen deprivation should be employed 
when prostate volume is >40cc. The role of pelvic lymph node dissection (mini-laparotomy 
or laparoscopic) should be considered in men at higher risk of having locally advanced 
disease based on the characteristics of their initial presentation (using the Roach or Partin 
nomograms identified above).
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The Technique of Cryosurgical Ablation of the Prostate
Our protocol requires a phosphate enema on the morning of surgery, after which the 
patient is anaesthetised, usually with general or regional anaesthetic. In the lithotomy 
position the patient is draped and the perineum prepared with aqueous iodine solution. A 
flexible cystoscopy is performed to check for possible urethral problems which might 
prevent placement of the warming system and the patient then has a catheter placed. A 
volume measurement is then performed and the number of probes necessary is calculated. 
A stepping unit mounted either on the floor or attached directly to the operating table may 
be used. Commercial software is available to optimise placement of the cooling probes 
based on the gland volume and the location of the critical structures (rectum and urethra) 
however this is not widely used and most operators place the cryoprobes freehand via a 
perineal template. For typical salvage cases this would result in the placement of 6-12 of 
the Galil Seednet probes in 2-3 rows, at approximately 10mm intervals. Thermocouples 
are then placed in 4 locations; anterior to Denonviliers fascia, in the anterior prostate, at 
the prostatic apex and in the sphincter, all under ultrasound control. The catheter is then 
removed and a flexible cystoscopy performed to allow placement of a guidewire in the 
bladder and the urethral warmer is placed over the guidewire. A typical setup for 
cryotherapy is reproduced in figure 3. The two freeze cycles are then commenced with 
careful monitoring of the freeze using the temperature probes and the ultrasound images. 
These techniques were used to produce the results in the series of patients treated at our 
institution^ .^
Figure 3. Setup for prostate cryotherapy with urethral warmer in situ, black cryoprobes, 
and white thermocouples inserted via a perineal template.
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Primary cryotherapy of the prostate
Cryotherapy has been used as a primary treatment for localized or locally advanced 
prostate cancer. Biochemical recurrence free survival (BRFS) rates were variable ranging 
from 60-90% at the last follow up. This depends on the criteria used in defining the cut­
off PSA recurrence rate. The outcome also varies depending on the risk groups with 
better outcome in the low risk patients (those with a PSA level <10 ng/ml, a Gleason 
score < 6 and a clinical stage < T2b) compared to the high risk patients (those with two or 
more unfavourable risk factors from a PSA level >10 ng/ml, a Gleason score > 7 and 
clinical stage > 2b)'^ *^ . The use of preoperative hormone ablation therapy impacts on the 
long term results of the procedure. Tables 1.1 and 1.2 summarize results and 
complications of the recent case series studies of primary prostate cryosurgery. Cohen et 
al.^  ^ assessed a series of 370 who had undergone prostate cryotherapy as primary 
treatment for locally advanced prostate cancer. Using a nadir plus 2 ng/ml definition for 
biochemical recurrence, the 10 year actuarial biochemical recurrence free survival 
(BRFS) for low risk, medium risk and high risk was 80.56%, 74.16% and 45.54% 
respectively. The 10 years positive biopsy rate was 23%. Hubosky et al."^ " retrospectively 
reviewed 89 patients for 11 months who have undergone primary cryotherapy of the 
prostate. Their results were comparable to Cohen et al."^  ^ series with regard to local cancer 
control. Long et al. presented multi-institutional report following primary prostate 
cryotherapy. A total of 975 patients were treated over 5 years. Two PSA thresholds were 
used (0.5 and 1 ng/ml) to define the biochemical disease recurrence. Seventy five percent 
of the patients were in the intermediate and high risk group. The 5-year actuarial BRFS 
rates were 60% in the low risk patients compared to 36% in the high risk group (PSA cut­
off 0.5ng/ml). The positive biopsy rates ranged from 18-24%. These results were 
comparable to the conformai radiotherapy and brachytherapy treatment. Bhan et al.^
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reported on 590 patients who underwent cryoablation of the prostate and followed for 7 
years, BRFS rate was defined as PSA level < 0.5 ng/ml. The 7-year actuarial BRFS rate 
were 61%, 68%, and 61% for the low-risk, intermediated-risk and high-risk groups 
respectively with a positive biopsy rate of 13%.
Complications of primary cryotherapy of the prostate
Complication rates are low following primary prostate cryotherapy apart from erectile 
dysfunction which remains a serious problem'^". Table 1.2 summarises the complication 
rate following primary cryotherapy of the prostate. Recto-urethral fistulae are very 
uncommon in modem primary cryotherapy series (<0.5% in reports from the last 
decade)"*^ . The impotence rate in the primary cryotherapy ranges from 53-96%. 
Donnelly et a l reported that the nerves have the potential to recover 12 months 
following cryotherapy and half of their patients had recovered potency by 36 months. 
Incontinence rates varied considerably but were <10% in most series.
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Table 1.1 Results of the primary cryotherapy series.
Series Year
Number
of
patients
Follow
up
(mean)
months
negative
biopsy
%
PSA
failure
% BRFS (risk group) 
Low Int. High
Cohen et 2008 370 150 7&9 Nadir +2 8&5 74.16 45.5
Hubosky et al.^^ 2007 89 11 N/A <0.4 74 70 60
Polascik et 2007 50 18 96 <0.5 90 all patients
El Hayek et al y 2007 21 41 42 <1 42.8 at 60 months
Prepelica et a l^ 2005 65 35 8T5 ASTRO 83 all patients
H m e ta iy  ^ 2003 106 12 N/A <0.4 75 at 12 months
Bahn et a l^ 2002 590 (65) 87 ASTRO 92 89 89
Donnelly et a l^ 2002 87 (50) 9&6 <0.3 60 77 48
Long et a iy 2001 975 24 82 <1 76 71 61
Koppie et a?^. 1999 176 (30.8) 62 <0.5 70 45
Wong et a iy 1997 83 30 17*90 - - - -
Shinohara et al y 1996 102 - 77 Undetectable 41 54 3
Miller et a iy 1994 62 (24) 79 <0.4 51 at 20 months
Onik et al.^ 1993 55 (23) 93 Biopsy results - - -
* Without temperature monitoring primary and salvage cases
Table 1.2 Complication rates following primary cryotherapy of the prostate.
Series Impotence%
Incontinence
%
Rectourethral 
Fistula %
Urethral 
Slough %
Pain
%
Stricture 
/ Retention
%
Cohen et a l^ N/A N/A N/A N/A N/A N/A
Hubosky et a iy N/A N/A N/A N/A N/A N/A
Polascik et al y 50 4 0 0 0 0
El Hayek et al y 96 8 0 N/A N/A N/A
Prepelica et al y N/A 3.1 0 N/A 3.1 3.1
R m e ta iy  ^ 87 8 0 5 2.6 3.3
Bahn et al y 8 9 j 15.9 0.004 N/A N/A 5.5
Donnelly et a iy 53 1.3 N/A 3.9 N/A N/A
Long et al y 93 7.5 0.5 N/A 2.3 13
Koppie et a ^ . N/A N/A N/A N/A N/A N/A
Wong et a iy 94 4 0 37 N/A 4
Shinohara et al y 84 4 1 N/A 3 23
Miller et a iy N/A 2.7 0 1.3 N/A 1.3
Onik et a y 64 0 2.9 4.4 N/A N/A
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Oncological results of salvage cryotherapy series
There has been controversy in evaluating clinical response following cryotherapy of the 
prostate. PSA level cut offs of 0.1, 0.2 (above nadir), 0.3, 0.4, and 0.5 ng/ml have been used 
to define biochemical failure^  ^ Connolley et demonstrated that PSA cut off value
of > 0.5 ng/ml is a strong predictor of positive biopsy at 12 months post cryotherapy. Table
1.3 summarises the outcome of the recent salvage cryotherapy case series.
In our centre the first 100 salvage cryotherapy patients were followed with 3 monthly serum 
PSA level over mean follow up period of 33 months. We used the American Society for 
Therapeutic Radiology and Oncology (ASTRO) definition and cut off value > 0.5 ng/ml to 
define biochemical failure. Using the ASTRO definition 60% of men remained disease free 
at 3 years follow up. Unsurprisingly, high risk patients showed the least favourable outcome. 
This may reflect undetected sub clinical systemic disease, persistent local cancer progression 
or involvement of the seminal vesicle^ .^ Seventy three percent of low risk patients with no 
risk factor remained free from biochemical recurrence at five years follow up.
A recent retrospective case series reported on 279 patients who had undergone salvage 
cryotherapy for recurrent prostate cancer^ .^ At 5 years, 59% were free from biochemical 
failure and 67.4% had a negative biopsy following the procedure. Bahn et a l^  presented the 
longest follow up series of salvage cryotherapy. At 7 years follow up, the combined 
biochemical disease free survival using PSA cut-off of 0.5 ng/ml was 59%. At the London 
Health Sciences Centre in Ontario, 187 patients with locally recurrent prostate cancer have 
been treated with salvage cryotherapy^* .^ They reported BRFS of 56% with a mean follow up 
of 39 months. Preoperative PSA level was an independent predictor for BRFS and patients 
with preoperative PSA less than 4 ng/ml had better outcome.
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Complications of salvage cryotherapy series
Almost all patients following salvage cryotherapy will have some degree of lower urinary 
tract symptoms (LUTS) secondary to urethral slough most of which will resolve in the 
first 6 months. Urethral slough rates have been reduced from 40%^  ^ to 5%^  ^ in many 
series since the introduction of urethral warming catheter which protects urethral mucosa 
during cryotherapy. In contemporary salvage cryotherapy series the urinary incontinence 
rate has dropped dramatically with recent studies reporting incontinence rates of 3-6%^  ^
Although urethral warming has been successful in reducing urinary morbidity, it may 
compromise cancer control by protecting a rim of prostatic tissue around the urethra from 
freezing^ "*.
Erectile dysfunction is the most frequently occurring complication following prostate 
cryotherapy"*  ^ primarily due to the ice ball extending into the neurovascular bundles 
when attempting to completely eradicate the tumour. The impotence rate in salvage cases 
range from 56-100%. In salvage cryotherapy most patients suffer from a degree of 
erectile dysfunction owing to previous hormone therapy and pelvic irradiation^^.
The most serious complication of salvage cryotherapy is the development of recto­
urethral fistula. New treatment advances and better control of the procedure have 
significantly reduced this complication to <4% in salvage cases^ "* .
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Table 1.3 Results of the salvage cryotherapy series.
Series Year No of patients
Follow up
(mean)
months
Negative
biopsy
%
PSA
Failure
%
% BDF survival 
(risk group)
Low Int. High
Pisters et a l^ 2008 279 21.6 67.4 ASTRO 58.9 all groups
.2007 187 (39) 8T4 Nadir +2 56 all groups
Ismail et al y 2007 100 (33.5) N/A >0.5 73 45 11
Robinson et a l^ 2006 46 24 N/A >0.3 48 at 2years
Lamer al y 2005 72 6 N/A N/A 90 at 6 months
Bahn et a iy 2003 59 (72.5) 100 >0.5 61 62 50
Ghafar et al y 2001 38 20.7 N/A >0.3 above nadir 74 at 2years
Chin et al y 2001 118 (18.6) 94 >&5 34 all groups
de la Taille et a iy 2000 43 (21.9) 63(5/8) <0.1 66 at 1 year
Pisters et al y 1997 150 (13.5) 77(85/110)
>0.2 above 
nadir 58
Baies et a iy 1995 23 12-23 59(13/22) <03 14 at 1 year
Table 1.4 Complication associated with salvage cryotherapy
Series Impotence
%
Incontinence
%
Rectourethral 
Fistula %
Urethral 
Slough %
Pain
%
Stricture 
/ Retention
Pisters et a iy 6&2 4.4 1.2 3.2 N/A 6.8
Ngera/.''*' N/A 3 (severe) 2 14 21
Ismail et a iy 86 6 (severe) 1 16 4 2
Robinson et a iy
56 29
( moderate to 
severe)
2
(early series)
24
(early
series)
16 6
(early series)
Lam et a iy 833 17.5 0 N/A 5 9
Bahn et a iy N/A 8 3.4 N/A N/A N/A
Ghafar et a iy N/A 7.9 0 0 39.5 0
Chin et a iy 6.7 3.3 5.1 8.5
de la Taille et a iy N/A 9 0 N/A 26 5
Pisters et a iy 72 73 1 22 8 67
Bales et a iy 100 95.5 N/A N/A N/A 40.9
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Areas for Potential Advances in the Management of Organ Confined Prostate 
Cancer Using Cryotherapy
Focal nerve sparing cryotherapy
In prostate cryotherapy the whole prostate gland is frozen including the peri-prostatic 
tissue with neurovascular bundles to eradicate all tumour cells. As a result, the incidence 
of erectile dysfunction is high. In an attempt to preserve potency, Onik et al, described 
focal nerve sparing prostate cryotherapy where they treated part of the prostate which 
contain the tumour. After a mean follow up of 50 months, 95% of the treated patients had 
stable PSA and 80% maintained their potency. In a different approach, the neurovascular 
bundle was successfully preserved by active warming, but this resulted in an incomplete 
ablation of prostate tissue^ .^ Lambert et al?^ presented 28 months (range 9 to 72 months) 
follow up of 25 patients treated with primary focal cryotherapy. Eighty four percent of 
patients had not experienced biochemical failure and only 14% showed positive biopsy on 
the treated site. Potency was maintained in 71% and no patient reported any worsening 
lower urinary tract symptoms or incontinence. Focal nerve sparing cryotherapy has not 
been applied in salvage treatment.
Laser assisted cryotherapy (LAC)
LAC is a new technique that attempts to protect healthy tissue around the prostate without 
limiting the cryoablation of unwanted tissue. Laser radiation administered from the urethra 
into the prostate during freezing process maintains the temperature in the urethral wall and 
surrounding region above the damaging level and at the same time lethal temperature is 
achieved in the surrounding prostate tissue. The margin of laser protected area increases with 
injecting light absorbing dye into the peri-urethral tissue^*.
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Rectal wall protection
The rate of recto-urethral fistula following prostate cryotherapy is low, however this remains 
a potentially catastrophic complication. Avoiding excessive freezing at the posterior margin 
of the prostate protects the rectum from freezing injury. Therefore, whole gland ablation 
which is necessary for complete eradication of prostate cancer will always be associated with 
risk of fistula. Modifying the cryotherapy technique to achieve lethal temperature (< -40°C) 
posteriorly while avoiding potential rectal injury was attempted using different techniques. 
Cytron et al. inserted 2 cryotherapy needles into the Denonvellier’s fascia for active 
warming using the thawing phase when the temperature drops below 0°C in the posterior 
prostate. This approach successfully maintained a PSA level of <0.5 ng/ml in 80.6% of the 
patients treated and no rectal injury was reported. Other studies have addressed this issue by 
manipulating the transrectal ultrasound probe to increase the distance between the rectal wall 
and the prostate. The mean distance was increased by 7.1 mm without impairing the 
ultrasound quality image^ .^
Adjuvant treatment with cryotherapy
There are limitations to the maximum improvement technical innovations in the delivery of 
cold to the prostate can achieve given the close relationship between the critical structures 
which surround the prostate. Other options for improving outcomes include the application 
of treatments adjuvant to the application of cold.
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Cryochemotherapy
Freezing results in necrotic cell death; 3 mechanisms are respor^ible for this* :^
a) Extracellular ice crystal formation which leads to cell hyper-osmolarity and post 
hypertonic lysis
b) Direct cell damage caused by intracellular ice crystal formation
c) Vascular stasis and tissue ischemia
The use of anticancer drugs as sensitising agents to enhance apoptotic cell death at the 
peripheral zone of the cryogenic lesion may improve the efficacy of cryotherapy. Clarke 
et a iy  demonstrate that the combination of cryotherapy and Tumour necrosis factor- 
Related Apoptosis-Inducing Ligand (TRAIL) resulted in enhanced prostate cancer cell 
death due to apoptosis at -10°C. The same group demonstrated enhanced efficacy of 
cryotherapy when combined with sub-lethal concentration of 5-fluorouracil in vitro^^.
Goel et al. investigated the ability of tumour necrosis factor alpha (TNF-a) to enhance 
cryoinjury in vivo. Temperature threshold for necrosis was increased with the addition of 
TNF-a prior to cryotherapy and the combined treatment resulted in growth delay of the 
tumour in the experimental animals which require further investigation.
Cryo-immunotherapy
Systemic anti-tumour immune response has been postulated following prostate 
cryotherapy. Clinical case reports observed regression of metastatic disease and 
symptoms relief following prostate cryotherapy which implies that a protective immune 
response may be induced^  ^ The mechanism of such clinical observation was not clear. 
Local tumour destruction by cryotherapy results in release large amount of cryonecrotic
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tissue and tumour antigens. This may enhance the uptake of these antigens by local 
dendritic cells and priming of naïve T cells in regional lymph nodes resulting in tumour 
specific immune response and tumour eradication^ .^ The cryoimmune response has been 
studied in several animal models. Both immunostimulatory and immunoinhibitory effects 
have been reported^ **'^ .^
The precise mechanism of the immunostimulatory effect is not clear. Early cytokine 
mediated response^ ** the involvement of T cell immunity and enhanced natural killer 
(NK) cells cytotoxicity^* and the development of anti tumour antibodies^^ have all been 
suggested as possible immune-stimulation. Suppressed immunity and enhanced tumour 
growth and métastasés have also been reported following cryotherapy^^
Conclusions
Prostate cryotherapy may be used to treat a variety of presentations including localised 
primary prostate cancer, locally advanced disease and for salvage after failed 
radiotherapy. The most established of the three roles is currently in salvage treatment. 
The relative merits of primary treatment with cryotherapy for localised and locally 
advanced disease compared with other existing modalities has yet to be fully explored 
with comparative studies. Contemporary randomised trials would be useful in each of the 
disease subgroups. The possible cryoimmune effects of treatment require further 
investigation.
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